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AML  acute myelogenous leukemia 
ATP  adenosine-5'-triphosphate 
BiFC   bimolecular fluorescence complementation  
BS3  bis(sulfosuccinimidyl)suberate 
CD   circular dichroism 
cDNA  complementary DNA 
CHO  Chinese hamster ovary 
CLP  common lymphoid progenitor 
CMP  common myeloid progenitor 
CSF  colony stimulating factor 
CSF-1R  colony stimulating factor-1 receptor 
DC  dendritic cell 
DMEM  Dulbecco's modified Eagle medium 
DMSO  dimethyl sulfoxide 
Dox  doxycycline 
DSS   disuccinimidyl suberate 
EDAC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride  
EGFR2  epidermal growth factor receptor-2 (a.k.a. ErbB2) 
EndoH  endoglycosidase H 
EPO  erythropoietin 
ERK   extracellular signal-regulated kinase (a.k.a. MAPK)  
ESI-MS  electrospray ionization mass spectrometry 
FACS  fluorescence activated cell Sorting 
FCS  fetal calf serum 
FGFR  fibroblast growth factor receptor 
FL  Flt3 ligand 
Flk-2  fetal liver kinase 2 
Flt3  fms-like tyrosine kinase 3 (a.k.a. STK-1 and Flk-2) 
FMS  feline McDonough sarcoma viral oncogene homolog (a.k.a. CSF-1R) 
FRET  förster resonance energy transfer  
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
G-CSF  granulocyte colony stimulating Factor 
GISTs   gastrointestinal stromal tumors  
GM-CSF granulocyte-macrophage colony stimulating factor 
GMP   granulocyte-monocyte progenitor 
 
 
GNTI  N-acetylglucosaminyltransferase I 
GRB2   growth factor receptor-bound protein 2  
HEK  human embryonic kidney  
HSC   hematopoietic stem cell 
IL  interleukin 
IMAC  immobilized metal ion affinity chromatography 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
ITC  isothermal titration calorimetry 
ITD  internal-tandem duplication  
JM  juxtamembrane 
Kd  dissociation constant 
kDa  kilodalton 
koff  dissociation rate constant 
kon  association rate constant 
Lin  lineage-associated surface markers 
LT-HSC long-term hematopoietic stem cell 
mAb  monoclonal antibody 
MAPK  mitogen-activated protein kinase  
M-CSF  macrophage colony-stimulating factor (a.k.a. CSF-1) 
MEP  megakaryocyte-erythroid progenitor 
MIR   multiple isomorphous replacement  
MPP  multipotent progenitor 
MR  molecular replacement 
MUSK  muscle specific kinase 
NCS  non-crystallographic symmetry 
NGFR  nerve growth factor receptor 
NK  natural killer cell 
NRTK  non-receptor tyrosine kinase 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PDB  Protein Data Bank 
PDGF-R platelet-derived growth factor receptor 
PEI  polyethyleneimine 
PI3K    phosphatidylinositol 3-kinase  
PKB   protein kinase B (a.k.a. AKT)  
PLCγ   phospholipase C-γ 
PlGF   placental growth factor 
PMF  peptide mass fingerprinting  
 
rhFL  recombinant human FL 
RMSD  root mean square deviation 
RTK  receptor tyrosine kinase 
RTKIII  receptor tyrosine kinase type III 
Sca-1  stem cell antigen-1  
SCF  stem cell factor 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC  size-exclusion chromatography 
Sf  Spodoptera frugiperda 
SH2  src homology-2 domain 
SH3  src homology-3 domain 
SIRAS  single isomorphous replacement with anomalous scattering 
SPR  surface plasmon resonance 
SRC   Rous sarcoma viral oncogene homolog 
STAT5  signal transducer and activator of transcription 5  
ST-HSC  short-term hematopoietic stem cell 
STK-1  stem cell tyrosine kinase 1 
Tc  tetracycline 
Thy1  thymocyte differentiation antigen-1  
TK  tyrosine kinase 
TKD  tyrosine kinase Domain 
TMD  transmembrane Domain 
TPO  thrombopoietin 
TrkA  tropomyosin-related kinase A (a.k.a. NGFR) 











LIST OF DISCUSSED STRUCTURES 
 
PDB code Description  Resolution (Å)   Reference 
1HMC Human CSF-1  2.5 Pandit et al., 1992 
1PDG Human PDGF-BB   3.0 Oefner et al., 1992 
1VPF Human VEGF-A  2.5 Muller et al., 1997 
1FLT Human VEGF-R1D2:VEGF-A complex 1.7 Wiesmann et al., 1997 
1EXZ  Human SCF  2.3 Zhang et al., 2000    
1SCF Human SCF  2.2 Jiang et al., 2000  
1ETE Human FL  2.2 Savvides et al., 2000  
1RJB  TKD of human Flt3   2.1 Griffith et al., 2004 
1RV6 Human VEGF-R1D2:PlGF complex 2.5 Christinger et al., 2004 
2O26 Murine KITD1-D3:SCF complex 2.5 Liu et al., 2007   
2O27 Murine SCF  2.2 Liu et al., 2007 
2EC8 Human KITD1-D5 ectodomain 3.0 Yuzawa et al., 2007 
2E9W Human KITD1-D5:SCF complex 3.5 Yuzawa et al., 2007 
3EJJ Murine CSF1-RD1-3:CSF-1 complex       2.4 Chen et al., 2008 
3KVQ Dimer of human VEGF-R2D7  2.7 Yang et al., 2010 
3MJG Human PDGF-RβD1-3:PDGF-BB complex 2.3 Shim et al., 2010 
2X1W Human VEGF-R2D2-D3:VEGF-C complex 2.7 Leppänen et al., 2010  
3QS7  Human Flt3D1-D4:FL complex 4.3 Verstraete et al., 2011 



























































Fms-like tyrosine kinase 3 (Flt3) is a type III receptor tyrosine kinase (RTKIII) expressed at 
the cell surface of hematopoietic stem cells and early hematopoietic progenitors and initiates 
signaling pathways crucial for the development of the pluripotent cell population that gives rise to 
the cellular repertoire of the human blood and immune systems.  
 
The Flt3 receptor is activated by the dimeric four-helical bundle cytokine termed Flt3 Ligand 
(FL). The aim of the research described in this work was to obtain molecular insights into the first 
key step of this activation process, namely the binding of the ligand to the extracellular region of its 
receptor, by methods as X-ray crystallography, small-angle X-ray scattering, negative-stain electron 
microscopy and isothermal titration calorimetry.  
 
In the first part of this thesis, Chapter 1, the existing scientific knowledge about RTKIII 
activation is reviewed. The chapter starts with an introductory section on the hematopoietic system 
and the diverse types of tyrosine kinase receptors. Next, the molecular properties of the Flt3 
receptor and its ligand are discussed and the homology with the other ligands and receptors in the 
RTKIII and RTKV families is highlighted. Then, following a short section about the important 
function of the Flt3 system in hematopoiesis, a detailed overview of the landmark experiments that 
lead to the current understanding of ligand-induced receptor activation in the RTKIII and closely 
related RTKV family is presented. The chapter ends with a discussion on the activation mechanism 
of the intracellular tyrosine kinase domains for both wild-type and oncogenic Flt3. 
 
Chapters 2, 3 and 4 present the results obtained during this doctoral research. In the first stage of 
the project, protocols for the efficient production of recombinant human FL and Flt3 ectodomains 
were established. As clarified in Chapter 2, a soluble bioactive form of FL could be obtained by 
refolding inclusion bodies produced in E. coli. Chapter 3 describes the production of Flt3 receptor 
ectodomain variants as secreted proteins in inducible mammalian cell lines, and the crystallization 
of Flt3 ligand-receptor complexes for structural studies by X-ray crystallography. In Chapter 4, the 
acquired structural and thermodynamic insights into the molecular mechanism that underlies the 
human Flt3 ligand-receptor interaction are presented, with a focus on the determined X-ray structure 
of a ternary Flt3 ligand-receptor complex. 
 




























































Introduction to the hematopoietic system 
 
The cellular compartment of blood, which constitutes about 45% of its volume, consists of the 
oxygen-transporting erythrocytes ('red blood cells'), the blood platelets that mediate clotting, and the 
leukocytes of the immune system (Fig. 1). The leukocytes or 'white blood cells' are a collection of 
diverse cell types on which both the innate and adaptive immune responses depend. They guard the 
peripheral tissues by circulating in the blood and lymphatic system. Innate immunity largely 
involves granulocytes and macrophages. The granulocytes include the phagocytic neutrophils, the 
eosinophils and the basophils. Dendritic cells (DCs) are the most potent antigen presenting cells and 
are thus important for initiating the adaptive immune response. The effector cells of the adaptive 
immune response are the B and T lymphocytes, which also provide the lifelong immunity that can 
follow exposure to disease or vaccination. The natural killer (NK) cells are a type of cytotoxic 















The vast majority of mature blood cells only have a limited life-span. For example, granulocytes 
remain functionally active for a few hours and erythrocytes live for an average of 120 days before 
they are cleared from the blood stream. To sustain steady-state levels of all blood and immune cell 
types, ~ 1011 - 1012 new cells must be produced every day to replace those lost due to natural decay. 
This lifelong process, termed hematopoiesis, is dependent on a small population of hematopoietic 
stem cells (HSCs) that reside in the bone marrow and are able to self-renew, proliferate and 
differentiate into all mature blood cell types (Fig. 2). In addition to maintaining steady-state 
hematopoiesis, the hematopoietic system also responds to physiological stresses, such as bleeding or 
infection. During hematopoietic development, HSCs gradually lose self-renewal potential as they 
start to differentiate towards their immediate progeny, the multipotent progenitor (MPP). These 
MPP cells lack in vivo self-renewal ability but have the capacity for multilineage differentiation, 
giving rise to the common myeloid progenitors (CMP) and common lymphoid progenitors (CLP). 




CLPs populate the lymphoid compartment, which consists of B and T lymphocytes and NK cells. 
CMPs can develop into the megakaryocyte-erythroid progenitor (MEP) and the granulocyte-
monocyte progenitor (GMP). The MEP progenitor can differentiate in megakaryocyte cells that are 
responsible for platelet production or into erythrocytes. The GMP progenitor gives rise to the 
different types of granulocytes and to the monocytes which develop into macrophages. DCs can 


























The earliest site of hematopoiesis during embryonic development is extra-embryonically in the 
yolk sac (Auerbach et al., 1996). From there HSCs migrate to the fetal spleen and liver, and finally 
to the bone marrow which is the major site of hematopoiesis in adults (Mikkola and Orkin, 2006).                
 The stem cell compartment of the bone marrow includes a heterogeneous population of cells that 
can be divided into two subpopulations based on their ability to reconstitute the hematopoietic 
system of lethally irradiated mice. The most immature fraction of the HSC compartment is the long-
term stem cell population (LT-HSC), which has the greatest capacity for self-renewal and the ability 
 
FIGURE 2. The hierarchy of hematopoietic development  
HSCs can be divided into LT-HSCs, highly self-renewing cells that repopulate an animal for its entire life span, or ST-
HSCs, which repopulate the animal for a limited period. ST-HSCs differentiate into MPPs, which do not or briefly 
self-renew, and have the ability to differentiate into oligolineage-restricted progenitors that ultimately give rise to 
differentiated progeny through functionally irreversible maturation steps. The CLPs give rise to T lymphocytes, B 
lymphocytes, and natural killer (NK) cells. The CMPs give rise to GMPs, which then differentiate into 
monocytes/macrophages and granulocytes, and to megakaryotic/erythroid progenitors (MEP), which produce 
megakaryocytes/platelets and erythrocytes. Both CMPs and CLPs can give rise to dendritic cells. All of these stem and 
progenitor populations are separable as pure populations by using cell surface markers.  






to repopulate the hematopoietic system of irradiated mice for more than six months and to 
subsequently be serially transplanted into secondary recipients (Morrison and Weissman, 1994). 
LT-HSCs generate their immediate progeny, short-term stem cells (ST-HSC) which are capable of 
multilineage commitment but have reduced self-renewal potential, and are only able to repopulate 
irradiated mice for 6-8 weeks and lack the ability to be serially transplanted (Adolfsson et al., 2001; 
Christensen and Weissman, 2001). Even though HSCs are present at a very low level in the bone 
marrow, it is possible to isolate them in nearly pure form based on their immunophenotypical 
characteristics. The finding that a single transplanted stem cell is capable of completely repopulating 
a host’s ablated hematopoietic system demonstrates the enormous power of HSC self-renewal 
(Camargo et al., 2006; Dykstra et al., 2007; Wagers et al., 2002).  
The hematopoietic process is orchestrated by the concerted action of cell surface-bound and 
soluble cytokines that activate their cognate receptors presented at the cell surface of HSCs and their 
progenitors. Cytokines of the hematopoietic system include stem cell factor (SCF), FL, colony-
stimulating factors (CSFs), interleukins (ILs), interferons, erythropoietin (EPO) and thrombopoietin 
(TPO) (Fig. 3). Many hematopoietic receptors belong to the type I cytokine receptor or type III 
























FIGURE 3. Hematopoiesis and the role of cytokines in vivo.  
Cytokines act on both multipotential HSC/progenitor cells and their committed offspring. Major points, pinpointed by 
gene-targeting studies, at which cytokines act to provide survival and proliferation signals and, in some cases, 




Two general models for the role of cytokines and their receptors in hematopoietic differentiation 
have been proposed: the instructive model and the stochastic model. In the instructive model, 
cytokines transmit specific signals to multipotential hematopoietic cells directing their lineage 
commitment and differentiation. In the stochastic, or permissive, model lineage commitment and 
terminal differentiation are intrinsically determined by a program of transcription factors with 
cytokines providing permissive growth and survival signals. The instructive model recognizes the 
role of transcription factors but proposes that cytokine signaling also plays a fundamental role in 
lineage determination. Evidence is accumulating that some, but not all, cytokine receptors can 
transduce a genuine lineage-determining signal at some points in hematopoiesis, especially at the 
point of divergence of the myeloid and lymphoid lineages. Further studies are however needed to 
fully explore the scope of instructive signaling (Robb, 2007).  
 
Receptor Tyrosine Kinases (RTKs) 
Protein kinases constitute a large and diverse family of enzymes that catalyze the transfer of the 
terminal phosphoryl group from a nucleoside donor, such as ATP to the hydroxyl side chain of a 
specific serine, threonine or tyrosine residue in a protein substrate and thereby regulate the activity 
of their target protein. Unlike serine and threonine protein kinases, which constitute the large 
majority of protein kinases in the human genome (Manning et al., 2002), and are conserved in both 
unicellular and multicellular eukaryotes, tyrosine protein kinases (TKs) are only found in 
Metazoans. In these organisms they are critical components of processes that require intercellular 
communication such as growth, differentiation, adhesion, motility and cell death. Many TKs are 
known as proto-oncogenes, which emphasizes their important role in cell signaling. 
TKs can be divided into two subgroups: the single-pass transmembrane receptor tyrosine kinases 
(RTKs), and the intracellular non-receptor protein tyrosine kinases (NRTKs). Complete sequencing 
of the human genome revealed that it encodes for 90 TKs of which 58 are of the receptor type              
(Fig. 4) (Robinson et al., 2000).  
The NRTKs are integral components of the signaling cascades triggered by RTKs and other cell 
surface receptors such as G protein-coupled receptors and cytokine receptors. Some NRTKs (Janus 
kinases) are directly associated with the membrane-bound type I and II cytokine receptors. Some 
types are anchored to the membrane by N-terminal modifications such as myristoilyation or 
palmitoylation (e.g. Src), and others types exist as intracellular soluble proteins (e.g. BRK/PTK6). 
In addition to a tyrosine kinase domain, NRTKs possess other domains - such as Src homology-2 
(SH2) and Src homology-3 (SH3) domains - that modulate their activity. 
The 58 RTKs are embedded in the membrane and have a similar modular structure composed of 
an extracellular ligand binding domain, a single transmembrane spanning helix and a well conserved 
intracellular tyrosine kinase domain. They are divided into 20 classes according to the molecular 













































FIGURE 4. Distribution of the 90 protein tyrosine kinase genes in the human genome. 
The chromosomal localization of the RTKIII genes for the KIT, CSF-1R, Flt3, PDGF-Rα and PDGF-Rβ receptors, 
and the RTKV genes for the VEGF-R1, VEGF-R2 and VEGF-R-3 receptors are indicated with a red box. The Flt3 
gene is located on chromosome 13. Adapted from Robinson et al., 2000. 
 
 
FIGURE 5. Domain organization for a variety of RTK classes.  
The extracellular portion of the receptors is on top and the cytoplasmic TKD below. The receptors as shown are only 
approximately to scale. The different types of domains found in the extracellular regions of RTKs are shown 
schematically on the right. The closely related RTKIII and RTKV families with 5 and 7 Ig-like domains, respectively, 
are indicated with a red box. The Flt3/Flk2 receptor (blue box) is a member of the RTKIII-family. Note the presence 




With the exception of members of the insulin receptor family, which are preformed dimers 
linked by a disulfide bridge, it is believed that most RTKs diffuse as inactive monomers in the cell 
membrane. However, for a number of RTKs, including EGFR (Moriki et al., 2001) and TrkA (Shen 
and Maruyama, 2011), it has been shown that they exist as inactive preformed dimers or in a 
monomer-dimer equilibrium. The techniques used to study the oligomeric state of these RTKs in the 
cell membrane include chemical crosslinking, FRET, bimolecular fluorescence complementation 
(BiFC), luciferase fragment complementation assays, fluorescence correlation spectroscopy    
 and, more recently, quantum-dot-based optical tracking of single molecules (Chung et al., 2010 ). 
 It is interesting to note that the type I cytokine receptors, EpoR and GHR also exist as 
preformed dimers (Constantinescu et al., 2001; Brown et al., 2005).  
RTKs are activated by the binding of a cognate protein ligand to their extracellular region. 
Ligand-binding, which can be accompanied by conformational changes in the receptor ectodomain, 
leads to the formation of a dimeric receptor assembly in which the adjacent intracellular TKDs are 
orientated in a state that allows their activation by a process termed trans-autophosphorylation. 
Subsequently, the activated TKDs initiate a signaling cascade that may lead to a cellular response. 























FIGURE 6. A diversity of mechanisms              
to dimerize RTKs.  
(A) A nerve growth factor dimer (red) crosslinks two TrkA 
receptors molecules without any direct contact between the 
two receptors (Wehrman et al., 2007). (B) A stem cell 
factor dimer (red) also crosslinks two KIT molecules. In 
addition, two Ig-like domains (D4 and D5), which reorient 
upon receptor activation, interact across the dimer interface 
(Yuzawa et al., 2007). Thus, KIT combines ligand-
mediated and receptor-mediated dimerization modes. (C) 
Two fibroblast growth factor receptor (FGFR) molecules 
contact one another through the Ig-like domain D2, and the 
accessory molecule heparin or heparin sulfate 
proteoglycans (white sticks) also contact this domain 
(Schlessinger et al., 2000). In addition, each fibroblast 
growth factor molecule (red) contacts Ig-like domains D2 
and D3 of both FGFR molecules. (D) Dimerization of ErbB 
receptors is mediated entirely by the receptor. Binding 
simultaneously to two sites (DI and DIII) within the same 
receptor molecule, the ligand drives conformational 
changes in the epidermal growth  factor receptor (EGFR) 
that expose a previously occluded dimerization site in 
domain II (Garrett et al., 2002; Ogiso et al., 2002). Adopted 





An increasing number of high-resolution structures of ligand-receptor complexes learn that there 
exist many different mechanisms by which ligands induce the dimerization of their receptor (Fig. 6). 
Receptor-dimerization can be entirely ligand-mediated, without the formation of receptor-receptor 
contacts (e.g. TrkA, Fig. 6A). On the other extreme, dimerization can be entirely receptor-mediated 
(e.g. ErbB, Fig. 6D). In such a case the ligand induces a conformational change in the unbound 
autoinhibited receptor that exposes a dimerization motif. Also complexes where both the ligand and 
the receptor directly contribute to the dimerization have been observed (e.g. KIT and FGFR, Fig. 
6B, C) (Hubbard and Miller, 2007; Lemmon and Schlessinger, 2010). 
 
That some receptor tyrosine kinases play an important role in hematopoietic development was 
established by the discovery of the RTKIII receptors, FMS and KIT. FMS (a.k.a. CSF-1R) is the 
cellular counterpart of v-FMS encoded by the leukemia-causing Feline McDonough Sarcoma virus 
and was shown to be the receptor for Colony Stimulating Factor-1 (CSF-1), a growth factor required 
for the proliferation and differentiation of monocytes (McDonough et al., 1971; Ralph et al., 1986; 
Sacca et al., 1986). KIT, the cellular counterpart of v-KIT, encoded by Hardy-Zuckerman 4 feline 
sarcoma virus, is the receptor for Stem Cell Factor (SCF) (a.k.a. Steel Factor). As its name implies, 
SCF directly acts on hematopoietic stem cells and their early progenitors. The genes for KIT and 
SCF were found to colocalize with the White Spotting (W) and the Steel (Sl) locus, respectively. In 
mice that carry mutations in these loci, hematopoiesis is severely affected (Besmer et al., 1986; 
Chabot et al., 1988; Huang et al., 1990; Zsebo et al., 1990).  
 
FLT3, a type III receptor tyrosine kinase 
 
Discovery and initial characterization of the Flt3 receptor  
In search for additional hematopoietic RTKs, Matthews and colleagues performed degenerate 
PCR on cDNA isolated from murine fetal liver. The primers they used were mixtures of 
oligonucleotides directed against two invariant amino acid motifs present in tyrosine kinase domains 
(Wilks and Kurban, 1988). As such, a unique tyrosine kinase sequence was discovered. 
Subsequently, its complete cDNA was cloned and shown to encode for a receptor tyrosine kinase. 
The newly identified protein was designated as Fetal liver kinase - 2 (Flk-2) (Matthews et al., 1991). 
The ligand for Flk-2 was yet unknown. 
In an alternative approach, Rosnet and collaborators performed low-stringency hybridization 
against murine cDNA libraries with a cDNA probe that encoded the FMS kinase region. The RTK 
they discovered was termed FMS-like tyrosine kinase 3 (Flt3) (Rosnet et al., 1991). Flt3 and Flk-2 
corresponded to the same protein. Using murine probes, the human Flt3 cDNA was consequently 





The human Flt3 gene is located on chromosome 13 and contains 24 exons that span a length of 
about 100 kbp (Abu-Duhier et al., 2001). Its cDNA encodes a 993 amino acids long protein that has 
an overall sequence identity of 86% with its murine ortholog. This level of identity is observed all 
along the molecule. Analysis of the human Flt3 protein sequence shows that it contains an                       
N-terminal signal peptide (residues 1-26) that is followed by an extracellular region (residues 27-
541) harboring 9 predicted N-linked glycosylation sites and 22 cysteines. This ectodomain is 
connected to a 21-residue long transmembrane helix (residues 542-562). On the intracellular site, 
the juxtamembrane region (residues 563-603) is followed by a tyrosine kinase domain                   
(residues 604-950) interspersed with a kinase insert region (residues 711 - 780) and ending with a     
C-terminal tail (951-993). The kinase insert region, which connects the N-and C-lobe of the tyrosine 
kinase domain, is a typical feature for members of the RTKIII and RTKV family (Fig. 5). 
 
Pulse-chase analysis of murine Flt3 in transfected COS-cells showed that it is expressed as an 
immature mannose-rich form of 143 kDa and a mature cell surface-expressed complex carbohydrate 
form of 158 kDa. Experiments with tunicamycin and enzymatic deglycosylation with various 
glycosidases showed that Flt3 is extensively N-glycosylated and bares little or no O-glycosylation 
(Lyman et al., 1993b; Maroc et al., 1993). 
 
Expression analysis of the Flt3 mRNA by RT-PCR and Northern blot analysis in murine and 
human tissues showed that the Flt3 gene is expressed in virtually all fetal and adult lympho-
hematopoietic organs, such as liver, spleen, thymus, lymph nodes, bone marrow and placenta. Flt3 
was also found to be expressed in a series of immature cell lines and leukemias of lymphocytic 
origin (Lyman et al., 1993b; Maroc et al., 1993), and in primary leukemia and lymphoma samples 
(Birg et al., 1992).  
 
Homology with other RTKs 
Sequence analysis of the extracellular region of the Flt3 protein revealed that it is a member of 
the RTKIII family. The members of this family have 5 immunoglobulin (Ig)-like domains in their 
ectodomain. The Ig-like domain is a module of about 100 residues and has a β-sandwich structure 
harboring 7 to 9 β-strands, labeled A to G. Typically, an intersheet disulfide bridge is formed 
between strands B and F. Apart from its presence in antibodies, the Ig-fold is found in many cell 
adhesion molecules and surface receptors. Ig-like domains can be classified according their number 


































The RTKIII family also includes the KIT, CSF-1R and the platelet-derived growth factor 
receptors α and β (PDGF-Rα and PDGF-Rβ), and is closely related to the RTKV family which 
harbors the vascular endothelial growth factor receptors (VEGF-R1, VEGF-R2 and VEGF-R3) with 
7 Ig-like domains in their ectodomain (Fig. 7B). The overall similarity in sequence and structure 
between the members of these two families, together with the chromosomal localization of their 
genes (Fig. 4), suggests that these receptors evolved from a common ancestral RTKIII/V gene. 
Based on a molecular phylogenetic analysis and the sequence of the surrounding genomic regions 
Grassot et al. proposed that the different RTKIII/V members arose by a series of cis and trans 
duplications, followed by gene loss (Fig. 8) (Grassot et al., 2006) . 
 
Flt3 is most homologous to the hematopoietic KIT and FMS receptors. Human Flt3 shows 
respectively 18% and 19% identity with KIT and FMS in the extracellular region, and 63% and 64% 
in the tyrosine kinase domain. FMS and KIT are more closely related to each other, because they are 
27% and 71% identical in their extracellular regions and kinase domains respectively. 
FIGURE 7  
(A) Structural diversity in the immunoglobulin-like superfamily. According to the number of strands and their 
topology Ig-like domains can be divided into several types: the V-, C1-, C2-, I- and E-types. Flt3 domains 1, 3 and 4 
belong to the I-set of Ig-like domains, while domains 2 and 5 belong to the C2-set. The characteristic disulfide bride 
between strands B and F is absent in Flt3 domains 1 and 4. There it is replaced by a pair of hydrophobic residues. 
Adopted from Sun et al., 2004. 
(B) Schematic representation of the structure of the RTKIII/V members. Flt3 is a member of the RTKIII-family 
whose members have 5 Ig-like domains (green loops) in their extracellular region. The RTKIII-family is closely 
related to the RTKV-family which harbors the VEGF receptors with 7 Ig-like domains.  
  

















Taken together, Flt3, KIT and CSF-1R share only 9% sequence identity in their extracellular 
domain (Appendix A). These conserved residues correspond to intramolecular disulfide bridges and 
other key residues that stabilize the different immunoglobulin folds in the ectodomain. The 
intracellular kinase domains are however strongly conserved and share an overall sequence identity 
of 57% (Rosnet et al., 1993). 
 
Flt3 exhibits some remarkable sequence features which are not present in the other RTKIII 
members. Strikingly, Flt3 contains an additional 12 cysteines which are not present in KIT or FMS. 
Furthermore, as characterized by a conserved spacing of cysteines, Flt3 Ig-like domains 1 and 2 
share significant homology with Ig-like domains 4 and 5 (Appendix B). This homology suggests 
that the Flt3 extracellular domain has arisen by an ancient duplication event. This level of intragenic 
homology is not found in the other RTKIII members (Matthews et al., 1991; Rosnet et al., 1991). 
  
Furthermore, in Flt3, the first Ig-like domain is preceded by an N-terminal sequence of 50 
residues that shows no homology to other known proteins. Secondary structure prediction suggests 
that this region contains several β-strands. In this respect, it is interesting to note that the exon/intron 
structure of the Flt3 gene in the region which encodes the N-terminal stretch and Ig-like domains 1 
and 2 is different from the one found in KIT and CSF-1R (Fig. 9). Further downstream the 
exon/intron organization between Flt3, KIT and CSF-1R is conserved (Abu-Duhier et al., 2001; 







FIGURE 8. Hypothetical scenario for the origin and divergence of class III and class V RTK. 
(A)  Cis duplications (D1 and D2) resulted in the shared ancestor of class III and class V RTK  
(B) Trans duplications resulted in class III and class V RTK diversification. Two rounds of duplication (D3 and D4) 
 were followed by gene loss. Adapted from Grassot et al., 2006. 
















In 1995, the Rosnet-group identified a murine isoform of the Flt3 receptor from a placental 
cDNA library. This isoform lacks domain 5 and is generated by the skipping of exons 11 and 12 
(Fig. 10). This variant was shown to be functional as Flt3 ligand induced the phosphorylation of 
both forms of the receptor equally well. RT-PCR analysis showed that the isoform is expressed in 
most tissues that were tested, together with the larger form, although at a much lower level. From 
this study it was concluded that the fifth Ig-like of Flt3 domain is not strictly necessary for either 
ligand-binding or kinase activation (Lavagna et al., 1995). The biological significance of this Flt3 












Similar isoforms have also not been reported for the other RTKIII/V members. On the contrary, 
deletion of the fifth Ig-like domain of KIT results in a receptor variant that is incapable of ligand-
induced phosphorylation (Broudy et al., 2001).  
For the KIT, PDGF-Rα and VEGF-R receptors, but not for Flt3, soluble forms of the receptor, 
resulting from ectodomain shedding from the cell surface or alternative splicing, have been reported 
and may serve as decoy receptors that modulate the function of their respective ligands (Broudy et 
al., 2001; Rajakumar et al., 2009; Tiesman and Hart, 1993; Wypych et al., 1995; Philo et al., 1996).  
FIGURE 9. Flt3 has a unique genomic structure in the N-terminal region.  
Comparison of the structural organization of the 5' end of the human Flt3 and KIT genes in relation to the first three 
Ig-domains. Bold numbers correspond to exon numbering while exon sizes (bp) are indicated in the corresponding 
boxes. The CSF-1R gene has a similar organization as the KIT gene. Adopted from Abu-Duhier et al., 2001. 
 
 
FIGURE 10. Active murine FLt3 isoform lacking the 5th domain.  
Loops represent the Ig-like domains. Shade and black boxes represent the transmembrane and the split tyrosine kinase 






Prior to the identification of the cognate ligand for the Flt3 receptor, Maroc et al. showed that a 
CSF-1R/Flt3 chimera in which the murine CSF-1R ectodomain (residues 1 - 497) was fused to the 
murine Flt3 transmembrane and tyrosine kinase regions (residues 535-993) could be phosphorylated 
by CSF-1, and was able to transform fibroblast cells in the presence of CSF-1. Thereby it was 
demonstrated that the cytoplasmic Flt3 TKD can generate a strong mitogenic signal upon 
stimulation of a heterologous extracellular domain (Maroc et al., 1993). 
 
FL is the cognate ligand for the Flt3 receptor 
 
Discovery and initial characterization of the Flt3 ligand  
Given the homology between the Flt3 and the KIT and CSF-1R receptors, the unidentified 
ligand for the Flt3 receptor was expected to be a dimeric four helical bundle cytokine, like SCF and 
CSF-1 (Pandit et al., 1992), the ligands for KIT and CSF-1R, respectively.  In 1993-94, the ligand 
for the murine Flt3 receptor was cloned by two different groups, based on its ability to bind an             
Flt3-Fc fusion construct. By screening a cDNA expression library from a murine T-cell line that 
presented a factor at its surface that was capable of binding Flt3-Fc, Lyman and colleagues 
identified the Flt3 ligand (FL) (Lyman et al., 1993a). In an alternative strategy, Hannum et al. 
isolated murine FL from the phytohemagglutinin-conditioned medium of a thymic stromal cell line 
by using an Flt3-Fc column (Hannum et al., 1994). Consequently, the human FL cDNA was cloned 
(Lyman et al., 1994; Hannum et al., 1994). 
 
The human FL gene maps to chromosome 19 and contains 8 exons. Its primary cDNA              
(exons 1-5 + 7 and 8) encodes for a homodimeric 235 amino acids long type I transmembrane 
protein consisting of four domains: 1) an N-terminal 26-residue signal peptide, 2) a 156-residue 
extracellular 'four-helical bundle' domain with a juxtamembrane tether region, 3) a 23-amino acid 
transmembrane domain and 4) a 30-residue cytoplasmic domain. Analyses of FL cDNA clones 
showed that alternative splicing of a putative sixth exon results in the generation of a soluble form 
of the FL protein (Lyman et al., 1995c). A second soluble form of the ligand can be generated by 
proteolytic cleavage from the membrane bound form (Horiuchi et al., 2009). The CSF-1 and SCF 
ligands have a similar genomic structure as FL and are also both active as a transmembrane or 
soluble form, generated by proteolytic cleavage or alternative splicing (Lyman and Jacobsen, 1998; 
Stein et al., 1990).    
 
In their extracellular domains, the mouse and human Flt3 ligands are 74% identical. This value 
is slightly below that of the extracellular domains of the mouse and human Flt3 receptor which are 
83% identical. Human and murine FL appear to have a good species cross-reactivity (Lyman et al., 
1994). This is unlike SCF and CSF-1. Murine SCF is active on human cells but the human protein 





CSF-1 is active on murine cells but the murine ligand does not activate the human receptor (Garceau 
et al., 2010).  
Human FL contains two potential N-linked glycosylation sites, which are conserved in murine 
FL. Murine FL, derived from a stromal cell line carries approximately 12 kDa of N- and O-linked 
carbohydrates on each chain (McClanahan et al., 1996). Human FL is reported to be N-glycosylated 
in vivo (Lyman and Jacobson, 1998).  
FL mRNA is found in almost every tissue that has been examined, with the highest levels in 
peripheral blood mononuclear cells. However, contrary to the widespread tissue expression pattern 
of FL mRNA, little FL is actually made, with stromal fibroblasts and T lymphocytes being the 
major producers (McClanahan et al., 1996). 
 
Structure and homology with SCF and CSF-1 
Residues 1 to 134 of mature FL, which encompass the four helical bundle fold, were shown to 
be sufficient for biological activity (Escobar et al., 1998). This fragment was crystallized and its 
structure was solved by multiple isomorphous replacement (MIR) to a resolution of 2.2 Å (Fig.11) 























FIGURE 11. X-ray structure of human Flt3 ligand (pdb 1ETE, 2.2 Å resolution).   
A cartoon representation of the FL structure (residues 1-134) in its transmembrane form is shown. The two protomers 
(green and red) adopt a four helical bundle fold (helices αA to αD) and interact in a 'head-to-head' arrangement through 
a hydrophobic dimer interface in which each subunit buries ~1,000 Å2 of surface area. The three intermolecular 
disulfide bridges are shown as yellow 'ball-and-sticks'. FL1-134 was refolded from inclusion bodies. 






The structure shows that FL is a non-covalently linked homodimer with 3 intramolecular 
disulfide bridges. The subunits adopt a short-chain 'four helical bundle fold' with an 'up-up-down-
down' topology and are arranged in a 'head-to-head' fashion. The twofold symmetry axis runs 
perpendicular to the bundle axis. The two FL protomers interact by a hydrophobic interface, in 
which each protomer buries 1000 Å2 of solvent accessible area. This arrangement results in a flat 
elongated structure with overall dimensions of 75 Å x 35 Å x 25 Å. Although the amino acid 
sequence identity between FL, SCF, and M-CSF is less than 15%, these 3 cytokines have a similar 
structure (Fig.12). Four cysteine residues that form two intrachain disulfide bridges are conserved in 
all three proteins.  
 
The helical bundle fold is found in many other cytokines, such as growth hormone (GH), 
erythropoietin (EPO), leptin, thrombopoietin and in many interleukins. These cytokines are 
however usually associated with type I and type II cytokine receptors that lack an intrinsic tyrosine 
kinase activity. As such, FL, SCF and CSF-1 constitute a small family of four helical bundle 


















The Flt3 ligand crystals contained two FL dimers in the asymmetric unit. The relative 
orientation of the protomers is identical in both FL dimers. On the other hand, available structures 
for SCF (pdb 1EXZ and 1SCF) show that the angle between the two protomers may vary by 2° to 6° 
(Yuzawa et al., 2007). A similar variation in the angle between CSF-1 protomers has been observed 
(Elegheert J., personal communication). 
 
 
FIGURE 12. FL is structurally 
homologous to SCF and CSF-1. 
Despite the low sequence similarity (< 15 % 
identity), FL (pdb 1ETE), SCF (pdb 1SCF/ pdb 
1EXZ) and CSF-1 (pdb 3EJJ) adopt a similar 
four helical bundle fold. Four cysteine residues 
that form 2 disulfide bridges are conserved. FL 
and SCF are both non-covalently linked 
homodimers, while CSF-1 is a disulfide linked 
homodimer. The sulfur atoms involved in 
disulfide bridge formation are shown as yellow 





FL and SCF are both non-covalently linked dimers while CSF-1 is a disulfide-linked dimer. By 
analytical gel filtration studies using radiolabeled SCF, it was shown that the majority of E. coli 
produced and refolded SCF exists as a monomer under physiological conditions (Hsu et al., 1997). 
The dimer dissociation constant of recombinant SCF was determined by equilibrium sedimentation 
and size exclusion chromatography as 2.5 to 5 nM. SCF has been shown to be present at 
concentrations of approximately 177 pM (SCF monomer)(3 ng/mL) in human serum. Based on the 
determined dissociation constant, more than 90% of the circulating SCF would be in the monomeric 
form. This monomer/dimer equilibrium was found to be dependent on the pH and salt concentration, 
which suggested that there exist polar interactions at the dimer-interface. Recombinant SCF from 
CHO-cells exchanged equally well with the E. coli-derived non-glycosylated SCF, indicating that 
the attached carbohydrate moieties had no effect on monomer exchange (Lu et al., 1995). 
Furthermore, a covalently linked form of recombinant SCF is reported to have a three times higher 
bioactivity then the wild-type (Lu et al., 1996). Since FL is, like SCF, a non-covalently linked 
dimer, it is possible that it also exists as a monomeric form in human serum. This has not been 
investigated yet.  Gel filtration studies with yeast-derived recombinant FL showed that it remains 
dimeric at concentrations as low as 500 nM (17 µg/mL) (Graddis et al., 1998). This concentration is 
however much higher then the concentration of FL found in human serum (3 – 300 pM) 
(Chklovskaia et al., 1999; Lyman et al., 1995b; Wodnar-Filipowicz et al., 1996). Lu and colleagues 
reported that a recombinant FL-FL fusion protein in which the two protomers were connected by a 
polyglycine linker had a ten times higher bioactivity (at a concentration of 800 pM (25 ng/mL) in 
their cell proliferation assay as compared to wild type FL (Lu et al., 2002). This suggests that at low 
concentrations FL, like SCF, might dissociate into monomers. 
 
 Mutagenesis data for FL 
A yeast-system based random mutagenesis screen indicated that the receptor-binding epitope of 
FL is located at the distal ends of the four helical bundles (Graddis et al., 1998). Three hotspot 
regions were identified (positions 8-15, 81-87 and 116-124) (Fig. 12). The N-terminal loop       
(residues 8 - 15) appeared to be most crucial for binding as single point mutations in this region 
completely abrogated the activity of the ligand (Fig. 13 & 14). Mutagenesis studies for SCF and 
CSF-1 showed that this region is also important for their activity (reviewed in Savvides et al., 
2000). A mutation (Leu27Pro) that disrupts the FL dimer interface was found to decrease the 
bioactivity. Ensuing analytical gel filtration experiments showed that this mutant exists as a 














































FIGURE 13. FL point-mutants that were found to have a effect on the bio-activity. 
(Top) Representation of FL, including the intramolecular disulfide linkage, placement of β-sheet segments, and 
placement of α-helices A–D. (Bottom) Primary structure representation of FL with a superimposition of the relative 
specific activity profile of mutants with single amino acid substitutions. Their specific activity was determined by 
subjecting the yeast medium (in which these mutant proteins were secreted) to an ELISA and a WWF7 cell 
proliferation assay, which measure the levels of expression and biological activity, respectively.  
Adopted from Graddis et al., 1998.  
 
 
FIGURE 14. Inactivating point mutations mapped onto the FL structure. 
The C-alpha atoms of residues, whose mutation resulted in reduced bio-activity are shown as red spheres. The residues 
in the N-terminal loop (residues 8-15) are labeled with their sequence number and one-letter amino acid code. The N- 






Role of the Flt3 ligand and receptor in hematopoiesis  
 
FL and Flt3 knockout mice 
FL-/- mice show a 27 to 45% decrease of the total number of complete nucleated cells in 
peripheral blood, bone marrow, spleen, and lymph nodes. In addition, the total number of 
granulocyte-monocyte progenitors (GMP) and B cell precursors is reduced. FL knockout mice also 
display about fivefold lower numbers of NK cells and 4 to 14 fold reduced, but functional DCs in 
lymphoid organs (McKenna et al., 2000). By using these knock-out mice, a crucial role for FL 
during immune reconstitution after bone marrow transplantation and high-dose chemotherapy has 
been proposed (Buza-Vidas et al., 2007).  
Flt3-/- mice have a less pronounced phenotype and develop into healthy adults with normal 
peripheral blood counts. However, pro-B cell numbers are diminished and the bone marrow 
progenitors of these mice display a reduced ability to competitively repopulate lethally conditioned 
recipients (Mackarehtschian et al., 1995). 
 
In vitro and in vivo effects of FL 
Numerous in vitro studies show that FL stimulates the growth of hematopoietic progenitors from 
the bone marrow, peripheral blood, and cord blood. FL is usually not sufficient when used as a 
single cytokine, but in synergy with other hematopoietic growth factors and interleukins it exerts 
pleiotropic effects on precursors of myeloid and lymphoid lineages. The combination of FL, SCF, 
TPO and IL-6 proved to be optimal for the ex vivo expansion of hematopoietic progenitors (Hudak 
et al., 1995; Lyman, 1998).  
When FL is administered to mice, hematopoiesis is significantly stimulated, leading to bone 
marrow hyperplasia, splenomegaly, and enlargement of the lymph nodes and liver (Brasel et al., 
1996). In combination with G-CSF, FL stimulates the mobilization of hematopoietic progenitors to 
the peripheral circulation in mice and primates (Molineux et al., 1997; Sudo et al., 1997). In vivo 
injection of FL also provides hematopoietic protection from total body irradiation (Gratwohl et al., 
1998).  
Besides the stimulation of early hematopoiesis, FL was shown to have the remarkable activity to 
induce large numbers of DCs and NKs in vivo (Karsunky et al., 2003; Maraskovsky et al., 2000; 
McKenna et al., 2000; Shaw et al., 1998). For example, in healthy human volunteers, who were 
administrated FL for 10-14 days, a mobilization of both myeloid- and lymphoid-derived DC1 and 
DC2 precursors by 48- and 13-fold, respectively was observed.  
In cancer immunotherapy, naive CD4+ and CD8+ T-cells must be presented with the tumor 
antigen and necessary co-stimulatory signals to enhance their maturation and activation. Since FL 
potently stimulates the expansion of dendritic cells much interest developed in its use as an 




growth and inducing a tumor infiltrate of DCs and cytotoxic T lymphocytes, as well as a clinically 
visible antitumor response (Dong et al., 2002; Fong et al., 2001).  
 
In vivo FL levels reflect the state of the stem cell compartment 
Under conditions of normal hematopoiesis, the FL concentration found in human serum is very 
low (< 3 pM) (Lyman et al., 1995b). However, in hematopoietic malignancies that affect the stem 
cell compartment, like Fanconi anemia and acquired aplastic anemia, FL serum levels are highly 
elevated, up to 300 pM (Wodnar-Filipowicz, 2003). A similar 100-fold increase in FL serum levels 
is observed in patients that underwent chemoradiotherapy. On the other hand, FL levels do not 
increase in diseases affecting single blood lineages and do not normalize upon single lineage 
correction. This suggests that the increase in FL levels reflects a compensatory response whose aim 
is to restore the HSC compartment, and as such FL serum levels may serve as a surrogate maker of 
the HSC content in the bone marrow.  
The mechanism that regulates FL serum levels is not completely understood but it is based on 
the release of preformed FL from intracellular stores by T lymphocytes, depending on the status of 
the stem cell compartment. By immunofluorescence confocal microscopy it was found that 
intracellular FL is stored within and close to the Golgi apparatus. The molecular mechanism that 
induces its release is not known (Chklovskaia et al., 1999). 
 
Flt3 expression profile in murine and human hematopoiesis 
The expression profile of the Flt3 receptor in the stem cell compartment seems to be different in 
mice and human (Fig. 15) (Kikushige et al., 2008). FACS-based analyses showed that in mice, the 
most primitive self-renewing HSC with long-term reconstituting (LT-HSC) activity are 
characterized by the following immunophenotype: (1) they lack the lineage-associated surface 
markers (Lin), they express high levels of KIT and Stem cell antigen-1 (Sca-1), (3) they show a low 
expression of Thymocyte differentiation antigen-1 (Thy1) and CD38 and (4) they are negative for 
CD34 and Flt3. Thus in mice LT-HSC are Lin−KIT+Sca-1+Thy1lowCD34−CD38lowFlt3−. Human LT-
HSC reside in the Lin−KIT+Sca-1+Thy1lowCD34+CD38−Flt3low compartment (Ebihara et al., 2002; 
Kikushige et al., 2008; Sitnicka et al., 2003). Thus contrary to mice, Flt3 seems to be expressed at 
low levels on LT-HSC in humans. In both species, Flt3 is upregulated in the later ST-HSC and MPP 
stages. In human, Flt3 is also expressed in early lymphoid and myeloid progenitors and in 
progenitors continuously along the granulocyte/macrophage pathway. In mouse, Flt3 is 
predominantly expressed in cells primed to the lymphoid pathway. Besides its role in early 
hematopoiesis, Flt3 expression is especially important, in both human and mice, for the 
development of dendritic cells, from both lymphoid and myeloid-committed progenitors. 
Furthermore, dendritic cells are the only mature hematopoietic cell type that express Flt3 (Karsunky 

























RTKIII-receptors are activated by structurally diverse ligands  
The cognate ligands for the Flt3, KIT and CSF-1R receptors are the hematopoietic four helical 
bundle cytokines FL, SCF and CSF-1. On the other hand, the ligands for the two other RTKIII 
receptors, PDGF-Rα and PDGF-Rβ, have a totally unrelated fold. They are 'cystine knot' cytokines 
and are structurally related to the ligands for the VEGF receptors of the RTKV family. These 
cytokines form covalently-linked dimers in which each protomer is folded into two highly twisted 
antiparallel pairs of β-strands. Each subunit also contains three intrachain disulfide bonds, from 
which two form a cystine ring through which the third bond passes. This motif is called a cystine 
knot. The various types of PDGF and VEGF molecules and their receptor specificity are shown in 








FIGURE 15. Proposed differential expression of human and mouse Flt3 in steady-state 
hematopoiesis.  
Cellular morphology of directly sorted progenitors is shown. In human, the most primitive LT-HSC expressed hFlt3 
at a low level and its expression is up-regulated at the early GM and the lymphoid progenitor stages, while it is 
down-regulated in MEPs. In contrast, the mouse LT-HSC lacks mFlt3 expression, and mFlt3 is expressed in cells 












































FIGURE 17. Binding specificity of various VEGF family members and their receptors.  
(A) The VEGF family consists of seven ligands derived from distinct genes (VEGF-A, -B, -C, -D and -E, placenta 
growth factor (PlGF) -1 and -2). In addition, specific family members, such as VEGF-A, may be expressed as isoforms 
due to mRNA alternative splicing. VEGF family members and isoforms have specific binding affinities to VEGF-R1, 
VEGF-R2 and VEGF-R-3 tyrosine kinase receptors as shown. In addition, neuropilin (NRP) -1 and NRP-2 are co-
receptors for specific isoforms of VEGF family members and increase binding affinity of these ligands to their 
respective receptors. Adopted from Hicklin and Ellis, 2005. (B) Structure of VEGF-A (pdb 1VPF). The VEGF-ligands 
are disulfide-linked cystine knot cytokines and are structurally homologous to the PDGF ligands (Muller et al., 1997). 
FIGURE 16. Binding specificity of various PDGF family members and their receptors.  
(A) The PDGF family consists of four different PDGF chains (A–D), which assemble into functional homodimers or a 
PDGF-AB heterodimer, and two PDGF-R tyrosine kinases (α and β), which form a homodimer or heterodimer on 
ligand binding. PDGF-AA binds only PDGF-Rα, whereas PDGF-BB binds both homodimer and heterodimer PDGF-
Rs. The less abundant PDGF-CC and -DD bind to PDGF-Rα and PDGF-Rβ homo-dimers, respectively, with both 
binding to the PDGF-Rαβ heterodimer. PDGF-C and -D are structurally more similar to the VEGF family than to the 
PDGFs (Ball et al., 2007). (B) Structure of PDGF-BB (pdb 1PDG). The structure is orientated with the two-fold axis 
perpendicular to the plane. The three disulfide bridges that form cystine knot in each protomer and the two interchain 
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The RTKIII family of tyrosine kinase receptors thus constitutes a rare example of a receptor 
family that interacts with protein ligands having fundamentally different folds (Fig. 18). However, 
there exist some remarkable similarities between both types of cytokines. They all function as 
dimers and have two-fold axes of symmetry perpendicular to the longest dimension of the dimeric 
scaffolds. Furthermore, they have almost identical overall dimensions of ~70 Å x ~35 Å x ~25 Å 
(Savvides et al., 2000). How these cytokines bind and activate their respective receptors will be the 
























Recently, a second ligand that can activate the CSF-1R receptor, termed interleukin-34 (IL-34) 
was identified (Lin et al., 2008). IL-34 is a secreted homodimeric cytokine that has a monomeric 
length of 222 residues. Surface plasmon resonance (SPR) analysis showed that it bound to an 
immobilized CSF-1RD1-D5-Fc construct with a dissociation constant of about 1 pM, while CSF-1 
bound with a Kd of 34 pM. IL-34 has no significant sequence identity with CSF-1 or any other 
cytokine. Secondary structure predictions indicate that it is mainly α-helical but currently it is 
unclear if IL-34 adopts a similar fold like CSF-1.  
 
FIGURE 18. Receptors of the RTKIII family are activated by structurally unrelated cytokines. 
Members of the RTKIII family are activated by 'four helical bundle' cytokines (SCF, CSF-1 and FL) or by 'cystine 
knot' growth factors (PDGF ligands). The PDGF molecules are structurally related to the ligands for the VEGF-R 
receptors of the RTKV family. The structures of FL and VEGF-A are shown as a representative member for both type 
of cytokines. The structures are oriented with their P2-axes in the plane of the paper, and are colored according to their 





It is also interesting to note that VEGF-A can signal through both the PDGF-Rα and PDGF-Rβ 
receptors. This reflects the close evolutionary and structural homologies that exist between these 
growth factors and their receptors (Ball et al., 2007). This form of cross-talk has not been reported 
for the helical RTKIII cytokines.  
 
Structure-function studies on Flt3, KIT and CSF-1R 
 
Receptor dimerization at the cell surface  
RTKs can exist in the membrane as monomers or as preformed dimers. In both cases, binding of 
their cognate ligand leads to the formation of active dimers. Cross-linking studies for KIT and Flt3 
indicated that the unbound receptors exist as monomers in the cell membrane and that the addition 
of ligand induces their dimerization (Fig. 19) and activation (Kiyoi et al., 2002; Lev et al., 1992a; 
Turner et al., 1996). For the CSF-1R receptor it was also shown that the ligand induces the 
formation of active dimers. One group suggested that the unbound form of CSF-1R exists, as 
indicated by cross-linking experiments, as an aggregate in the cell membrane (Li and Stanley, 
1991). However, Carlberg and colleagues found that free CSF-1R behaves as a monomeric protein 
(Carlberg and Rohrschneider, 1994). For the binding of SCF to KIT, it was observed by cross-
linking experiments that there occurs no dissociation of KIT dimers at high excess of SCF, in 
agreement with the absence a bell-shaped dose-response curve in cellular assays. This suggested 
that receptor dimerization is not only attributed by the bivalent nature of the ligand and that 



















(A) Dimerization of Kit receptor in response to SCF binding. 
COS-cells, expressing the KIT receptor, were incubated with increasing concentrations of recombinant SCF (as 
indicated). Consequently, the cells were incubated with 15 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDAC). After cross-linking, the cell lysates were subjected to immunoprecipitation and Western blot 
analysis with anti-KIT-antibodies. A similar experiment with radiolabeled SCF indicated that SCF is contained in the 
cross-linked species. Adopted from Lev et al., 1992a.  
(B) Cross-linking of Flt3 at the cell surface.  
Flt3 transfected 32D cells were incubated with 3 nM (100 ng/mL) recombinant FL and consequently incubated with            
1 mM bis(sulfosuccinimidyl)suberate (BS3). Cell lysates were subjected to immunoprecipitation and Western blot 
analysis with anti-Flt3-antibodies. Adopted from Kiyoi et al., 2002.   
 
  





SCF-induced KIT dimerization at the cell surface was also investigated by FRET. Donor and 
acceptor fluorochromes were coupled to a non-neutralizing KIT antibody. It was found that SCF 
induced a dose-dependent increase in KIT receptor dimerization that correlated well with the 
concentrations of SCF required to stimulate cell proliferation. Receptor dimerization was detectable 
within 3 minutes after the addition of SCF and was maximal 30 minutes after the addition of SCF 
(Broudy et al., 1998).    
 
Scatchard analysis of binding data obtained by the displacement of cell-bound radiolabeled 
ligand, indicated that SCF and CSF-1 bind to their receptors with an affinity of 2 nM and 35 pM, 
respectively (Lev et al., 1992a; Wang et al., 1993). Using the same approach, the affinity for the 
binding of FL to the full length Flt3 receptor was determined - in various cell lines - as 200 to          
500 pM (Turner et al., 1996).  
 
In vitro complex formation with the soluble ectodomain 
Size-exclusion chromatography (SEC) experiments with the purified soluble KIT and CSF-1R 
ectodomains (KITD1-D5 and CSF-1RD1-D5), produced in CHO-cells and Sf9 insect cells, respectively, 
showed that they were capable of forming complexes with their cognate dimeric ligands, as 
























FIGURE 20. The soluble KIT and CSF-1R ectodomains form ternary complex with their ligands. 
(A) KITD1-D5 at 40 mg/ml (0.72 mM) was incubated with levels of E. coli-derived SCF ranging from 6.6 to 52.4 mg/ml 
(0.18–1.40 mM of SCF dimer) on a Superose 6 column. These represented molar ratios of sKit to SCF dimer of 4, 2, 1,  
and 0.5 (chromatograms 6, 5, 4, and 3, respectively). Chromatogram 2 represents SCF alone (in the amount used in 
chromatogram 3), and chromatogram 1 represents sKit alone. The MW of each component was analyzed by light 
scattering and equilibrium sedimentation. Adopted from Philo et al., 1996. 
(B) Superimposed SEC analyses (Superose 6) of the soluble extracellular domain of the CSF-1R receptor, CSF-1RD1-D5 
(solM-CSF R), a CSF-1(M-CSF) dimer, and a complex formed from a 2:1 M ratio mixture of these two molecules. The 




The expected 2:1 stoichiometry for these complexes, namely, the binding of two receptors to 
one ligand, was confirmed by SEC combined with light scattering and later, by isothermal titration 
calorimetry (ITC) (Chen et al., 2008; Koths, 1997; Lemmon et al., 1997; Lev et al., 1992b; Philo et 
al., 1996). The dissociation constants for the full length complexes as obtained by ITC were 55 nM 
for the human KITD1-D5:SCF complex (at 25° C) (Lemmon et al., 1997) and 9 nM for the murine 
CSF-1RD1-D5:CSF-1 complex (at 30° C). The stoichiometry and the dissociation constant of the 
human KITD1-D5:SCF complex were also determined by equilibrium sedimentation analysis. By this 
method a Kd-value of 17 nM (at 25° C) was obtained (Philo et al., 1996).   
 
Native molecular weight estimations for unbound KITD1-D5 and unbound CSF-1RD1-D5, obtained 
by light scattering, indicated that they both are monomeric proteins in solution, and sedimentation 
equilibrium analysis on KITD1-D5 showed that it behaved as an ideal single monomeric species, with 
no appreciable self-association at concentrations up to about 18 µM (1 mg/ml) (Philo et al., 1996; 
Koths, 1997). 
 
It was further found, by SEC and equilibrium sedimentation, that glycosylated SCF, produced in 
CHO-cells, has a much lower affinity for KITD1-D5 then E. coli-derived SCF (590 nM vs 17 nM) 
(Philo et al., 1996). This observation was consistent with its lower in vitro biological activity 
compared to non-glycosylated SCF. These differences were shown to be caused particularly by 
glycosylation at Asn93 and at Asn65 and presumably represent steric effects of the glycosylation 
(Lu et al., 1992). This raises the awareness that glycosylation can strongly influence the strength of 
cytokine-receptor interactions. 
 
Almost no biophysical or structural data about the Flt3 ligand-receptor interaction is available in 
the scientific literature. Moreover, the recombinant production of Flt3D1-D5 or smaller ectodomain 
variants has never been reported. Thus, any assumptions about the molecular mechanism that 
underlies FL binding and receptor activation could only be made from structure-function studies on 
the homologous ligand-receptor complexes in the RTKIII family, and the closely related RTKV 
family. These studies will be discussed in the next section.   
In one report however, the affinity and kinetics of binding of human FL to an Flt3D1-D5-Fc fusion 
protein were analyzed by SPR. Recombinant FL from two different sources was compared: non-
glycosylated E. coli-derived FL and glycosylated FL produced in Baby Hamster Kidney (BHK)-
cells. The determined affinity for the E. coli-derived FL was 40 nM, with kon = 0.86 x 106 M-1s-1 and 
koff = 34 x 10-3 s-1. For glycosylated FL, a Kd value of 73 nM was obtained, with kon = 0.37 x 106 M-
1s-1 and koff = 25 x 10-3s-1 (Streeter et al., 2001). Thus both forms bind Flt3-Fc with high affinity, 
although mammalian-derived FL binds slightly weaker. In agreement with these affinity 
measurements, a significant difference in the biological activity between glycosylated and non-





Delineation of the ligand-binding epitope CSF-1R and KIT ectodomain  
In order to investigate which Ig-like domains in the CSF-1R ectodomain contribute to ligand 
binding, a series of domain-deletion mutants (Fig. 21) were produced in Sf9 insect cells. Their 
binding affinity to CSF-1 was analyzed by competitive plate-binding immunoassays in which         














From these experiments it was concluded that the first two N-terminal Ig-like domains do not 
interact with CSF-1 but, in combination with the third Ig-like domain, provide the high-affinity 
CSF-1 binding site. A construct that contained the fourth and fifth Ig-like domain, CSF-1RD4-D5 did 
not exhibit CSF-1 binding. 
Similar conclusions were drawn for the KIT:SCF interaction. By using human-mouse KIT 
interspecies chimera's and by mapping the binding epitope of antibodies that inhibited SCF binding, 
it was found that the SCF-binding site is contained in the first three N-terminal domains of KIT 
(Blechman et al., 1993a; Lev et al., 1993). Furthermore, cell-based competition binding-assays, 
employing recombinantly produced ectodomain variants, demonstrated that the third Ig-like domain 
is necessary for high-affinity binding (Blechman et al., 1993b).  
 
Probing the role of the membrane-proximal domains  
In SEC experiments with the KIT ectodomain there was no evidence for the formation of ligand-
receptor complexes in which only one receptor is bound to the ligand, even in the presence of a 
large excess of SCF. This indicated that receptor binding is positively cooperative and led to the 
hypothesis that the membrane-proximal domains (D4 and D5) might stabilize ligand-induced 
receptor dimers. By screening a series of monoclonal antibodies (mAb) directed against the KIT 
ectodomain that exerted little or no effect on ligand-binding, a mAb was identified that allowed 
SCF-binding but appeared to inhibit ligand-induced dimerization. When SCF was incubated with a 
KIT-expressing cell line, the presence of this antibody prevented chemical cross-linking of receptors 
 
FIGURE 21. CSF-1R domain deletion mutants. 
CSF-1R extracellular domain segments produced as soluble 
proteins in Sf9 insect cells in order to delineate the ligand-
binding epitope. The upper line of the diagram shows the 
predicted protein structural features of the murine CSF-1R 
extracellular domain with the cytoplasmic domain truncated 
just after the transmembrane (TM) region. The individual Ig-
domains are designated Dl to D5, and intradomain disulfide 
bonds along with all nine potential sites for N-linked 
carbohydrate addition (small branched structures) are 




although SCF was able to bind (Fig. 22A). Moreover, this antibody was unable to recognize 

























To map the binding epitope of this antibody several soluble and membrane-bound KIT mutants 
were generated (Fig. 22B). By co-immunoprecipitation experiments and cell-binding assays it was 
shown that the antibody bound to the fourth Ig-like domain. Further experiments showed that the 
antibody inhibited SCF-induced phosphorylation of KIT and a receptor mutant lacking domain 4 
was unable to signal. Based on these observations, it was proposed that the fourth Ig-like domain of 
KIT mediates homotypic receptor-receptor contacts and as such couples ligand binding to signal 
transduction.  
 
Subsequently, Lemmon and colleagues investigated the possible contribution of the membrane- 
proximal domains (D4 and D5) to the overall stability of KITD1-D5:SCF complex by biophysical 









   
FIGURE 22  
(A) mAb K27 allows SCF-binding but inhibits SCF-induced cross-linking to receptor dimers.  
Monolayers of murine fibroblasts that overexpress human KIT were incubated with radiolabeled SCF in the 
presence of the indicated concentrations of various mAbs to Kit. Ligand-receptor complexes were covalently cross-
linked with EDAC. Cell lysates were then analyzed by SDS-PAGE and the resulting autoradiograph is shown. 125I-
SCF, cross-linked to receptor monomers (M) and dimers (D) is indicated by arrows. It was concluded that mAb K27 
allows ligand binding but inhibits cross-linking to KIT dimers in a concentration dependent manner.  
(B) Epitope mapping of the mAb K27.   
Schematic representation of the various recombinant soluble and membrane KIT proteins - expressed in CHO-cells 
- used to map the binding of epitope of mAb K7. Cysteines and conserved tryptophan residues are indicated.  






(Fig. 23) it was found that KITD1-D3 dimerizes upon SCF binding in a manner indistinguishable from 
that seen with KITD1-D5. It is interesting to note that it was not possible to chemically cross-link the 
receptor fragments in the KITD1-D3:SCF complex. Consequently, Lemmon argumented that the 
inhibitory antibody used by Blechman and colleagues, which was specific for D4, most likely did 
not prevent the ligand-induced dimerization of KITD1-D5. The absence of cross-linked receptors was 
most likely the result of a differential availability of reactive functional groups (Lemmon et al., 















Since domains 4 and 5 do not contribute to the overall stability of the complex, it was concluded 
that KIT dimerization is primarily driven by the bivalent nature of its ligand. However, if bivalent 
binding of SCF were the only driving force for receptor dimerization, it should be possible to 
disrupt the KIT2:SCF dimer into monomeric KIT:SCF complexes by the addition of excess SCF. In 
the SEC experiments for both KITD1-D5 and KITD1-D3 the formation of such monomeric complexes 
upon the addition of excess SCF could not be detected. Hence, it was suggested that the 









FIGURE 23. Calorimetric analysis of the binding of SCF to KITD1-5 and KITD1-3. 
SCF binds to KITD1-D5 (left) with an affinity of 54.9 nM (with ΔH= -8.7 kcal/mol ), while for KITD1-D3 (right) the 
affinity was determined as 49.2 nM (with ΔH = -10.2 kcal/mol). The stoichiometry of both complexes is identical: 
one dimeric ligand binds two receptors. Binding is enthalpically driven and coupled to a small entropic penalty.  





Structure of the murine KITD1-D3:SCF complex 
A ternary complex formed between E. coli-derived murine SCF and KITD1-D3, produced in Sf9 
insect cells, yielded crystals that diffracted to 2.5 Å. To improve the crystal quality one of the three 
N-linked glycosylation sites present in KITD1-D3 had been removed by mutagenesis. The structure 
was phased by 'single isomorphous replacement with anomalous scattering' (SIRAS) from an iodide 


















The structure shows that each KITD1-D3 interacts with only one SCF, and no KIT:KIT interaction 
is observed (Fig. 24). Overall, about 2200 Å2 of solvent-accessible surface is buried between each 
protomer of SCF and KITD1-D3, which can be subdivided into 610 Å2 for site 1, the D1/SCF epitope, 
760 Å2 for site 2, the D2/SCF epitope, and 830 Å2 for site 3, the D3/SCF epitope. Consistent with 
thermodynamic data which showed that KIT:SCF binding is enthalpically driven, the KIT:SCF 
binding interface buries large areas of hydrophilic surface, with abundant salt bridges and hydrogen 
bonds. 
To assess any conformational changes that the ligand might undergo upon receptor binding, the 
X-ray structure of unbound murine SCF was determined (pdb 2O27). The unbound ligand showed a 
significant amount of surface regions disordered, including the N-terminal polypeptide chain (up to 
residue 11), the 92–104 loop and the 129–136 loop, as compared to the complexed form. The 
flexibility of these regions was also observed in free human SCF (pdb 1EXZ and pdb 1SCF). The 
disparity between the unbound and bound states suggested that the conformations of the N-terminal 
segment and the 92–104 loop of SCF are imposed by the receptor.  
FIGURE 24. Ternary assembly of the murine KITD1-D3:SCF complex (pdb 2O26). 
(A) Each KITD1-D3 fragment (orange and magenta) binds one SCF protomer (blue and green) and the receptor 
fragments do not interact. The 3 interaction sites, one for each Ig-domain in KITD1-D3 are indicated. N-linked 
carbohydrates are shown as green sticks. (B) Surface representation of the complex, showing how the KITD1-D3 






Based on the structural positions of the glycosylation sites in SCF, the authors argue that the 35-
fold lower binding affinity and lower biological activity of glycosylated SCF as compared to  E. coli 
derived-SCF (see higher) can be attributed to steric hindrance of the glycan chains. 
Since no receptor-receptor contacts are seen for KITD1-D3 it is difficult to rationalize a 
cooperative mode of binding as suggested by SEC experiments (Lemmon et al., 1997). However, as 
outlined above, the ligand undergoes a series of conformational changes upon receptor binding. It 
cannot be excluded that the binding of the first receptor to one SCF protomer is communicated to 
the second protomer to form a high-affinity receptor binding site. 
 
Structures of the human KITD1-D5 ectodomain and the KITD1-D5:SCF complex 
In 2007, Yuzawa and colleagues reported the crystal structures for the full length human KITD1-
D5 ectodomain alone, and in complex with its ligand SCF. KITD1-D5 was produced in Sf9 insect cells 
and crystals of the partially deglycosylated protein diffracted to 3.0 Å. The dataset was phased using 
a combination of multi-wavelength anomalous dispersion (MAD) and multiple isomorphous 
replacement with anomalous scattering (MIRAS) from K2Pt(NO2)4 and NaI derivatives. The 























FIGURE 25. Structure of the KITD1-5 ectodomain (pdb 2EC8) and SCF:KITD1-5 complex.  
The figure shows a comparison between the unbound KITD1-D5 ectodomain (pdb 2EC8, left) and the KITD1-D5:SCF 
complex (pdb 2E9W, right).  A SCF dimer interacts symmetrically with D1, D2, and D3 of two corresponding              
KITD1-D5. In addition, KIT ectodomains form homophylic interactions through lateral contacts between D4 (orange) 
and between D5 (pink) of two neighboring receptors. Note that D1, D2 and D3 adopt the same configuration in the 
unbound and SCF-bound state. N-linked carbohydrates are represented as sticks. The arrow marks the large cavity in 






Crystals of the ternary KITD1-D5:SCF complex diffracted to 3.5 Å and this structure was solved 
by molecular replacement (MR) using the structure of the KIT ectodomain and the previously 
determined structure of human SCF (pdb 1EXZ). The complex structure shows that domains 1 to 3 
wrap around one SCF protomer each, in a conformation similar to that seen in the murine            
KITD1-D3:SCF complex structure, while D4, and possibly D5, mediate homotypic receptor-receptor 
interactions (Fig. 25).  
The solvent accessible surface area buried at the interface between KITD1-D3 and each SCF 
protomer is approximately 2060 Å2. A comparison of unbound KITD1-D5 with SCF-bound KITD1-D5 
shows that domains 1 to 3 are superimposable with an RMSD of 1.1 Å for 274 aligned Cα residues 
of the D1-D3 region. Thus, KITD1-D3 can be considered as a functional unit that is poised for SCF 
binding. Its conformation is maintained by the D1-D2 and D2-D3 interdomain interface regions that 
bury a surface area of 1240 Å2 and 780 Å2, respectively.                                  
As was observed for free SCF in the murine KITD1-D3:SCF complex, several loop regions of 
human SCF - such as the N-terminal loop - undergo a conformational change upon receptor binding. 
In addition, in the full length KITD1-D5:SCF complex, an increase in the tilting angle of about 3° to 
9° between both SCF-protomers is observed when compared to the structures for unbound SCF 















In the transition from the unbound to bound state, the orientations of D4 and D5 undergo a large 
rearrangement accompanied by the formation of D4-D4 receptor-receptor interactions (Fig. 27A). 
This occurs by a rotation along an axis in the linker connecting D3 to D4 and a rotation along an 
axis in the linker connecting D4 to D5, running through the D3-D4 and D4-D5 interface 




FIGURE 26. The angle between the two SCF protomers is altered upon KIT binding. 
The view shows a cartoon diagram of free SCF (green) and SCF bound to KIT (magenta). Complex formation with  
KITD1-D5 results in an increase in tilting angle of about 5°. Note the different conformation at the N-terminal loop 














































    A                           B 
FIGURE 27. Domain 4 and 5 undergo a large conformational change upon ligand binding.         
(A)  The black outline shows the location of D4 and D5 in the KITD1-D5 ectodomain monomers. They are bridged by 
SCF binding to the ligand-binding region. Reconfiguration of D4 and D5 leads to a movement of the C termini of 
two neighboring ectodomains from 75 Å to 15 Å from each other. 
(B)  Superposition of D3 from the KITD1-D5 monomer with D3 of KITD1-D5 bound to SCF (both colored blue) shows that 
D4 of the bound form (red) moves by 22° relative to the position of D4 of the free form (green). Superposition 
(right panel) of D4 of the two forms (both in blue) shows that D5 of the SCF-bound form (red) moves by 27° 
relative to the positions of D5 of the free form (green). Adopted from Yuzawa et al., 2007. 
A     B 
FIGURE 28. Conservation of the dimerization motif in the RTKIII and RTKV family.  
(A)  A zoomed view on the pair of salt bridges that mediated the D4-D4 interactions in the SCF:KITD1-D5 complex. 
 The distances between interacting atoms (dashed lines) are indicated.  
(B)  These salt bridges and surrounding residues in the EF-loop are conserved in D4 or D7 of the other members of 




The KIT D4-D4 contacts are mediated by a pair of salt bridges that reside in the EF loop of D4 
(Fig. 28A). Structure-based sequence alignments indicated that a L/IxRΦxxxD/ExG dimerization 
motif is present in the EF loop of D4 of most type III RTKs, including CSF-1R, PDGF-Rα and 
PDGF-Rβ (Fig. 28B). However, this fingerprint is clearly absent in Flt3 (Appendix A). 
Surprisingly, the sequence motif is also found in the membrane-proximal Ig-like domain of all 
members of the type V RTKs. This lead to the hypothesis that receptor-receptor interactions similar 
to those seen in the D4-D4 interface of KIT will also take place through a similar D7-D7 interface in 
the VEGF receptors.  
 
In the KITD1-D5:SCF complex, the two copies of KITD5 are arranged in a parallel fashion. The 
adjacent domains D5 appear however to be too far separated from each other to allow direct 
contacts between side-chains. The authors speculated that any specific D5-D5 interactions could be 
water or metal ion mediated. However no such interactions could be detected in this area of weak 
electron density.  
The role of D4 homotypic contacts in receptor activation was investigated by site-directed 
mutagenesis (Fig. 29). It was found that SCF-induced phosphorylation of KIT was severely 
compromised by point mutations in the conserved residues Arg381 and Glu386 of the D4 
dimerization motif. These point mutants appeared to bind the ligand with similar affinity as the wild 
type receptor, as shown by a cell-based radio-displacement assay. These findings now also 
rationalized the activation-inhibiting effect of the antibody that was employed by Blechman and 


















FIGURE 29. Disruption of D4-D4 contacts compromises SCF-induced phosphorylation. 
3T3 cells stably expressing wild-type KIT (WT) or the R381A mutant were treated with different concentrations of SCF. 
Lysates from unstimulated or SCF-stimulated cells were subjected to immunoprecipitation with anti-KIT antibodies 
followed by  SDS-PAGE and immunoblotting with anti-KIT or anti-p-Tyr antibodies. By cell-based displacement assays 
using 125I-SCF, it was shown that the R381A mutant bound the ligand with similar affinity as the wild-type receptor. 

















Earlier structure-function studies on KIT had already demonstrated that domains 4 and 5 are not 
necessary for ligand-induced receptor dimerization (Lemmon et al., 1997). In other words, KIT 
dimerization is primarily driven by the bivalent nature of the ligand. Thus, rather than playing a role 
in receptor dimerization, homotypic D4, and possibly homotypic D5 interactions between 
neighboring receptors are required for the precise positioning of the membrane-proximal regions at 
a distance and orientation that enable interactions between their cytoplasmic domains resulting in 
tyrosine kinase activation. The binding affinities of D4 toward D4 and D5 toward D5 are probably 
too low to facilitate KIT ectodomain dimerization before the local receptor concentration on the cell 
surface is increased by SCF-driven dimerization and by the effect of their restricted spatial 
confinement (Fig. 30) (Yuzawa et al., 2007).  
 
 
Structure of the murine CSF-1RD1-3 :CSF-1 complex 
 
Crystals of the complex formed between murine CSF-1 and CSF-1RD1-D3 (both expressed in Sf9 
insect cells) diffracted to 2.4 Å resolution. Prior the crystallization, the C-terminal His-tags were 
removed by carboxypeptidase A. The structure (Fig. 31A) was solved by MR using the previously 
determined structure of human CSF-1 (pdb 1HMC, Pandit et al., 1992). After rebuilding and 
refinement of the murine CSF-1, ensuing density modification protocols, using the phases of the 
partial solution,  revealed discernible density for domain 3 and at later stages, for domains 1 and 2 
(Chen et al., 2008). 
Remarkably, the structure shows that only one CSF-1RD1-D3 receptor is bound by the dimeric 
ligand, although the crystallization mixture contained more than a two-fold molar excess of receptor 
to ensure the formation of a full dimeric complex (Fig. 31B). This observation was however 
supported by ITC binding data, which showed that, in solution, the murine CSF-1RD1-D3 fragment 
only forms a 1:1 complex with CSF-1 (Kd = 455 nM), whereas the full length ectodomain                 
CSF-1RD1-D5 forms a 2:1 complex with much higher affinity (Kd = 9.0 nM). The existence of a 
stable 1:1 complex suggests that the binding affinity at the second CSF-1 binding site is 
FIGURE 30. Activation mechanism of KIT.  
Binding of SCF to preformed binding sites on KIT  
contributed by Ig-domains 1 to 3, leads to KIT 
dimerization. This assembly facilitates the formation 
of homotypic receptor-receptor contacts between D4 
and D5, that consequently orient the tyrosine kinase 
domains in a signaling competent state.  





significantly lower than at the first site, possibly resulting from conformational changes imposed by 
the binding at the first site. Although there exists a wide array of side chain conformational 
differences between the occupied and the unoccupied CSF-1 protomers, the main chain 
conformation seems rigid. Hence, the structure of the complex does not provide a clear mechanism 





























The binding data reported by Chen and co-workers, are however in direct and sharp contrast 
with ITC data for the CSF-1R:CSF-1 complex obtained by Elegheert and colleagues (Elegheert et 
al., in preparation). They showed that both murine and human CSF-1RD1-D3 (produced in 
HEK293T-cells) form dimeric complexes with their E. coli-derived ligands, with an affinity of             
348 nM and 213 nM, respectively. For the full length murine and human CSF-1RD1-D5:CSF-1 
FIGURE 31. Structure of the murine CSF-1RD1-3:CSF-1 complex (pdb 3EJJ). 
(A) Ribbon representation of the complex, with the CSF-1 (a.k.a. M-CSF) protomers in green and blue, and the            
CSF-1R (a.k.a. FMS) D1, D2, and D3 domains in orange, pink, and purple, respectively. The two N-linked 
glycans attached to FMS are depicted as sticks.  
(B) Surface representation of a completed, dimeric complex in which the absent copy of CSF-1RD1–3 is modeled, based 
on the 2-fold symmetry between the CSF-1 protomers.  
(C) The different modes of ligand recognition between CSF-1R and KIT as revealed by a comparison between                 
the CSF-1D1-D3:CSF-1(left) and KITD1-D3:SCF(right) complexes. For clarity only one pair of receptor and ligand 
from each complex is shown. The ligands are in the same orientation.  
(D) Superposition of CSF-1RD1-D2 and KITD1-D2 showing that D1 and D2 form an integral, rigid module. 







complexes, an affinity of 22 nM and 13.6 nM, respectively,  was determined. Moreover, structural 
models calculated from small-angle X-ray scattering (SAXS) data also indicate that both murine and 
human CSF-1RD1-D3 and CSF-1RD1-D5 form ternary complexes in solution. The origin of the different 
behavior of the CSF-1D1-D3 complexes in both groups is currently unknown. It seems, however, that 
D4 and D5 of CSF-1R play a more important role in stabilizing the complex as compared with the 
KIT system.   
 
The CSF-1RD1-D3:CSF-1 structure further shows that the CSF-1R:CSF-1 interaction is 
dramatically different from the KIT:SCF binding mode. CSF-1 is bound only by Ig-like domains 2 
and 3 of the receptor, while KIT binds SCF in a wrapping fashion, with all three of the first domains 
interacting with SCF. Furthermore, CSF-1RD2 and KITD2 use opposite sides of the Ig-like domain 
for binding.  
 A total surface area of 1740 Å2 is buried between CSF-1 and CSF-1RD1-D3, which can be divided 
into 900 Å2 for site 1 (D2) and 840 Å2 for site 2 (D3) (Fig. 31A). The ligand-receptor interface is 
mostly hydrophilic, with salt bridges and hydrogen-bounds outnumbering hydrophobic contacts. A 
total of surface area of 1240 Å2 is buried at the CSF-1R D1-D2 interface, and D1 and D2 apparently 
adopt the same relative conformation as KIT D1-D2 (Fig. 31D). Thus D1-D2 can be considered a 
structural unit that is differently orientated in both complexes, mediated by a rotation around the 
D2-D3 linker (Fig. 31C). The CSF-1R D2-D3 interface itself is minimal, with few interactions 
between D2 and D3. Without the binding of CSF-1, the D2-D3 junction likely has hinge flexibility. 
 The relative orientation of D3 to the helical bundle cytokine is conserved between KIT and 
CSF-1R. In both complexes, the DE loops and the BC loops of D3 are used to contact the N-
terminal segment of their ligand. There is, however, no similarity in the pattern of hydrogen bonds 
and van der Waals interactions between the two complexes.  
 
Function of the CSF-1R membrane-proximal domains 
As outlined above, the dimerization motif found in the KITD4 is conserved in CSF-1R. Low-
resolution structural studies for the human CSF-1RD1-D5:CSF-1 complex by small-angle X-ray 
scattering (SAXS) and negative-stain electron microscopy showed that homotypic interactions 
mediated by the fourth Ig-like domain are indeed present. Furthermore, the CSF-1R-D5 domains 
point away from each other (Elegheert et al., in preparation). Interestingly, mutations in the CSF-
1R that lead to its ligand-independent activation are localized to fourth Ig-domain (Carlberg and 
Rohrschneider, 1994). It is possible that the activating effects of these mutations are caused by 








Structure-function studies on PDGF ligand-receptor complexes 
Structure of the PDGF-RβD1-3:PDGF-BB complex 
Early binding studies, employing domain deletion mutants of the PDGF-Rα and PDGF-Rβ 
receptors, had shown that receptor domains 2 and 3 are sufficient for the high-affinity binding of 
their respective ligands (Lokker et al., 1997). Recently, the crystal structure of the ternary complex 
between PDGF-BB and PDGF-RβD1-D3 has been reported (Shim et al., 2010). PDGF-BB and PDGF 
-RβD1-D3 were co-expressed in HEK293S GnTI-/- cells, and following purification, the complex was 
glycan minimized using endoglycosidase F1 and treated with carboxypeptidase A. This protocol 
yielded crystals of the complex that diffracted to 2.3 Å resolution. The structure was solved by MR 
using the previously determined structure of PDGF-BB  (pdb 1PDG, Oefner et al., 1992) and D2 of 
VEGF-R1 (pdb 1FLT, Wiesmann et al., 1997). After refinement of the partial model, NCS-averaged 



















The structure (Fig. 32) shows that each receptor molecule interacts with both ligand molecules. 
PDGF-BB binds in the cleft between D2 and D3 and the resulting interface buries 2870 Å2 of 
solvent-accessible surface area. D1 points away from the ligand and is not involved in ligand 
binding. The D1-D2 interface buries 1060 Å2 and the bent conformation between D1 and D2 is 
similar among PDGF-RβD1-D2 and KITD1-D2 or CSF-1RD1-D2. The D2–D3 junction of PDGF-Rs, with 
little direct interactions between D2 and D3, appears to be prone to hinge flexibility when the ligand 
is absent.  
 
FIGURE 32. Structure of the PDGF-RβD1-3:PDGF-BB complex (pdb 3MJG).  
Side view of the ribbon model of the complex with the PDGF-BB protomers in green and blue, and the PDGF-Rβ 
receptors in pink and orange. The N-linked glycans attached to PDGF-Rβ are depicted as sticks.  






Function of the PDGFR membrane-proximal domains 
The residues that form the pair of salt bridges that mediate homotypic contacts between the 
domains 4 of KIT are conserved in the PDGF-R receptors. Earlier studies had already indicated that 
PDGF-RD4 has an important role in signaling. Two groups  identified a monoclonal anti-D4 
antibody that allowed ligand binding but inhibited activation of the PDGF-Rβ receptor (Lokker et 
al., 1997; Shulman et al., 1997) and, studies on the activation mechanism for PDGF-Rα, which has 
a sequence identity of 30% with the PDGF-Rβ receptor, showed that a soluble D4-GST fusion 
protein acted as a receptor antagonist (Omura et al., 1997).  
 
Yang et al. showed that PDGF-Rβ receptors harboring point mutations in the D4 dimerization 
motif bound the PDGF-BB ligand with equal affinity but their ligand-induced activation was 
severely affected as compared to the wild-type receptor. Cross-linking studies showed that these 
mutant receptors are dimerized by the ligand at the cell surface, thereby proving that these point 
mutations do not affect the ligand-induced dimerization (Yang et al., 2008). These findings 
indicated that the fourth Ig-like domain of the PDGF-R receptors couples ligand-binding to receptor 
activation in a similar way as D4 of the homologous KIT complex.  
 
Structure-function studies on VEGF:VEGF-R ligand-receptor complexes 
Structure of the VEGF-R1D2:VEGF and VEGF-R1D2 :PlGF complexes 
Similar to the findings for the PDGF-Rα/β receptors, binding studies with VEGF-R1 and 
domain deletion mutants showed that the second and third Ig-like domains are sufficient for high-
affinity VEGF-A binding (Barleon et al., 1997; Davis-Smyth et al., 1996; Fuh et al., 1998). 
Ensuing, the high-resolution X-ray structures of VEGF-R1D2 in complex with VEGF-A (Wiesmann 
et al., 1997) and PlGF (Christinger et al., 2004) were reported. Non-glycosylated forms of VEGF-
R1D2, VEGF-A and PlGF were produced in E. coli as inclusion bodies and refolded in vitro. The 
structures for these minimal ligand-receptor complexes were solved by MR using the available 
ligand-structures and showed that two copies of VEGF-R1D2 bind symmetrically to the distal ends 











FIGURE 33. Superposition of the PlGF:VEGF-R1D2 and VEGF-A:VEGF-R1D2 complexes.  
The PlGF homodimer (2.5 Å resolution, pdb 1RV6) is shown in orange and wheat and its bound VEGF-R1D2  receptor 
domains in green. The VEGF-A:VEGF-R1D2 complex (1.7 Å resolution, pdb 1FLT) is shown in blue. Adopted from 





Structure of the VEGF-R2D23:VEGF-C complex 
Recently, the X-ray structure for VEGF-R2D23 in complex with VEGF-C was reported           
(Fig. 34) (Leppänen et al., 2010). VEGF-C and a VEGF-R2D23-Fc fusion protein were both 
produced in Sf9 insect cells.  After complex formation and purification with protein-A affinity 
chromatography, the Fc fragment was proteolytically removed. The resulting complex crystals 


















A comparison of the VEGF-R2D23:VEGF-C and the VEGF-R1D2:VEGF-A and                   
VEGF-R1D2:PlGF structures shows that VEGF-R1 and VEGF-R2 utilize the same D2 interface for 
ligand binding. The buried surface area at the VEGF-R2D23:VEGF-C interface is around 1300 Å2. It 
is noteworthy that the conformation of VEGF-R2D2-3 and Kit receptor domains 2 and 3 is 
structurally very similar despite the fact that the ligands are structurally dissimilar (Leppänen et al., 
2010).  
 
Function of the membrane-proximal domains in the VEGF receptors 
In RTKIII members, the evolutionarily conserved dimerization motif is present in D4. Sequence 
analysis showed that this sequence fingerprint is present in D7 of all three VEGF receptors of the 
RTKV family (Yuzawa et al., 2007). A negative-stain electron microscopy study for the isolated 
VEGF-R2D1-7:VEGF-A complex showed that the membrane-proximal domains D7, and possibly 
D4, mediate homotypic receptor-receptor interactions (Fig. 35). Complexes formed between VEGF-
A and a mutant VEGF-R2 ectodomain in which D7 was replaced by D6, did not reveal these well 
defined conformations, suggesting that D7 mediates specific contacts (Ruch et al., 2007).  
 
FIGURE 34.  Structure of the VEGF-R2D23:VEGF-C complex (pdb 2X1W).  
The VEGF-C homodimer is shown in orange and green, and the two VEGF-R2D23 receptor chains are colored in light 
blue. The sugar moieties and the disulfide bonds are shown as purple and yellow sticks, respectively.  










































To further investigate the role of homotypic receptor contacts in VEGF-R2 activation, a 
mutagenesis study was carried out. It was found that receptors with single point mutations in the 
FIGURE 35. Ligand binding of VEGF-R2 promotes dimerization of membrane-proximal regions.  
(A)  Class averages (top) and graphic representations (bottom) of the monomeric VEGF-R2 ectodomain in complex 
 with VEGF. Scale bar, 15 nm.  
(B)  Proposed model for the instigation of intracellular signaling upon VEGF binding to VEGF-R.  
 Adopted from Ruch et al., 2007 
FIGURE 36. VEGF-R D7-D7 interactions are crucial for ligand-induced activation. 
(A)  3T3 cells stably expressing a VEGF-R2-PDGF-Rβ chimeric receptor (composed of the ectodomain of VEGF-R2 
 connected to the TM and the cytoplasmic region of PDGF-R) or chimeric receptors harboring mutations in D7 
 region (R726A, D731A, or an R726/D731 double mutation designated RD/2A) were stimulated with VEGF-A. 
 Lysates from unstimulated or stimulated cells were subjected to immunoprecipitation with antibodies against the 
 cytoplasmic region of the chimeric receptor followed by immunoblotting with either anti-pTyr or anti-FLAG 
 antibodies, respectively. 
(B)  Cross-linking experiments with the disuccinimidyl suberate (DSS) showed that the R726/D731 mutations do not 
 effect VEGF-A-induced receptor dimerization at the cell surface. Adopted from Yang et al., 2010. 
   





dimerization motif in D7 showed a severely compromised ligand-induced activation as compared to 
the wild-type receptor (Fig. 36A). Cross-linking studies showed that these mutations did not affect 
ligand-induced dimerization (Fig. 36B). On the other hand, mutations in the EF-loop of D4, which 
contains a sequence related to the dimerization motif in D7, did not affect receptor activation (Yang 
et al., 2010). This suggests that interactions in the EF-loop of VEGF-R2D4 are not necessary for 
signaling. It remains however possible that D4-D4 interactions, as suggested by the negative-stain 
EM class averages, are mediated by another region of D4. 
 
Yang et al. also produced the isolated VEGF-R2D7 by refolding from inclusion bodies. Crystals 
were formed which diffracted to 2.7 Å, and the structure was solved by MR. Surprisingly, although 
D7 behaved monomeric in solution, it crystallized as a dimeric assembly. The structure shows how 
two VEGF-R2D7 domains interact in a way very similar as the D4 interaction in the KITD1-D5:SCF 
complex (Fig. 37A). The position of the EF loop in the two structures is nearly identical, and the 
distance between the C-termini is approximately 15 Å for both D4 and D7 dimeric structures (Fig. 
37B) (Yang et al., 2010). The high similarity between VEGF-R2D7 and KITD4 in both structure and 
function suggests a well-conserved mechanism for RTK activation and provides further evidence for 



















Subsequently, the self-association behavior of the isolated domain D7 of VEGR-R2 was studied 
by equilibrium sedimentation. It was found that it remained monomeric in solution at concentrations 
as high as 160 µM (1.9 mg/mL). Similar experiments with isolated D4 or D5 of the KIT or PDGF-R 
 
 
FIGURE 37. Structure of VEGF-R2D7 homodimer (pdb 3KVQ). 
(A)  A ribbon diagram and a transparent molecular surface of the D7 homodimer structure. Asp731 and Arg726  are 
 shown as sticks.  
(B)  View of the superimposed VEGF-R2D7 and KITD4 regions reveals a high similarity in domain arrangement and 
 homotypic contacts. D7 of VEGF-R2 is colored in green and its EF loop in yellow, while D4 of KIT is colored in 
 gray with its EF loop is in orange. Adopted from Yang et al., 2010. 
 





receptors led to the same observation. These experiments led to the conclusion that homotypic 
receptor-receptor interactions are inherently weak. It is hypothesized, however, that the reduced 
dimensionality at cell surface would enable the formation of stable homotypic contacts. Moreover, 
the homotypic contacts between membrane-proximal Ig-like domains in type-III and type-V RTKs 
are possibly supported by additional lateral interactions that take place between the TM and 
cytoplasmic regions of neighboring receptors (Yang et al., 2010). 
 
Role of the transmembrane helices in receptor activation 
 
In RTKs, the extracellular ligand-binding domain is connected to the intracellular kinase domain 
by a single transmembrane (TM)-spanning α-helix of about 20 amino acid residues. These helices 
are however not just passive membrane anchors. A variety of studies on different RTKs indicate that 
lateral helix-helix interactions play a critical role in RTK signaling. This view is also supported by 
the large number of pathogenic point mutations identified in the TM-domains of many different 
RTKs (Li and Hristova, 2006).  
Biophysical studies on isolated TM-domains by techniques as SDS-PAGE, equilibrium 
sedimentation and Förster resonance energy transfer (FRET) (Merzlyakov and Hristova, 2008; You 
et al., 2005) have shown that the TM-domains of various RTKs have a weak or strong dimerization 
capacity, both in micelles and detergents (Oates et al., 2009; Li et al., 2005). Furthermore, in a 
recent systematic study, employing the E. coli-based TOXCAT-assay (Russ and Engelman, 1999), 
Finger and coworkers demonstrated that the TM-domains of all 58 human RTKs have an intrinsic 
propensity to dimerize and accordingly suggested that all RTK TM-helices encode self-interactions 
(Finger et al., 2009).  
TM-domain dimerization is believed to be mediated by specific motifs present within the 
helices. For example the GxxxG motif, as seen in the NMR-structure for glycophorin A (MacKenzie 
et al., 1997), appears to frequently mediate and stabilize TM helix-helix interactions in membranes 
and is present in many RTKs (Sternberg and Gullick, 1990). Another dimerization motif, the 
leucine-zipper, is predicted to stabilize interhelical interactions in the PDGF-Rβ (Oates et al., 2009) 
and DDR1 receptors (Noordeen et al., 2006). Furthermore, motifs involving other small residues 
(such as Ala, Ser, or Thr) can also mediate and stabilize defined TM helix-helix interactions. Small 
residues are believed to allow two helices to come into close contact so that other forces, such as 
van der Waals interactions and hydrogen bonding, can stabilize a given TM-helix bundle (Finger et 
al., 2009). The determination of more high-resolution NMR-structures, like those for the dimeric 
ErbB2, EphA1 (Fig. 38) and EphA2 TM-domains (Bocharov et al., 2008a; Bocharov et al., 2008b; 
Bocharov et al., 2010) will provide more insights on the mechanisms and diversity of RTK TM-






















Studies with non-native TM-helices showed that dimerization of the TM-domain (TMD) is not 
enough to drive the activation of the kinase domain. Bell and colleagues engineered ErbB2 receptor 
constructs (with or without the extracellular region) to carry artificial transmembrane domains 
which are dimerized by a pair of glutamic acid residues. These TMDs consisted of 23 valine and 
two glutamic acid residues, spaced 7 residues apart in different positions of the transmembrane 
helix. All of these 'TM-shift' mutants gave rise to membrane-bound protein dimers but only proteins 
dimerized by distinct TM-domains were active. The authors concluded that such activating TMDs 
must adopt a specific conformation that allows trans-activation of the kinase domains.  Similar 
experiments for the RTKIII receptors, PDGF-Rβ and VEGF-R2, led to the same conclusion (Bell et 
al., 2000; Dosch and Ballmer-Hofer, 2010). Furthermore, when a non-activating but dimerizing 
TM-variant was introduced in the full length VEGF-R2 receptor, this completely blocked ligand-
induced phosphorylation. On the other hand, activating TM-peptides caused phosphorylation of the 
receptor, both in the presence or absence of the ligand. These experiments further highlight the need 
for a correct orientation of the TM-domains in order to activate the kinase domains.  
 
In many RTKs - including the RTKIII and RTKV family members - the juxtamembrane domain 
has an autoinhibitory function on the kinase activity (see further). It is hypothesized that the specific 
orientation of the 'activating' TM-helices allows productive interactions between the opposing 
juxtamembrane domains that relieves this autoinhibition and consequently, the tyrosine kinase 
domains are activated (Fig. 39) (Stuttfeld and Ballmer-Hofer, 2009).  
 
 
FIGURE 38. Spatial structure of the EphA1-TM dimer.  
Ensemble of 12 NMR-derived structures of the EphA1-TM dimer obtained by solution NMR in lipid bicelles. Side 
chain and backbone heavy atom bonds are shown in gray and black, respectively. EphA1 transmembrane segments 
associate in a right-handed parallel-helical bundle, through the N-terminal glycine zipper motif AX3GX3G.  




















For RTKs that exist as dimers in the absence of ligand, ligand-binding may initiate TM-domain 
interactions or a rearrangement of a preformed TM dimer - which may have multiple dimerization 
motifs - that finally results in the active conformation of the intracellular domains (Fleishman et al., 
2002).  
 
For the VEGF-R2 receptor it was also shown that the full length membrane-bound wild-type 
receptor is monomeric, while constructs that lack the ectodomain have a tendency to dimerize. This 
effect is possibly mediated by repulsive interactions between the ectodomains (Dosch and Ballmer-
Hofer, 2010). Remarkably, Tao and colleagues found that VEGF-R2 mutants in which the 
membrane proximal domains are deleted are constitutively phosphorylated (Tao et al., 2001).  
Repulsive interactions between receptor ectodomains in the absence of the ligand have also been 
proposed for the FGF-R3 receptor (Chen et al., 2010).  
 
It is believed that oncogenic mutations in the TM-region stabilize the active conformation of the 
TM-helices by the formation of specific, mutant amino-acid mediated contacts such a as hydrogen 
bonds, cation-Π interactions or disulfide bonds. For example, it was shown by FRET that the 
pathogenic mutation Ala391Glu found in the TM-domain of the FGF-R3 stabilizes the formation of 
dimers with a change in free energy of dimerization of 1,3 kcal/mol, in agreement with the 
hypothesis of the formation of a hydrogen bond (Fig. 40) (Li et al., 2006). This seemingly modest 
value was calculated to have a significant effect on the monomer-dimer equilibrium. It should be 
noted that it is very difficult to observe these interactions directly since high-resolution NMR-




FIGURE 39. Schematic representation of the activation mechanism of VEGF-Rs. 
A covalently linked VEGF dimer (green) binds to VEGF-R (blue) leading to dimerization of two receptor monomers. 
Additional interactions between Ig-like domains 4 and 7, the transmembrane domains, and the juxtamembrane 
domains (dark blue) stabilize the VEGF-VEGF-R-complex resulting in kinase activation and autophosphorylation of 


















From a variety of studies it has become clear that in many RTKs lateral interactions between 
TM-helices are required to activate the tyrosine kinase domains. The necessity for these interactions 
could be exploited to develop peptide-based therapeutics that mimic the TM-helix and interfere with 
its self-association. A proof-of-concept study in human cell lines on the EGF and ErbB2 receptors 
showed that peptides encompassing the native TM-helix can indeed specifically inhibit the signaling 















FIGURE 40. Molecular model of the wild-type and mutant TM domain dimer of FGFR3. 
Contacts between the two helices are mediated by residues Leu377, Val381, Phe384, and Ile387. The side-chains of 
one helix (blue) pack against the side-chains of the other helix (purple). Ala391 (shown in yellow), which is mutated 
to Glu in Crouzon syndrome with acanthosis nigricans and cancer, faces the dimer interface. A model for the putative 
hydrogen bond between Glu391 (yellow) and Ile387 (pink) in the mutant dimer is shown on the right.  






Tyrosine kinase activation  
 
Activation by trans-autophosphorylation 
Binding of the cognate ligand to the extracellular domains of RTKs induces the formation of a 
dimeric assembly in which the adjacent intracellular kinase domains become activated in a process 
termed trans-autophosphorylation (Fig. 41). The first step in this process is the trans-
phosphorylation of key tyrosine residues located in regulatory regions of the kinase domain. Once 
these are phosphorylated the TKD adopts its fully active form and can phosphorylate additional 
tyrosine residues in its sequence. These phosphotyrosine residues act then as 'beacons' which attract 
signaling proteins that contain Src homology-2 (SH2) or phosphotyrosine-binding (PTB) domains 














The so-called activation loop is a key structural element in the regulation of catalytic activity. 
This polypeptide segment, which is approximately 20–25 residues long, usually contains 1 to 3 
tyrosine phosphorylation sites. This segment contributes residues both for catalysis and for 
substrate-peptide binding and exists in two conformational states. When the activation loop is not 
phosphorylated, it is not positioned optimally for phosphoryl transfer. It is believed that 
FIGURE 41.  General mechanism of RTK activation. 
(A) In the absence of ligand, the tyrosine kinase domain is inactive through the inhibitory interactions of the 
 juxtamembrane region (orange) and/or the carboxy-terminal tail (blue) with the kinase domain. In addition, the 
 activation segment (yellow) is not optimally positioned for catalysis.  
(B)  After ligand (pink)-mediated dimerization of the extracellular domain (blue), the cytoplasmic domains are 
 juxtaposed, which facilitates the trans phosphorylation of tyrosine residues (shown as circles) in the 
 juxtamembrane region, activation segment and carboxy-terminal tail. 
(C) After phosphorylation and reconfiguration of the inhibitory segments, the kinase domains become fully active 
 (green) and a subset of phosphotyrosines (black spheres) are available as recruitment sites for proteins that 
 contain SH2- or PTB-domains.  





phosphorylation of the activation segment in trans, by the other receptor in the ligand-stabilized 
dimer, is accompanied by a conformational change that secures the segment in a catalytically 
competent configuration. The precise mechanism by which a productive receptor dimer results in 
the stimulation of tyrosine kinase activity is however not completely understood and could differ 
among receptor subclasses. One possibility is that the ligand-stabilized dimer merely results in an 
increase in the substrate concentration (that is, the other receptor) for efficient trans- 
phosphorylation within the dimer. In addition to facilitating transphosphorylation, dimerization 
might also stabilize a direct physical interaction between the two cytoplasmic domains, which is 
stimulatory for catalytic activity. Recent structural studies suggest that asymmetric TKD dimer 
formation is a common phenomenon, critical for the activation and autophosphorylation of RTKs 
(Bae and Schlessinger, 2010).  
In many RTKs, regions other than the activation loop also contribute to autoinhibition and 
activation, namely the juxtamembrane (JM) region and the carboxy-terminal tail. These regions 
often contain tyrosine residues and they can both function as recruitment sites for downstream 
signaling proteins and, in some receptors, as a means of regulating catalytic activity. Many 
oncogenic mutations in RTKs disrupt these autoinhibitory mechanisms and cause constitutive 
signaling of the receptor. 
 
Autoinhibition and activation of the Flt3 tyrosine kinase domain 
In 2004, Griffith and colleagues determined the X-ray structure of the Flt3 TKD in its inactive, 
unphosphorylated state. The structure provided the molecular basis for the mechanism of Flt3 
autoinhibition by the JM-domain and explains the activating effect of oncogenic mutations found in 
this region (Griffith et al., 2004). 
 
The authors crystallized a recombinant form of the cytoplasmic region of Flt3 (residues 564-
993), expressed in High-5 insect cells, that lacked the kinase insert domain. The resulting crystals 
diffracted to a resolution of 2.1 Å and the structure (pdb 1RJB) was solved by MR using the 
previously determined structure of the VEGF-R2 TKD. A small region of the JM-domain that forms 
the linker with the TM-helix (residues 564-571), the linker between the tyrosine kinase lobes and 












Autoinhibited Flt3 adopts the typical kinase fold with an N- and C-terminal lobe (Fig. 42). The 
activation loop is located near the active site between the two kinase lobes and is folded in a 















The structure further shows that the first residues of the JM-domain which are visible in the 
electron density (residues 572 to 578) are buried in the TKD and directly interact with some of the 
active site residues. Extending from this region, the JM-domain folds into a two-stranded β-twist 
(residues 579 to 592) and then continues to connect with the N-lobe of the TKD (residues 593 to 
603). 
 
A comparison with the structures of activated tyrosine kinases showed that when the activation 
loop would adopt its active conformation it would structurally coincide with the N-terminal region 
of the juxtamembrane domain. Thus, this conformation of the JM-domain autoinhibits the tyrosine 
kinase by sterically hindering the activation loop from adopting is active conformation. Note, that 
the inactive conformation of the activation loop is stabilized by tyrosine 842 (Fig. 42). 
 
FIGURE 42. Structure of the autoinhibited Flt3 tyrosine kinase domain (pdb 1RJB).  
Cartoon representation of the Flt3 TKD in its autoinhibited state. The N-terminal region of the JM-region (orange) 
occupies the active site, formed between the N- (blue) and C-lobes (green) of the TKD. The activation loop (red) 
adopts its inactive conformation. Regulatory tyrosine residues are labeled and shown as sticks. The N-terminus (N) 
corresponds to the first residue of the JM-region that was visible in the electron density (Tyr-572).  






The JM-domain contains several structurally important tyrosine residues (Tyr-572, Tyr-589, 
Tyr-591 and Tyr-599) which are hydrogen bonded to the kinase domain, and are thought to stabilize 
its observed autoinhibitory conformation. It is believed that once these tyrosine residues are 
phosphorylated, the JM-region would no longer be able to fold properly and position itself next to 
the C-lobe, and as a consequence the activation loop would be able to adopt its active conformation. 
The sequence and the structurally important tyrosine residues of the Flt3 JM-region are well 
conserved throughout the RTKIII family (Fig. 43), indicating that the mechanism of autoinhibition 
is conserved as well. The later determined crystal structures of the autoinhibited KIT and CSF-1R 
TKDs showed that their JM-regions essentially adopt the same conformation as seen in the Flt3 
structure (Mol et al., 2004; Walter et al., 2007). Although autoinhibition by the JM-region is not a 
general mechanism, the JM-region plays a key role in the inhibition and activation process of 












Although these structural studies provided valuable insights into autoinhibitory mechanism, they 
do not explain the precise process of trans-autophosphorylation and the order in which tyrosine 
residues need to be phosphorylated to transform the inactive kinase into its fully active form. 
Activation loop tyrosine trans-phosphorylation is generally thought to regulate kinase activation of 
RTKs but may play different roles in different RTKs (Huse and Kuriyan, 2002). Phosphopeptide 
mapping of KIT revealed that only the tyrosine residues in the JM-region contribute to kinase 
activation. It was found that the single tyrosine residue in the activation loop of KIT is not 
phosphorylated until very late in the activation process (DiNitto et al., 2010). Similar to the findings 
 
FIGURE 43.  Conservation of the juxtamembrane region in the RTKIII family. 
Sequence alignment of the JM-domain for FLT3, PDGF-Rα, PDGF-Rβ, KIT, and CSF-1R. Identical (green) and 
homologous (orange) residues are highlighted. In the Flt3 structure, the JM-Binding region (JM-B, residues 572-578) 
occupies that active site, the JM-switch region (JM-S, residues 579-592) forms the β-twist motif and the JM-zipper 
region (JM-Z) links the JM-domain with the N-lobe of the TK domain. The asterisks below PDGF-R indicate the 





for the KIT receptor, Razumovskaya and colleagues reported that phosphorylation of tyrosine 842 in 
the activation loop of Flt3 is not required for activation (Razumovskaya et al., 2009). The fact that 
phosphorylation of the Flt3 JM-region is critical for activation is also supported by the observation 
that a Tyr589Phe-mutant cannot be activated (Kiyoi et al., 1998). 
Oncogenic mutations in Flt3 
Oncogenic mutations in the Flt3 gene have been found to be the most common genetic 
abnormality in acute myelogenous leukemia (AML) (Stirewalt and Radich, 2003). AML is one of 
the most common leukemias in adults, and its incidence increases with age. Although AML is a 
relatively rare disease, it accounts for approximately 10.000 cancer deaths per year in the United 
States alone (Jemal et al., 2010). AML is characterized by a rapid expansion of myeloid white blood 
cancer cells, which compete against and block the function of normal bone marrow cells. The 
standard treatment regimen is conventional chemotherapy combined with, depending on the subtype 
diagnosis, hematopoietic stem cell transplantation (Chan, 2011).  
Several types of oncogenic Flt3 mutations can be discerned. Internal-tandem duplications (ITD) 
in the JM-region (residues 563-603) are present in 25% to 30% of adult AML patients. These 
duplications range from 4 to about 68 amino acid residues, are always in frame and limited to the 
JM-region (Nakao et al., 1996; Thiede et al., 2002). The DNA sequence that encodes residues 593 
to 602 is partially palindromic and it is believed that when a hairpin structure would be formed in 
the lagging strand during DNA replication an FLT3/ITD would be generated by replication slippage 
(Fig. 44) (Kiyoi et al., 1998). Additionally, activating point mutations in the Flt3 JM-domain have 


















FIGURE 44. Internal tandem duplications in Flt3  
(a)   ITDs in Flt3 cluster around residues Y597-Y599.  
(b) Proposed mechanism for the generation of FLT3-ITD. Single-strand DNA corresponding to D593 to K602 
potentially forms a palindromic intermediate. If this occurs in the lagging strand during DNA replication, FLT3-
ITD would be generated by replication slippage.  




It is hypothesized that these mutations in the JM-region make the autoinhibition mechanism 
leaky by disturbing the inhibitory conformation of the JM-domain. Numerous naturally occurring 
mutations (typically deletions) also exist in the JM-regions of the KIT and PDGF-Rα receptor and 
give rise to gastrointestinal stromal tumors (GISTs) (Heinrich et al., 2003; Hirota et al., 1998). 
However, ITDs in the JM-domain of KIT and CSF-1R are not found (Zheng et al., 2004a).   
 
In vitro transduction studies showed that Flt3-ITDs promote ligand-independent dimerization, 
auto-phosphorylation and constitutive activation of the receptor (Kiyoi et al., 1998). Kiyoi and 
colleagues further investigated the mechanism of these activating ITDs. When wild-type (WT) Flt3 
and a construct containing an ITD but lacking the complete TKD were co-expressed in IL3-
dependent 32D cells, this resulted in factor-independent proliferation (Fig. 45). It was further shown 
that WT-Flt3 and ITD-5'/JM-myc formed a heterocomplex and that WT-Flt3 was constitutively 
phosphorylated. When WT-Flt3 was co-expressed with a similar variant that contained the wild-
type JM-domain, WT-Flt3 was not activated and no heterocomplex was formed. These experiments 













A second class of activating mutations found in Flt3 are point mutations in the activation loop. 
These account for about 7% of AML cases. The most common nucleotide substitution 
(GAT→TAT) changes an aspartic acid to tyrosine (D835Y). Other mutations in codon 835, such as 
deletions, have also been described, but these are far less common. These mutations likely promote 
the active conformation of the activation loop (Stirewalt and Radich, 2003). 
 
Recently, a high-throughput screening study, in which the entire Flt3 coding sequence in AML 
patients was sequenced, led to the discovery of a novel oncogenic mutation in the extracellular 
region (S451F). This mutation is located in the membrane-proximal domain 5 and causes 
constitutive signaling in the absence of FL. It probably accounts for < 1% of AML cases (Fröhling 
et al., 2007). 
FIGURE 45. ITD-JM mutation are transactivating. 
When Wt-Flt3 and ITD-5'/JM-myc were co-transfected in IL3-dependent 32D cells this resulted in constitutive 
receptor activation and factor-independent proliferation. By co-immunoprecipitation it was show that both constructs 
physically interact. On the other hand, co-transfection of Wt-Flt3 with Wt/JM-myc did not result in receptor activation 






Activation of wild-type Flt3 is also believed to be involved in the process of leukemogenesis 
since Flt3 is expressed at high levels in 70 - 100 % of AML blasts cells (Carow et al., 1995; Peng et 
al., 2008). Zheng and colleagues proposed that the activation of wild-type receptor is caused by 
autocrine signaling loops, since FL was found to be co-expressed with its receptor in the large 
majority of primary AML samples that were analyzed (Zheng et al., 2004b). Another possible 
mechanism is that an increase in Flt3 expression levels raises the basal signaling rate. 
     Aberrant Flt3 signaling usually confers a poor prognosis (Chillon et al., 2004; Pemmaraju et al., 
2011). Several small molecule FLT3-tyrosine kinase inhibitors have been developed and examined 
in AML patients as single agents or in combination with chemotherapy. These clinical trials gave 
promising results but are however variable due to the occurrence of primary and secondary 
resistance (Kancha et al., 2007; Kindler et al., 2010; Parcells et al., 2006).  
 
Recently, it was found that FL serum levels dramatically increase in AML patients that are 
treated with chemotherapy in combination with the FLT3 inhibitor lestaurtinib. Subsequent in vitro 
studies showed that the FL concentrations found in these patients mitigate the inhibition and 
cytotoxicity of various Flt3 inhibitors. These findings could have important implications regarding 
the design and outcome of trials of FLT3 inhibitors, and furthermore suggest a rationale for 
targeting FL as a therapeutic strategy (Sato et al., 2011). 
 
An alternative approach, which employs a monoclonal antibody (IMC-EB10) directed against 
the Flt3 ectodomain, is currently being investigated in a phase 1 clinical trial (Youssoufian et al., 
2010). This antibody inhibits FL-stimulated proliferation of the WT-Flt3 expressing leukemic cell 
line, EOL-1 and, the ligand-independent proliferation of BaF3-Flt3/ITD cells. In both EOL-1 
xenograft and BaF3-Flt3/ITD leukemia models, treatment with IMC-EB10 significantly prolongs 
the survival of leukemia-bearing mice. IMC-EB10 binds to Flt3 with an affinity of 158 pM and 
blocks the binding of FL. Besides preventing FL binding, the antibody possibly mediates the 
internalization and degradation of cell-surface Flt3 (Li et al., 2004). 
Phosphorylation sites in wild-type and oncogenic Flt3 
In total, the intracellular region of Flt3 contains 23 tyrosine residues. Six are located in the JM-
region, one in the activation loop, two in the kinase insert domain, two in the C-terminal tail and the 
remaining twelve are located in the N- and C-lobes of the tyrosine kinase domain. It is instructive to 
note that most of the known tyrosine phosphorylation sites in RTKs reside outside the kinase 
domains (with exception of the activation loop tyrosines and some other rare cases) (Heldin et al., 





The phosphorylation sites in wild-type Flt3 and in the oncogenic Flt3-ITD and Flt3-D835Y 
mutants were identified by Razumovskaya and colleagues. They employed a panel of specific anti-
phosphotyrosine antibodies that were raised against a set of synthetic phosphotyrosine-peptides 














The sites of autophosphorylation in the wild-type receptor are: Tyr589, Tyr591 and Tyr599 in 
the JM-region, Tyr726 and Tyr768 in the kinase insert region, Tyr793 in the C-lobe, and Tyr955 in 
the C-terminal tail (Fig. 46). The phosphorylation of Tyr842 in the activation loop is apparently not 
required for the activation of the kinase.  
Some sites were found to be activated in a similar fashion, whereas other sites were activated 
selectively either by the Flt3-ITD or the Flt3-D835Y mutant. For example only in the activation 
loop mutant, D835Y, tyrosine residue 842 becomes phosphorylated. The use of different 
phosphorylation sites may result in the differential recruitment and activation of downstream 





FIGURE 46. Phosphorylation sites in wild-type and oncogenic Flt3. 
Schematic picture of the wild-type Flt3, Flt3-ITD, and FLT3-D835Y and their phosphorylation sites. The size 






Flt3 signal transduction pathway  
FL-mediated activation of the Flt3 receptor induces the autophosphorylation of specific tyrosine 
residues which act then as recruitment sites for various signal transducing proteins that contain Src 
Homology-2 (SH2) domains (Fig. 47). Subsequently, these signaling proteins themselves become 
activated - by a conformational change upon binding or by tyrosine phosphorylation by Flt3 - and 
activate other downstream proteins or molecules that are involved in pathways connected with 






















The two main Flt3 signaling routes are the PI3K–PKB/Akt and the Ras–Raf–MAPK/ERK 
pathways. Flt3-mediated PI3K activation induces the transcription of crucial regulatory genes and 
blocks apoptosis by phosphorylation of the Bcl-2 family protein Bad. Unlike the murine Flt3 
receptor, human Flt3 does not have a PI3K binding site but activates the PI3K indirectly (Zhang and 
Broxmeyer, 1999). The stimulation of the Ras–Raf–MAPK/ERK pathway results in the 
transcription of genes involved in cell proliferation (Zhang and Broxmeyer, 2000; Stirewalt et al., 
2003a; Parcells et al., 2006). Signaling is down-regulated by the rapid internalization and 




FIGURE 47. Activated Flt3 recruits various SH2-containing signal transducing molecules.  
Ligand binding causes receptor dimerization and phosphorylation of regulatory tyrosine residues.  Phospho-tyrosines 
then act as docking sites for SH2 domains of a variety of signal transduction proteins. STAT5: signal transducer and 
activator of transcription 5 SRC: Src-family tyrosine kinase; PI3K:  phosphatidylinositol 3-kinase; PKB: protein 
kinase B (AKT); GRB2: Growth factor receptor-bound protein 2; ERK: extracellular signal-regulated kinase (MAPK); 




Different groups have observed that FLT3-ITD activates STAT5 and its downstream effectors, 
whereas ligand-stimulated wild-type FLT3 does not. It was shown that phospho-Tyr-589 and 
phospho-Tyr-591, both located in the JM-domain are the docking sites for STAT5. Thus, the 
disruption of the JM-region by ITDs allows the binding and ensuing phosphorylation of the STAT5 
transcription factor (Choudhary et al., 2007; Rocnik et al., 2006). That wild-type and mutant 
receptors can trigger different signaling pathways has also been observed for other receptors 
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Flt3 ligand (FL) is an early-acting hematopoietic cytokine that stimulates the proliferation 
and differentiation of hematopoietic progenitor cells by activating its cognate receptor, Flt3. 
Recently, FL was shown to potently contribute to the development and expansion of antigen-
presenting dendritic cells and CD34+ natural killer cell progenitors in vivo. Here, we report a 
comprehensive method for the production of bioactive recombinant human FL (rhFL) in E. coli, 
suitable for structural, biophysical and physiological studies. A soluble form of human FL capable 
of binding to the Flt3 receptor could be overexpressed in the E. coli strain Rosetta-gami(DE3) as 
inclusion bodies. We have established protocols for the efficient in vitro refolding and ensuing 
purification of rhFL to homogeneity (>95%), with yields approaching 5 mg of pure rhFL per liter of 
culture. The ability of rhFL to adopt a bioactive conformation was confirmed via a cell-proliferation 
assay and the activation of the Flt3 receptor in the human leukemic cell line, OCI-AML3.  





Hematopoiesis, the making of blood cells, is an exquisitely regulated process in which 
progenitor cells originating from a self-renewing population of hematopoietic stem cells (HSC) are 
directed to proliferate and differentiate. The development of HSCs and subsequent cell progenies is 
largely orchestrated by the synergistic activity of soluble and cell-bound hematopoietic growth 
factors which bind to the extracellular domains of their cognate receptors at the cell surface to 
initiate appropriate intracellular signaling pathways (Bryder et al., 2006; Li and Li, 2006; Metcalf, 
2007; Ross and Li, 2006). 
Flt3 ligand (FL) stimulates early hematopoiesis by activating the Fms-like tyrosine kinase 3 
(Flt3) receptor, which is expressed on a variety of early hematopoietic precursors in the bone 
marrow (Lyman and Jacobsen, 1998; Matthews et al., 1991). As is the case for many cytokines, the 
hematopoietic effects of FL are most pronounced when acting in synergy with other growth factors 
such as interleukin 3 (IL-3), stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating 
factor (M-CSF) (Chklovskaia et al., 2004; Hudak et al., 1995; Shah et al., 1996; Wodnar-
Filipowicz, 2003). In recent years an ever growing body of evidence has linked FL to the 
development, expansion and mobilization of antigen-presenting dendritic cells, thus prompting the 
emergence of recombinant FL as a promising player in cancer immunotherapy (Antonysamy and 
Thomson, 2000; Dong et al., 2002; Fong et al., 2001; Karsunky et al., 2003; Wu and Liu, 2007). 
Other in vivo effects of recombinant FL include the mobilization of hematopoietic progenitors to the 
peripheral circulation (Papayannopoulou et al., 1997), and the protection and increased recovery of 
the hematopoietic system following irradiation (Gratwohl et al., 1998).  
The search for the ligand of the Flt3 receptor led to the cloning of FL cDNA which was shown 
to code for a type I membrane protein consisting of 235 amino acid residues (Lyman et al., 1993a; 
Lyman et al., 1993b; Hannum et al., 1994) . In contrast to the limited tissue distribution of the Flt3 
receptor, FL is ubiquitously expressed both in hematopoietic and non-hematopoietic tissues. Yet the 
presentation of FL protein at the cell surface is rather limited due to a cytokine-specific, regulatory 
retention mechanism (Chklovskaia et al., 1999). Mature human FL lacks the first 26 amino acid 
residues which constitute the signal peptide. The extracellular domain is therefore defined by 156 
amino acid residues harboring the receptor-binding epitope, and is followed by a 23 amino acid 
transmembrane helix and a 30 amino acid cytoplasmic tail. 
 The biologically active extracellular domain of FL exhibits a non-covalently linked 
homodimeric structure in which two short-chain four-helical bundles, each with three 
intramolecular disulfide bridges, interact head-to-head (Graddis et al., 1998; Savvides et al., 2000). 
In mice and humans soluble, bioactive forms of FL can be generated by proteolytic cleavage of the 




two other hematopoietic cytokines: SCF and M-CSF. Together, these three growth factors constitute 
a unique subset of helical-bundle cytokines that activate receptor tyrosine kinase type III receptors 
from the platelet-derived growth factor receptor (PDGF-R) family, which groups receptors targeted 
by cystine-knot growth factors such as PDGF and vascular endothelial growth factor (VEGF) 
(Savvides et al., 2000).  
Constitutive Flt3 signaling, caused by the overexpression of the wild type receptor or the 
expression of oncogenic forms of the Flt3 receptor has been linked to a number of hematopoietic 
malignancies. In fact, Flt3 mutations are the most frequent genetic alterations in acute myelogenous 
leukemia (AML) and indicate a poor prognosis (Gilliland and Griffin, 2002; Kiyoi et al., 2005; 
Stirewalt et al., 2003b). Furthermore, FL has been suggested to play a role in leukemogenesis by an 
autocrine signaling loop mechanism (Zheng et al., 2004b). Strategies aimed to tackle constitutive 
Flt3 signaling include the development of specific small molecule tyrosine kinase inhibitors 
(Kancha et al., 2007; Schmidt-Arras et al., 2004) and more recently, therapeutic monoclonal 
antibodies (Sternberg and Licht, 2005). Gaining insights into how FL triggers Flt3 activation could 
lead to novel strategies to treat leukemias such as AML, and to the design of agonist molecules that 
could facilitate the ex vivo and in vivo expansion of hematopoietic progenitors.                                            
We have launched an interdisciplinary research initiative aiming to elucidate the kinetic, 
thermodynamic and structural determinants of Flt3 activation by FL. To meet the high demands of 
the underlying experimental methods for the individual proteins, we have developed a cost-effective 
and efficient method for the production of milligram quantities of bioactive recombinant human FL 
(rhFL) in E. coli. To our knowledge, our work constitutes the first comprehensive protocol for the 
production of rhFL in a prokaryotic host, and complements the previously reported production of 
glycosylated rhFL in the methylotrophic yeast Pichia pastoris (Zhang et al., 2005).  
 
MATERIALS AND METHODS 
 
Plasmid Construction and Expression of Recombinant Human FL in E. coli 
A cDNA clone containing the full-length human Flt3 ligand cDNA (Clone ID 
IRALp962K2428Q) was obtained from IMAGENES (Berlin, Germany). The fragment encoding 
residues 1-134 was PCR amplified with Easy-A HiFi Polymerase (Stratagene, La Jolla, CA, USA). 
The forward primer (5’ cgatgacatatgacccaggactgctccttc 3’) carried the NdeI restriction site 
(underlined) and the reverse primer (5’ caggatccttagggctgacactgcagctc 3’) contained a stop codon, 
immediately followed by the BamHI restriction site (underlined). The PCR was performed using the 
following conditions: denaturation for 1 min at 95° C, annealing for 1 min at 55° C and extension 
for 2 min at 72° C for 30 cycles and a final extension step for 10 min at 72° C. The resulting PCR 
product was purified using the Qiaquick Gel Extraction KIT (Qiagen, Hilden, Germany) and ligated 
into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA), creating pCR2.1-rhFL. 
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Subsequently, pCR2.1-rhFL was digested with NdeI/BamHI and the gel-purified rhFL fragment 
was ligated into NdeI/BamHI cut pET15b vector (Novagen, Madison, WI, USA), using T4 DNA 
ligase (Promega, Madison, WI, USA). The resulting expression construct was verified by 















pET15b-rhFL was used to transform the Rosetta-gami(DE3) strain (Novagen) which carries the 
chloramphenicol-selectable pRARE plasmid. Expression cultures were grown at 37° C in Luria-
Bertani medium, containing 100 µg mL-1 carbenicillin and 34 µg mL-1 chloramphenicol. Expression 
of rhFL was induced at a culture OD600 of 0.6, by the addition of isopropyl-β-D-
thiogalactopyranoside (ITPG) to a final concentration of 1 mM, after which the culture was allowed 
to grow for an additional 4 h. The levels of recombinant protein expression were markedly lower 
when the culture was allowed to grow for longer periods of time. The bacteria were harvested by 
centrifugation (6,000 g for 20 min at 4° C) and the cellular paste was stored at -80° C.  
 
Isolation of rhFL Inclusion Bodies and Purification of rhFL Under 
Denaturing Conditions  
The bacterial pellet was thawed and resuspended in lysis buffer: 50 mM Tris pH 8.0, 100 mM 
NaCl, 1% Triton X-100, 1 mM EDTA, 0.2 mM PMSF and 1x Complete protease inhibitor mix 
(Roche Diagnostics, Mannheim, Germany). The cells were lysed by sonication on a 250-D Branson 
sonifier (total run time of 4 min with 30 s pulses at 30% output interspersed with 30 s of down 
time). Cell debris and inclusion bodies were isolated by centrifugation at 4° C (20,000g for 30 min). 
The inclusion bodies were subsequently washed twice based on the following protocol: the pellet 
containing the inclusion bodies was solubilized in lysis buffer and sonicated for 30 s at 30% output. 
FIGURE 1. rhFL expression-plasmid and 
protein sequence.  
The human FL cDNA, encoding residues 1–134 of 
the mature human FL protein was cloned between the 
NdeI and BamHI sites of the pET15b vector. This 
cloning strategy allows the expression of rhFL as a 
fusion protein with a cleavable N-terminal 
hexahistidine tag. The thrombin recognition sequence 
is underlined and the thrombin cleavage site is 
indicated with an arrow. Amp: ampicillin resistance 






The suspension was incubated on a ‘head-over-head’ shaker for 30 min followed by centrifugation 
at 4° C (20,000g for 30 min) to harvest the pellet containing the inclusion bodies.  
The washed inclusion bodies were solubilized in urea buffer (8 M urea, 100 mM NaPO4, 10 mM 
Tris, 10 mM β-mercaptoethanol, pH 8.0) by gentle rotation in a ‘head-over-head’ shaker at room 
temperature for 2 h. Insoluble material was removed by high speed centrifugation at 4° C (100,000g 
for 30 min). The clarified supernatant was loaded onto a Ni-Sepharose 6 FF (GE Healthcare) 
column, equilibrated with urea buffer, pH 8.0. Next, the column was washed with five column 
volumes (CV) of urea buffer at pH 6.3 and pH 5.8. Denatured rhFL was eluted with five CV urea 
buffer at pH 4.5 and neutralized with Tris pH 8.0. The total amount of rhFL was estimated based on 
the absorbance of the sample at 280 nm and a calculated extinction coefficient of 19,855 M-1 cm-1.  
 
In vitro Refolding of rhFL and Purification of Refolded rhFL 
Denatured rhFL was added drop wise to refolding buffer (100 mM Tris, pH 8.5, 1 M L-arginine, 
5 mM GSH, 0.5 mM GSSG and 0.2 mM PMSF) at 4° C under rapid mixing, to a final protein 
concentration of 0.1 mg mL-1. The refolding mixture was gently stirred overnight and was 
subsequently dialyzed against 20 mM Tris pH 8.0, 300 mM NaCl, 0.2 mM PMSF. Aggregates were 
removed by high speed centrifugation and the clarified refolding mixture was loaded onto a                   
Ni Sepharose 6 FF column, equilibrated with 50 mM NaPO4, 300 mM NaCl, pH 8.0. Refolded rhFL 
was eluted with equilibration buffer containing 500 mM imidazole. 
To remove the N-terminal His-tag, the protein solution was desalted into phosphate-buffered 
saline (PBS) (10 mM NaPO4, 150 mM NaCl, pH 7.0) and consequently incubated overnight at room 
temperature with one unit of biotinylated thrombin (Novagen) per milligram rhFL. The progress of 
proteolytic cleavage was monitored by SDS–PAGE. Biotinylated thrombin was removed using 
streptavidin-agarose (Novagen), following the manufacturer’s recommendations. Thrombin-treated 
rhFL was subsequently injected onto a Prep-Grade HiLoad 16/60 Superdex 75 column                         
(GE Healthcare, Buckinghamshire, UK) connected to an ÄKTAPurifier system (GE Healthcare), 
equilibrated with PBS. The fractions corresponding to rhFL were pooled and diluted into cation-
exchange running buffer (20 mM MES pH 6.0), to give a final NaCl concentration of 25 mM. The 
protein sample was loaded onto a MonoS HR 5/5 column (GE Healthcare) connected to an ÄKTA 
explorer system. rhFL was eluted using a linear gradient from 0 to 1 M NaCl. Finally, to assess the 
correct removal of the His-tag, the digested protein was subjected to N-terminal sequence analysis 
by automated Edman degradation performed on a model 476A pulsed liquid protein sequencer 
(Applied Biosystems, Foster City, CA, USA).  
To confirm the quaternary structure of refolded, purified rhFL analytical gel filtration was 
carried out on a Superdex-200 PC3.2 column, connected to an Ettan LC system (GE Healthcare) 
with PBS as running buffer. The gel filtration columns were calibrated with an equimolar mixture of 
ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa), ribonuclease (13.7 kDa) and aprotinin (6.5 kDa).  
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Far-UV Circular Dichroism (CD)  
Analysis CD spectra were recorded at 25° C on a Jasco J-600 spectropolarimeter (Jasco, Tokyo, 
Japan). Samples containing 0.3 mg mL-1 of rhFL in PBS buffer were analyzed using a 1 mm path 
length quartz cell. Spectra were recorded from 195 to 250 nm with 0.5 nm resolution, at                         
20 nm min-1, with a response time of 4 s and a bandwidth of 1 nm. Data analysis was based on five 
averaged measurements after subtracting the buffer contribution. 
 
ESI-MS 
Purified, refolded rhFL was desalted using ZipTip pipette tips (Millipore). Trifluoroacetic acid 
(TFA) was added to the sample to a final concentration of 0.1%. A 10 µL ZipTip was wetted with 
100% acetonitrile and equilibrated with 0.1% TFA. After binding the sample, the tip was washed 
with 0.1% TFA. The protein was eluted with 1% formic acid/50% acetonitrile. ESI-MS spectra 




OCI-AML3 and THP-1 cells are monocytic human leukemic cell lines and were purchased from 
the German Collection of Microorganisms and Cell Cultures (DSMZ) (Braunschweig, Germany). 
OCI-AML3 cells were cultured in alpha-MEM with nucleosides (Gibco, Karlsruhe, Germany) and 
THP-1 cells were cultured in RPMI-1640 (Gibco, Karlsruhe, Germany), with both media 
supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (Gibco, Karlsruhe, Germany) 
and 1% (v/v) Penicillin/Streptomycin (PAA Laboratories, Pasching, Austria) at 37° C and 5% CO2, 
in a humidified atmosphere. As a positive control, rhFL produced in insect cells was purchased 
from R&D Systems (Minneapolis, MN, USA).  
 
Cell Proliferation Assay 
The proliferation behavior of cells was assessed using the CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay kit from Promega (Madison, WI, USA) according to manufacturer‘s 
recommendations. In brief, 5,000 cells were seeded per well of a 96-well-plate in medium with                  
1% FCS (starvation medium) with or without the addition of rhFL and cultured for 70 h at 37° C 
and 5% CO2, in a humidified atmosphere. After adding the CellTiter 96® aqueous one solution 
reagent, cells were incubated for further 2 h at 37° C and 5% CO2. Absorbance was recorded at 450 
nm in an Anthos htll spectrometer (Anthos Labtec Instruments, Wals, Austria). Each experiment 








Mouse monoclonal anti-phosphoFLT3 antibody, rabbit polyclonal anti phospho-MEK1/2 
antibody, and mouse monoclonal anti-MEK1/2 antibody were purchased from Cell Signaling 
Technology (Danvers, MA, USA). Mouse monoclonal anti-human FLT3 antibody was purchased 
from R&D Systems. A mouse monoclonal anti-GAPDH antibody was purchased from Abcam 
(Cambridge, UK).  
 
Protein Extraction and Western Blot Analysis  
Cells were lysed in lysis buffer (10 mM Tris/HCl pH 7.5, 130 mM sodium chloride, 5 mM 
EDTA pH 8.0, 1% Triton-X 100, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 20 mM 
disodium hydrogenphosphate, 20 mM sodium dihydrogen phosphate, 1 mM sodium orthovanadate, 
1 mM glycerol phosphate) supplemented with protease inhibitor cocktail from Roche Diagnostics 
(Mannheim, Germany) and 10 mM AEBSF-Hydrochloride (AppliChem, Darmstadt, Germany).           
30 µg of total protein in 2X sample buffer (100 mM Tris pH 6.8, 200 mM DTT, 4% SDS,                  
0,05% bromophenol blue, 20% glycerol) were separated on reducing SDS–PAGE (8%) gels and 
transferred to PVDF membranes. Western blot analysis was performed with indicated antibodies 
followed by horse raddish peroxidase-conjugated anti-mouse IgG antibody or horse raddish 
peroxidase-conjugated anti-rabbit IgG antibody, and detection was performed with enhanced 




SDS–PAGE analysis was performed according to Laemmli (Laemmli, 1970) using 15% 
polyacrylamide gels. Samples were mixed with an equal amount of 2X sample buffer (125 mM 
Tris–HCl, pH 6.8, 20% glycerol, 4% SDS, 0.005% bromophenol blue, and 10% of                                    




Overexpression of rhFL in E. coli 
The human Flt3 ligand (hFL) cDNA, encoding residues 1–134 of the hFL ectodomain was 
cloned between the NdeI and BamHI sites of the pET15b vector. This vector allows high-level 
expression of recombinant proteins under control of the inducible T7 promoter (Fig. 1). Our cloning 
strategy focused on expressing rhFL as a fusion protein with a cleavable hexahistidine tag at the N-
terminus, to facilitate purification (Fig. 1). Expression of rhFL in the Rosetta-gami(DE3) strain 
(Fig. 2, Lanes 2, 3) resulted in clear production of rhFL after induction with IPTG, which was 
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further confirmed by peptide mass fingerprinting (PMF) (results not shown). The Rosetta-
gami(DE3) strain carries the chloramphenicol-selectable pRARE plasmid that encodes for five extra 
tRNAs which correct for eukaryotic codon bias. Interestingly, expression of rhFL could not be 
obtained in the BL21-CodonPlus(DE3)-RIL and BL21-CodonPlus(DE3)-RP strains, which also 
contain plasmids that encode for extra tRNAs. As is often the case for eukaryotic proteins expressed 
in E. coli, rhFL was produced as inclusion bodies. An exploration of a variety of culture growth 
parameters such as growth temperature and the inducer (IPTG) concentration failed to result in the 




FIGURE 2. SDS–PAGE analysis of expression and purification of rhFL. 
The predicted  molecular weights for reduced His-tagged and thrombin-treated rhFL are 17.738 and 15.856 kDa, 
respectively. Lane 1: protein standards; Lane 2: bacterial cell lysate before induction; Lane 3: bacterial lysate at 4 h 
post-induction; Lane 4: washed IB; Lane 5: solubilized IB; Lane 6: Eluate from Ni-sepharose column at pH 4.5 under 
denaturing conditions; Lane 7: Capture of refolded rhFL on Ni-sepharose column; Lane 8: rhFL after removal of the 
His-tag by thrombin-digestion; Lane 9: Eluate from MonoS ion-exchange column. 
 
In vitro Refolding and Purification of rhFL 
The cells were lysed by sonication and cell debris and inclusion bodies (IB) were separated from 
the soluble fraction by centrifugation. To remove hydrophobically associated proteins, the IB were 
washed with buffer containing Triton X-100. Subsequently, the IB were solubilized under reducing 
conditions in 8 M urea. Material that could not be solubilized was removed by high speed 
centrifugation and the supernatant was loaded onto a Ni-Sepharose column. rhFL was eluted using a 
stepwise pH gradient (Fig. 2, Lanes 4–6). The cytokine was refolded overnight, at 4° C by the drop-
wise addition of denatured rhFL to a refolding buffer containing a GSH:GSSG redox couple. The 
inclusion of 1 M arginine in the refolding buffer greatly improved the refolding efficiency (data not 
shown). Prior to the His-tag capture step of the refolded protein, arginine was removed by dialysis 
because it is not compatible with IMAC (immobilized metal affinity chromatography) matrices. 




using biotinylated thrombin. Complete digestion was confirmed by SDS–PAGE (Fig. 2, Lane 7, 8). 
Thrombin was efficiently removed using streptavidine-agarose beads.  
N-terminal sequence analysis identified the first seven residues as GSHMTQD which 
demonstrates that the fusion protein was correctly processed by thrombin (Fig. 1). rhFL was further 
purified using gel filtration and cation exchange chromatography (Fig. 3). The final purity of rhFL 
was estimated to be 99% on basis of Coomassie stained SDS–PAGE gel (Fig. 2, Lane 9). The 
protein yield across the different stages of the purification process is summarized in Table I. 
 
FIGURE 3. Cation exchange purification of refolded rhFL. 





Table I.  Efficiency of purification of rhFL from inclusion bodies 
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Protein Characterization and Bioactivity Assays 
The homogeneity of purified, refolded rhFL was demonstrated by ESI-MS (Fig. 4). The 
determined molecular weight was 15,849.92 ± 0.51 kDa, which is very close to the theoretical 
molecular weight of rhFL (15,850.2 kDa). Far-UV CD spectra showed that the refolded cytokine 
had a high α-helical content (Fig. 5), and analytical gel filtration experiments on a calibrated 
column using proteins of known molecular weight demonstrated that the refolded protein possessed 





















FIGURE 4. ESI-MS of refolded, purified rhFL.  
The experimentally determined molecular weight of 15,849.92 ± 0.51 kDa agrees well with the  



































FIGURE 5.  Far UV-CD spectrum of refolded, purified rhFL.  







FIGURE 6. Analytical gel-filtration on refolded, purified rhFL. 
The elution volume corresponds well to the molecular weight of dimeric rhFL (31,7 kDa), indicating that the refolded 
cytokine possesses the correct quaternary structure. The elution volumes and molecular weight of the protein standards 








The biological activity of the refolded cytokine was tested using the human leukemic cell lines 
OCI-AML3 (Wang et al., 1989) and THP-1 (Tsuchiya et al., 1980), which express the wild type 
Flt3 receptor (Quentmeier et al., 2003) and proliferate in response to FL (Dehmel et al., 1996; 
Drexler et al., 1999). Our rhFL strongly stimulated the proliferation of both cell lines. rhFL-
dependent phosphorylation of the Flt3 receptor and the downstream signaling molecule MEK, were 
monitored by Western blot analysis. Data for the OCI-AML3 cell line are shown in Fig. 7. Similar 















FIGURE 7. OCI-AML3 proliferation assay and Western blot analysis.  
(A) rhFL stimulates the proliferation of the leukemic cell line, OCI-AML3 which expresses the wild type Flt3 receptor. 
Each experiment was performed in triplicate and three independent experiments were done. (B) rhFL induces 
phosphorylation of Flt3 and its downstream target, MEK.  Commercially available rhFL, produced in insect cells, was 
used as a positive control. GAPDH shows equal loading of the cell lysates. His-tagged rhFL showed the same 
bioactivity as tag-free rhFL. 
 
His-tagged rhFL exhibited the same bioactivity as tag-free rhFL. The two bands of the Flt3 
receptor in the immunoblot represent two different Flt3 receptor species: (1) a faster migrating, 
mannose-rich, immature form; and a slower migrating, cell-surface expressed, complex sugar-type 
form (Lyman et al., 1993a; Lyman et al., 1993b; Maroc et al., 1993). Notably, the anti-
phosphoFLT3 antibody recognizes both FLT3 species: the high-mannose form of the protein is 
detected under every condition tested, whereas the complex glycosylated form is detected only after 
addition of exogenous rhFL. We propose that the intracellular high mannose form of FLT3 might be 
constitutively phosphorylated in a ligand independent manner, like in FLT3-ITD (Schmidt-Arras et 
al., 2005), whereas the complex glycosylated form at the cell surface becomes phosphorylated only 









A detailed method for the production of human glycosylated Flt3 ligand in the methylotrophic 
yeast P. pastoris system has been reported previously (Zhang et al., 2005). Remarkably, however, 
the production of recombinant hFL via more conventional expression systems, such as E. coli, is 
inadequately described in the scientific literature. We have successfully overexpressed the 
extracellular domain of hFL (residues 1–134) capable of activating the Flt3 receptor (Escobar et al., 
1998), in the E. coli Rosetta-gami(DE3) strain. Interestingly, expression of rhFL could not be 
obtained in the BL21-CodonPlus(DE3)-RIL and BL21-CodonPlus(DE3)-RP strains, despite the fact 
that they all, like the Rosetta-gami(DE3) strain, contain plasmids that encode for extra tRNAs. This 
highlights the need for testing protein expression in a variety of cell strains, especially when one 
tries to express eukaryotic proteins in prokaryotic expressions systems. An initial exploration of 
expression conditions indicated that rhFL consistently ended up in the insoluble fraction which 
suggested the formation of inclusion bodies. We therefore focused our efforts on maximizing the 
yield of rhFL inclusion bodies and in developing efficient protocols for the in vitro refolding and 
ensuing purification of rhFL.  
One of the greatest challenges underlying the in vitro refolding of proteins that contain 
disulfide-bridges in their native state, is the correct matching of the relevant cysteine residues 
during the folding process. In our construct of rhFL we expected three disulfide bridges per subunit 
(Cys4-Cys85, Cys44-Cys127, Cys93-Cys132). To facilitate disulfide-bridge formation we used the 
GSH:GSSG redox couple and maintained the refolding buffer at an alkaline pH (Singh and Panda, 
2005). Importantly, we found that the inclusion of 1 M arginine in the refolding buffer dramatically 
improved the yields of refolded protein from about 1 mg per liter of culture to a final yield of 5 mg 
of pure rhFL. The role of arginine in protein refolding has been the subject of extensive 
investigation in recent years. It is currently accepted that arginine serves to suppress protein 
aggregation during refolding, rather than to facilitate the refolding process (Arakawa and Tsumoto, 
2003; Singh and Panda, 2005). The established purification protocols for rhFL feature three 
standard chromatographic steps which can be readily adapted for the large scale purification of 
rhFL. Indeed, one of the advantages of expression systems based on E. coli is the relative ease with 
which protein production can be scaled up.  
We have sought to confirm the bioactivity of rhFL using a cell-proliferation assay and the 
activation of the Flt3 receptor in the human leukemic cell lines OCI-AML3 and THP-1 which 
express the wild-type Flt3 receptor. This activity-benchmarking is essential before a recombinant 
protein can be used for cellular, physiological, and biophysical studies. We have shown that rhFL 
produced in E. coli is at least as active as commercially available rhFL produced as a glycoprotein 
in insect cells (Fig. 7). rhFL decorated with N- and O-linked glycans produced in yeast (P. pastoris) 
has also been shown to be sufficiently bioactive (Zhang et al., 2005). The levels of bioactivity we 
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have observed for unglycosylated rhFL produced in a bacterial host, indicate that glycosylation is 
not important for receptor binding and activation, at least in vitro. Furthermore, the bioactivity of 
rhFL carrying an N-terminal His-tag exhibits proliferative and signaling activity that is for all 
practical purposes indistinguishable from tag-free rhFL. The availability of His-tagged bioactive 
rhFL may indeed prove an important tool in biochemical and cellular assays. For instance, one may 
use rhFL immobilized on a Ni-NTA matrix to trap FL-Flt3 complexes, or in SPR experiments to 
study ligand–receptor interactions.  
In this report, we have described a comprehensive, cost-effective and efficient method leading 
to the production of milligram amounts of highly active recombinant hFL in E. coli. Our methods 
respond to a growing need for the efficient production of high-value recombinant human cytokines 
for biochemical, biophysical, physiological, and clinical studies. 
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The extracellular complex between the hematopoietic receptor Flt3 and its cytokine ligand (FL) 
is the cornerstone of signaling cascades central to early hematopoiesis and the immune system. Here 
we report efficient protocols for the production of two ectodomain variants of human Flt3 receptor, 
Flt3D1-D5 and Flt3D1-D4, for structural studies. We established tetracycline-inducible stable cell lines 
in HEK293S cells deficient in N-acetylglycosaminyltransferase I (GnTI-/-) that can secrete the target 
proteins with limited and homogeneous N-linked glycosylation to milligram amounts. The ensuing 
preparative purification of Flt3 receptor-ligand complexes yielded monodisperse complex 
preparations that were amenable to crystallization. Crystals of Flt3D1-D4:FL and Flt3D1-D5:FL 
complexes diffracted  to Bragg spacings of 4.3 Å and 7.8 Å, respectively, and exhibited variable 
diffraction quality even within the same crystal. The resulting data led to the successful structure 
determination of the two Flt3 receptor-ligand complexes via a combination of molecular 
replacement and density-modification protocols exploiting the non-crystallographic symmetry and 
high solvent content of the crystals. 





The Fms-like tyrosine kinase 3 (Flt3) receptor and its cognate cytokine, termed Flt3 ligand (FL), 
initiate signalling pathways in hematopoietic stem cells and early hematopoietic progenitors of 
myeloid and lymphoid origin to develop the pluripotent cellular population of the human 
hematopoietic and immune systems (Lyman et al., 1993b; Hannum et al., 1994; Stirewalt and 
Radich, 2003; Drexler and Quentmeier, 2004; Parcells et al., 2006; Onai et al., 2007; Kikushige et 
al., 2008; Liu and Nussenzweig, 2010). Flt3 receptor is primarily expressed on early hematopoietic 
progenitors in the bone marrow environment and is crucially involved in the development and 
homeostasis of antigen-presenting dendritic cells (Onai et al., 2007; Waskow et al., 2008; Schmid et 
al., 2010). Injection of exogenous FL leads to a massive expansion of dendritic cells and this has 
prompted its use in cancer immunotherapy (Fong et al., 2001). On the other hand, overexpression of 
wild type or oncogenic forms of the Flt3 receptor and/or FL autocrine signaling loops are associated 
with various hematologic malignancies (Kiyoi et al., 1998; Stirewalt and Radich, 2003; Griffith et 
al., 2004; Zheng et al., 2004b; Parcells et al., 2006; Kiyoi and Naoe, 2006). Most notably, 
mutational fingerprints in Flt3 are the predominant prognostic factor in acute myeloid leukemia 
(AML) (Eklund, 2010) and have rationalized the targeting of Flt3 in a clinical setting (Kindler et al., 
2010).                                                                                                          
Flt3 is together with platelet-derived growth factor receptors (PDGFRα/β), colony-stimulating 
factor 1 receptor (CSF-1R), and KIT, a member of the type III receptor tyrosine kinase (RTKIII) 
family (Grassot et al., 2006).  As such, Flt3 has been predicted to  exhibit a modular structure 
featuring an extracellular segment with five immunoglobulin (Ig)-like domains (residues 27-543), a 
single transmembrane helix (TM, residues 544-563), a cytoplasmic juxtamembrane domain (JM, 
residues 572-603) and an intracellular kinase module (residues 604-958) (Lyman et al., 1993b; 
Maroc et al., 1993). A fully functional Flt3 isoform that lacks the fifth Ig-domain has been 
identified in mice (Lavagna et al., 1995). FL is a non-covalently linked dimeric four-helical bundle 
cytokine that is structurally homologous to Stem Cell Factor (SCF) and Colony Stimulating Factor 1 
(CSF-1), which are the ligands of KIT and CSF-1R, respectively (Lyman et al., 1993a; Hannum et 
al., 1994; Savvides et al., 2000).  
Several FL-splice variants have been identified (Lyman et al., 1995a; McClanahan et al., 1996) 
leading to biologically active membrane-bound or soluble forms of FL (Escobar et al., 1998), which 
activate the receptor by ligand-induced dimerization (Kiyoi et al., 2002).  Despite the staggering 
body of biomedical literature on the physiological and clinical importance of the Flt3-FL complex, 
the structural basis of the Flt3 extracellular assembly has remained uncharacterized. Here we report 
protocols for the efficient production of Flt3 ectodomain variants and the crystallization of their 





MATERIALS AND METHODS 
Expression constructs 
A cDNA clone (Image ID 5272266) encoding the full-length human Flt3 receptor was 
purchased from IMAGENES. PCR-fragments encoding residues 1 to 540, 27 to 540 and 27 to 437 
were gel-purified (Qiagen, cat. No. 28704) and subcloned into the pCR2.1-TOPO vector 
(Invitrogen, Cat. No. KNM4500-01). Mammalian expression constructs were generated in the 
pHLsec (Aricescu et al., 2006) and pcDNA4/TO (Invitrogen, cat. No. V1020-20) vectors, by 
restriction site-dependent cloning. Modified versions of these vectors contained the human  
cystatine S (Barash et al., 2002) or chicken receptor protein tyrosine phosphatase σ (RPTPσ) 
(Aricescu et al., 2006) secretion signal at their multicloning site. All expression constructs included 
a C-terminal hexahistine tag. Plasmid-DNA was propagated in E. coli TOP10-cells (Invitrogen, cat. 
No. C4040-50) and purified by chromatography (Qiagen, cat. No. 12145). PCR was performed 
using Easy-A polymerase (Stratagene, Cat. No. 600400). Restriction enzymes were purchased from 
New England Biolabs. Inserts were ligated into the expression vectors using the LigaFast ligation 
system (Promega, Cat. No. M8221). The final expression constructs were sequence verified 
(Cogenics, Meylan, France) and matched the human Flt3 reference sequence in the NCBI database 
(NP_004110.2). 
 
Transient expression of Flt3 in HEK293 cells 
The human embryonic kidney cell lines, HEK293T (ATCC no. CRL-1573) and HEK293S 
GnTI-/- TetR cells (Reeves et al., 2002) were grown in DMEM/F12 medium (GIBCO/Invitrogen, 
cat. No. 32500-043) supplemented with 10% heat-inactivated foetal calf serum (FCS) (Sigma, Cat. 
No. F7524), 3 mM L-glutamine (Sigma, Cat. No. G3126), 106 units per liter of penicillin G (Sigma, 
Cat. No. P7794) and 1 g/L streptomycin (Sigma, Cat. No. S9137), in a 5% CO2 atmosphere at 37°C. 
Small-scale transient expression tests were performed in 6-well tissue culture plates (Corning, Cat. 
No. 3506) as described (Aricescu et al., 2006). The medium of confluently grown cells was 
replaced with serum-free medium containing 5 µM kifunensine (Toronto Research Chemicals, Cat. 
No. K450000) and purified plasmid-DNA mixed with 25-kDa branched polyethyleneimine (Sigma, 
Cat. No. 408727) was added. Transfected cells were allowed to express the recombinant protein for 
5 days and samples were prepared by mixing the medium with half a volume of Laemmli-buffer 
containing β-mercaptoethanol. Recombinant proteins in the conditioned medium were separated by 
SDS-PAGE (15% gel), followed by Western blot analysis using a HRP-coupled antibody directed 
against the C-terminal His-tag (Invitrogen, cat. No. R931-25). Femto Luminol (Thermo Scientific, 
cat. No. 34095) was used as the chemiluminescent substrate. Large-scale expression experiments in 
HEK293T cells were performed in roller-bottles (GBO, cat. No. 681070).  




Tetracycline-inducible stable HEK293S  GnTI-/- TetR cell lines secreting 
recombinant Flt3 
pcDNA4/TO expression contructs (containing the RPTPσ secretion signal) were linearized in a 
non-essential region using the SapI-restriction enzyme (New England Biolabs) and the DNA was 
repurified using Qiaquick-spin columns (Qiagen, cat. No. 28104). Four hours prior to transfection, 
the medium of 50% confluent HEK293S GnTI-/- TetR cells grown in a 75 cm2 tissue culture flask 
(Corning, cat. No. 430725) was replaced with fresh medium. Cells were transfected according to the 
calcium phosphate method using 30 µg of linearized DNA per flask. Four hours post-transfection, 
the medium was replaced again with fresh medium. After 24 hours the transfected cells were 
detached with trypsin/EDTA and diluted in three 175 cm2 flasks at different dilutions, under 
selective pressure (200 µg/mL Zeocin, Invivogen, Cat. No. ant-zn-1). Consequently, the medium 
was refreshed every 3-4 days until foci appeared (after 2-3 weeks). Ten foci were isolated using 
filter papers soaked with trypsin/EDTA and transferred to 24-well tissue culture plates, and 
subsequently expanded to 175 cm2 flasks (Greiner Bio-One, cat. No. 660160). Concomitantly, the 
clones were tested for protein expression in 6-well format. To induce expression, the growth 
medium of confluently grown cells was replaced with serum-free medium supplemented with 2 
μg/mL tetracycline (Duchefa, cat. No. T0150) and 5 mM sodium butyrate (Sigma, cat. No. 303410). 
The expression level of the clones was compared by Western blot analysis. The most strongly 
expressing clones were prepared for long-term storage at 193 K using a mixture of 50% cells in 
DMEM/F12 (supplemented with 10% FCS) and 50% freezing solution (80% FCS and 20% DMSO 
(Sigma, catalogue No. D2650)). For large-scale expression experiments, the medium of fifty 175 
cm2 tissue culture flasks was used. Five days post induction, the medium was collected and clarified 
from cell debris by centrifugation and, finally stored at -20° C until further use. 
Selenomethionine labelling of recombinant Flt3D1-D4 
Stable transfected HEK293S GnTI-/- cells were grown to confluence in DMEM/F12 medium 
containing 10% FCS. Prior to induction, the cells were washed once with phosphate-buffered saline 
(PBS) in order to remove most of the residual methionine. Subsequently, serum-free DMEM 
medium, devoid of methionine (MP Biomedicals, cat. No. 091642254) but supplemented with             
30 mg/L selenomethionine (Acros Organics, cat. No. 259960010), 2 μg/mL tetracycline and 5 mM 
sodium butyrate, was added to the cells. We observed a significant reduction in protein expression 
compared to our standard protocols, which we attribute to increased levels of cell death owing to the 







Protein purification  
Defrosted medium (2.5 L) was filtered through a 0.22 µm bottle-top filter (Corning, cat. No. 
431174) and, without further additions, was loaded overnight onto a Talon Superflow column 
(Clontech, cat. No. 635507) with a bed volume of 20 mL connected to an ÄKTApurifier (GE 
Healthcare) system and equilibrated with 300 mM NaCl, 50 mM NaH2PO4, pH 7.2 at a flow rate of 
5 mL/min. After loading, the column was washed with equilibration buffer containing 5 mM 
imidazole and the protein was eluted with buffer containing 200 mM imidazole. EDTA (1 mM) and 
protease inhibitors (Roche, cat. No. 11873580001) were added to the protein solution (~ 30 mL). 
Next, the protein was concentrated to 1 mL using a Vivaspin concentrator with a molecular weight 
cutoff of 10 kDa (Sartorius, cat. No. VS15RH02). 
Subsequently, the partially purified recombinant Flt3 was injected onto a Superdex 200 column 
(GE Healthcare, cat. No. 17-1069-01) with 150 mM NaCl, 10 mM HEPES, pH 7.2 as running 
buffer. The fractions corresponding to recombinant Flt3 were pooled and concentrated to 1 mL 
using a Vivaspin concentrator (Sartorius, cat. No. VS0404). As a final polishing step, the protein 
solution was diluted 5-fold with 20 mM Tris/HCl pH 7.0 and loaded onto a MonoQ-column (GE 
Healhcare, cat. No. 17-5166-01) equilibrated with 20 mM Tris/HCl, pH 7.0. The protein was eluted 
using a linear gradient from 0 to 1 M NaCl and collected in fractions of 200 µL, and was stored at   
- 80° C until further use.  
Crystallization of Flt3 ligand-receptor complexes 
Flt3 ligand-receptor complexes were formed by mixing excess molar amounts of purified FL (2 
x 138 residues, 31.7 kDa) (Verstraete et al., 2009) with the purified receptor ectodomains. Protein 
concentrations were determined by absorbance at 280 nm using a NanoDrop spectrophotometer and 
the calculated extinction coefficients of the recombinant proteins: ε280(Flt3D1-D5) = 76205 M-1cm-1,    
ε280(Flt3D1-D4) = 50850 M-1cm-1 and ε280(FL) = 39710 M-1cm-1. The complex was separated from 
excess FL by gel filtration using a Superdex 200 column equilibrated with 150 mM NaCl, 10 mM 
HEPES, pH 7.2. Fractions corresponding to the complex were pooled and concentrated using a 
Vivaspin concentrator (Sartorius, cat. No. VS0404) to a final concentration of 5 mg/mL. The 
concentrated protein solution was aliquoted and flash frozen into liquid nitrogen and subsequently 
stored at -80° C until further use. 
Initial crystal screening was carried out using the ProPlex (Molecular Dimensions, cat. No. 
MD1-38), Crystal Lite (Hampton Research, cat. No. HR2-128) and PEG ION I (Hampton Research, 
cat. No.  HR2-126) screens. Crystallization drops were set up manually at 293 K in 24-well sitting-
drop crystallization plates (Hampton Research. Cat. No. HR3-160) by mixing 1 µL of reservoir 
solution (500 µL) with 1 µL of protein solution at a concentration of 5 mg/mL. Crystallization 
conditions were optimized using chemicals of the highest purity available. 




Derivatization of Flt3D1-D4:FL crystals with heavy-atoms for phasing 
Flt3D1-D4:FL crystals were incubated in stabilisation buffer (artificial mother liquor containing a 
10% higher concentration of precipitant) containing 0.5-5 mM of candidate heavy-atom 
compounds. A variety of Pt2+, Pb2+, and Hg2+ salts as well as the tantalum cluster Ta6Br12, were tried 
under different incubation times ranging from 1 minute to several hours. 
X-ray data collection and analysis 
Single crystals were transferred to a drop of stabilisation buffer (artificial mother liquor 
containing a 10% higher concentration of precipitant) with the use of a nylon loop (Hampton 
Research) mounted onto SPINE standard cryocaps (Molecular Dimensions, cat. No. MD7-406). The 
concentration of cryoprotectant was gradually adjusted by adding increasing amounts of stabilizing 
buffer containing a higher concentration of cryoprotectant to the drop until the desired concentration 
of cryoprotectant was reached. A 3-minute equilibration time was allowed between subsequent 
additions. Subsequently, the crystals were flash-frozen into liquid nitrogen and loaded into 
SPINE/ESRF pucks for storage and transport. Diffraction experiments were conducted at beamlines 
X06SA (PXI) and X06DA (PXIII) of the Swiss Light Source (Paul Scherrer Institute, Villigen, 
Switzerland) and ID23-1 of the ESRF (Grenoble, France). All data were integrated and scaled using 
the XDS suite (Kabsch, 2010). Molecular replacement was performed using Phaser (McCoy et al., 
2007). MR-search models for individual Flt3 Ig-domains were prepared with Chainsaw (Stein, 
2008) and the KIT structure (Yuzawa et al., 2007) as template. Density modification was performed 
using PARROT (Cowtan, 2010) and rigid-body refinement was conducted in PHENIX (Adams et 
al., 2010).  
RESULTS AND DISCUSSION 
Protein expression and purification 
Obtaining sufficient amounts of the Flt3 ectodomain for structural studies proved to be 
challenging. Our initial strategy was to express the full-length His-tagged Flt3 ectodomain           
(Flt3D1-D5) by transient expression in HEK293T cells in the presence of kifunensine (Aricescu et al., 
2006; Chang et al., 2007) to ensure properly folded recombinant receptor carrying limited N-linked 
glycans that could be further reduced by treatment with deglycosylating enzymes such as 
endoglycosidase H (EndoH) for crystallization purposes. However, despite the high quality and 
stability of recombinant Flt3D1-D5 obtained via this approach, Flt3D1-D5 yields were very low (0.1 mg 
per liter of culture medium) which posed tremendous hurdles for extensive crystal screening and 
additional biophysical studies.  
Inspired by the work of Barash et al., we exchanged the native Flt3 secretion signal with the 





introduced signal peptides resulted in a moderate increase in the expression level with the RPTPσ 
secretion signal showing the largest effect (Fig. 1A). After verification by N-terminal sequencing 
that the leader sequence was correctly processed, the RPTPσ secretion sequence was retained as a 
general approach to improve the yields of secreted recombinant Flt3. Additional comparisons 
investigating the expression efficiency of pHL- and pcDNA4/TO-expression constructs showed 
similar yields of Flt3 indicating that the presence of the SV40-ori (present on pcDNA4/TO), which 
allows episomal replication of the expression plasmid in HEK293T cells, had no obvious effect on 











(A) Transient expression of Flt3D1-D5 in HEK293T cells.  
HEK293T cells, seeded in 6-well plates, were transiently transfected with pHL-Flt3D1-D5 (lanes 1-3) and pcDNA4/TO-
Flt3D1-D5 (lanes 4-6): Five days post-transfection, the expression of Flt3D1-D5-His in the medium was analyzed by 
Western blot immunodetection using anti-His-HRP. Lanes 1 and 4: native Flt3 secretion signal (Native), Lanes 2 and 
5: chicken RPTPσ secretion signal (RPTPσ), Lanes 3 and 6: human cystatine S secretion signal (Cyst S).  
(B) Inducible expression in stably tranfected HEK293S GnTI-/- cell lines.  
A stable HEK293S GnTI-/- TetR Flt3D1-D5 clone was analyzed for inducible expression. Cells were seeded in 6-well 
plates and induced for 5 days as indicated (Lane 1: serum-free medium (No ind.), lane 2: induction with 2 μg/mL 
tetracycline (Tc) and 5mM sodium butyrate (But), Lane 3: induction with 2 μg/mL tetracycline (Tc) alone, lane 4: 
induction with the tetracycline analogue doxycycline (Dox), 2 μg/mL). As a control a sample of transiently transfected 
HEK293T cells was loaded in lane 5. Immunodetection was performed as in (A). 
 
In an effort to further improve our production of recombinant Flt3 (with the RPTPσ secretion 
signal), we decided to establish stable cell lines in HEK293S GnTI-/- TetR cells. The use of this 
HEK293 variant offers two major advantages. First, this cell line is devoid of                                           
N-acetylglucosaminyltransferase I (GnTI) activity and is thereby able to express target proteins with 
limited and homogeneous N-linked glycosylation that is very sensitive to EndoH-treatment (Chang 
et al., 2007; Reeves et al., 2002). Second, this cell line is stably transfected with the pcDNA6-TR 
 




vector encoding the tetracycline-responsive repressor, which binds and blocks the promoter in the 
absence of tetracycline or an analogue such as doxycycline. This allows tetracycline-regulated 
expression (Yao et al., 1998; Reeves et al., 2002). Inducible expression systems allow growth of 
cell cultures under optimal conditions up until the moment of induction, which could have a 
beneficial effect on the protein yield as compared to constitutive expression.  
Inducible HEK293S GnTI-/- cell lines were established as described and found to secrete             
Flt3D1-D5 in high amounts upon treatment with tetracycline or doxycycline, when compared to 
transient expression experiments (Fig. 1B). The addition of sodium butyrate, a histone deacetylase 
inhibitor (Monneret, 2005), further boosted the expression levels. Using the same approach, a stable 
cell line that expressed an Flt3 ectodomain variant lacking the fifth Ig-domain (Flt3D1-D4) was 
established. Our rationale for targeting this construct for structural studies was based on the 
existence of a fully active splice-variant of murine Flt3 lacking extracellular domain 5 (Lavagna et 
al., 1995). Following large-scale expression experiments, the ectodomains were purified form the 
medium by a combination of metal-affinity chromatography, gel filtration and anion-exchange 
chromatography. The use of a Talon matrix employing immobilized Co2+ in the important first 
capture step via metal-affinity chromatography gave the best results in terms of overall yield and 
purity. We observed that Ni sepharose column matrices consistently suffered from depletion of Ni2+ 
upon passage of clarified culture medium containing the secreted target proteins.  The final yields of 
purified Flt3D1-D5 and Flt3D1-D4 were ~ 2 mg per liter of medium. Flt3 ligand-receptor complexes 
were formed by the addition of recombinant FL produced in E. coli (Verstraete et al., 2009) and 









FIGURE 2. Coomassie-stained SDS-PAGE gel of the purified Flt3:FL complexes.  
Lane 1: Flt3D1-D5:FL and lane 2: Flt3D1-D4:FL. The molecular weight of the processed His-tagged Flt3 ectodomains 
without glycosylation is calculated as 59.7 kDa for Flt3D1-D5 (527 residues) and 48.0 kDa for Flt3D1-D4 (423 residues). 






The strategy to develop inducible expression in stably transfected HEK293 GnTI-/- cells could 
be generally applicable for structural studies involving eukaryotic receptor ectodomains that are 
difficult to express. Moreover, the high costs associated with low-level transient expression -
originating from large-scale plasmid-DNA preparation kits and kifunensine - can thereby be 
significantly reduced. 
Crystallization of Flt3 complexes and data collection  
 
Flt3D1-D5:FL complex 
Using commercially available sparse-matrix screens, a dozen of hits for the Flt3D15:FL complex 
were identified. These conditions were characterized by the presence of medium molecular weight 
polyethylene glycols  (PEG 3350 – PEG 8000) in the concentration range of 10 to 15 % and various 
salts (chlorides, citrates, phosphates, sulphates, acetates) at 0.1 – 0.2 M as co-precipitant. The pH-
range varied from 6.5 to 8.5. Crystal optimization coupled to extensive screening via X-ray 
diffraction experiments identified 200 mM lithium citrate, 12 – 14% w/v PEG 3350 and 100 mM 
Tris/HCl/HCl pH 7.0 as the best condition. The crystals grew within one week and had a plate-like 









 FIGURE 3. Crystallization and data collection for the Flt3D1-D5:FL complex 
 (A)  Plate-like crystals of the Flt3D1-D5:FL complex. 
 (B)  Silver-stained SDS-PAGE gel of dissolved crystals. 
 (C)  X-ray diffraction image from the Flt3D1-D5:FL crystal that led to a complete 7.8 Å dataset. 
 
However, many crystals were not single or showed obvious physical defects. Flt3D1-D5 crystals 
typically diffracted anisotropically to ~10 Å resolution using highly collimated synchrotron X-ray 
beams. Extensive efforts to improve crystal quality using a variety of approaches including 
 




microseeding, crystallization additives, and crystal dehydration and annealing protocols (Heras and 
Martin, 2005), failed to provide consistent improvements in diffraction quality. Furthermore we 
were able to grow crystals of the complex after reduction of glycosylation using EndoH, albeit 
without obtaining the desired improvement in diffraction quality. Nonetheless we found that 
optimization of the cryoprotection protocol based on incremental adjustments of the cryoprotecting 
solution to a final 20% (v/v) glycerol consistently gave better results. We therefore embarked on a 
large-scale screening of crystals, which resulted in a complete dataset to 7.8 Å resolution (Fig. 3C, 
Table I).  
Flt3D1-D4:FL complex 
Initial crystallization experiments identified numerous hits for the Flt3D1-D4:FL complex. By 
analogy to the crystallization condition consensus for the Flt3D1-D5:FL complex, these conditions 
were based on a  medium molecular PEG, 0.1 – 0.2 M salt at pH 6-8.5. Based on crystal 
morphology arguments (overall crystal size, crystal thickness in the third dimension, singleness), a 
dozen conditions were selected for optimization. Diffraction experiments indicated 11-13 % w/v 
PEG 4000, 100 mM MgCl2, 50 mM MES pH 6.0 as the most promising condition. Rod-like crystals 
appeared after 2-3 days and reached their final size within 10 days. They grew as single rods 
measuring 0.3 x 0.1 x 0.02-0.05 mm3 (Fig. 4A,B) or as clusters that could easily be separated by 










 FIGURE 4. Crystallization and data collection for the Flt3D1-D4:FL complex. 
 (A) Rod-like crystals of the Flt3D1-D4:FL complex. 
 (B) Silver-stained SDS-PAGE gel of dissolved crystals.  







Flt3D1-D4-FL crystals generally diffracted to Bragg spacings of 5 to 4.5 Å. In contrast to the 
broad crystallization propensity of the GlcNac2Man5-glycosylated complex, we were not able to 
obtain crystals of the complex after treatment with EndoH, consistent with the notion that the extent 
of glycosylation is often not a strong predictor of crystallization behaviour (Mesters and 
Hilgendfeld, 2007). A recurring phenomenon we observed during the course of crystal screening 
and characterization was often the dramatic variation in diffraction quality even within the same 
crystal. Thus, we were unable to successfully employ data collection strategies based on collecting 
partial datasets by systematically irradiating different parts of the crystal, followed by merging of 
the resulting data failed to deliver data of good quality.  Cryoprotection of Flt3D1-D4:FL crystals with 
20% PEG 400 combined with a stochastic approach to crystal screening resulted in final dataset to 














Values in parentheses correspond to the highest resolution shell as indicated. 
a Rmeas = ∑h√nh/(nh-1) ∑h∑i|I(h,i)-‹I(h)›| / ∑h∑iI(h,i), where nh is the multiplicity, I(h,i) is the intensity of the ith 
measurement of reflection h,  and ‹I(h)› is the average value over multiple measurements. b Estimates of solvent 
content and Matthews coefficients were calculated via www.ruppweb.org/mattprob/ using the theoretical weight of the 
complexes without taking into account N-linked glycosylation (Matthews, 1968; Kantardjieff and Rupp, 2003). 
 
Structure determination of the Flt3D1-D4:FL complex 
Due to the superior diffraction quality of Flt3D1-D4:FL crystals we initially focused our efforts on 
the structure determination of the Flt3D1-D4:FL complex. Phasing information for the crystal 
structure of Flt3D1-D4:FL was initially determined at 4.3 Å resolution by maximum-likelihood 
 Flt3D1-D4:FL Flt3D1-D5:FL 
DATA COLLECTION   
Source ESRF ID23-1 ESRF ID23-1 
Wavelength  (Å) 0.9714 1.0762 
Detector ADSC-Q315R ADSC-Q315R 
Resolution (Å) 40.00 - 4.30 (4.45 - 4.30) 40.00 - 7.80 (8.00 - 7.80) 
Space group P21 P21 
 










Wilson B (Å2) 135 436 
Unique reflections 20184 (1942) 5575 (374) 
Redundancy 3.8 (3.8) 3.1 (3.0) 
Completeness (%) 98.8 (98.9) 95.3 (90.8) 
Rmeas (%)a 10.8 (75.9) 12.5 (75.9) 
Average I/σ(I) 12.04 (2.08) 8.8 (1.8) 
Solvent content (%)b, 
Matthews Coefficient (Å3/Da) 
59, 3.0 71, 4.2 
No. complexes in asu 2 2 
TABLE I. X-ray data collection statistics 
 




molecular replacement as implemented in PHASER (McCoy et al., 2007), using the structure of 
human FL (PDB entry 1ETE)  (Savvides et al., 2000) and a homology model for Flt3D3 based on the 
structure of human KITD3 (PDB entry 2E9W) (Yuzawa et al., 2007). This revealed the presence of 
two Flt3D1-D4:FL complexes in the crystal asymmetric unit (asu) that packed against each other via a 
broad interface between the two FL ligands (Fig. 5A). This packing arrangement was consistent 
with all major peaks in the self-rotation function as calculated with MOLREP (Vagin and 
Teplyakov, 2010). Furthermore, the corresponding electron density map revealed a clear protein-
solvent boundary for the two Flt3D1-D4:FL complexes in the asu but was not of sufficient quality to 
allow model building. In our efforts to obtain additional experimental phase information we were 
confronted with the prohibitively poor diffracting capacity of Flt3D1-D4:FL crystals derivatized with 

















(A) Partial molecular replacement solution for the Flt3D1-D4:FL complex showing the presence of two complexes in the 
crystal asymmetric unit. Two neighbouring symmetry mates along the b-axis are shown with appropriate depth cueing. 
FL (red and blue) and the MR-model for Flt3D3 (green and yellow) are shown in ribbon representation. 
(B) Density-modified electron density map (contoured at 1σ) showing clear and complete electron density for 
unmodelled Flt3 extracellular domains (dashed ellipses). The map (2mFo - DFc-like) is the result of phase-
improvement protocols implemented in the program PARROT based on the partial model obtained by MR, using an 
NCS masking radius of 15 Å and 20 cycles of NCS-averaging and solvent flattening. FL (red) and the MR-model for 
Flt3D3 (green) are shown in ribbon representation. 
 
We therefore sought to improve phase quality via density modification approaches exploiting 
the presence of improper 4-fold non-crystallographic symmetry (NCS) and the high solvent content 
of the crystals (59%). Such approaches have been sparsely applied to structure determinations via 
molecular replacement due to possible limitations and phase bias imposed by the unimodal phase 
distribution inherent to calculated phases from protein models. However, when carefully applied, 






can be very effective for both high and low resolution analyses (Keller et al., 2006; Huyton et al., 
2007). Indeed, density modification protocols as implemented in the program PARROT (Cowtan, 
2010) starting with Hendrickson-Lattman coefficients for the phase probability distribution 
calculated in PHASER based on our rigid-body refined molecular replacement solution (covering 
only about 40% of the scattering mass in the asymmetric unit), revealed contiguous density for 
several unmodelled Flt3 domains (Fig. 5B) including direct evidence for N-linked glycans. We note 
that extending the NCS-mask radius parameter in PARROT from its default value of 6 to 15-20 was 
crucial for maximizing the quality of the electron density maps and coverage of the asymmetric unit 
content. We subsequently used the dramatically improved electron density maps to select the correct 
MR solution for a homology model of Flt3D4 based on KITD4, and to manually place a model for 
Flt3D2 based on KITD5. Model (re)building and refinement, including modelling of the elusive Flt3D1 
into electron density, are under way and will be reported elsewhere. The crystallized Flt3D1-D4:FL 
and Flt3D1-D5:FL complexes undoubtedly constitute a major milestone towards elucidating the 
overall architecture and organization of the extracellular Flt3:FL assembly, as well as towards 
gaining insights into the main features of the interaction epitope. We are currently working to 
develop shorter receptor constructs in light of the structural insights obtained from the Flt3D1-D4:FL 
and Flt3D1-D5:FL complexes in an effort to obtain crystals that will allow a detailed dissection of the 
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The class-III receptor tyrosine kinase (RTKIII) Flt3 and its cytokine ligand (FL) play central roles 
in hematopoiesis and the immune system, by establishing signaling cascades crucial for the 
development and homeostasis of hematopoietic progenitors and antigen-presenting dendritic cells. 
However, Flt3 is also one of the most frequently mutated receptors in hematological malignancies 
and is currently a major prognostic factor and clinical target for acute myeloid leukemia (AML). 
Here, we report the structural basis for the Flt3 ligand-receptor complex and unveil an unanticipated 
extracellular assembly unlike any other RTKIII/V complex characterized to date. FL induces 
dimerization of Flt3 via a remarkably compact binding epitope localized at the tip of extracellular 
domain 3 of Flt3, and invokes a ternary complex devoid of homotypic receptor interactions. 
Comparisons of Flt3 with homologous receptors and available mutagenesis data for FL have 
allowed us to rationalize the unique features of the Flt3 extracellular assembly. Furthermore, 
thermodynamic dissection of complex formation points to a pronounced enthalpically-driven 
binding event coupled to an entropic penalty. Together, our data suggest that the high-affinity        
Flt3-FL complex is driven in part by a single preformed binding epitope on FL reminiscent of a 
'lock-and-key' binding mode, thereby setting the stage for antagonist design. 





Hematopoiesis is a finely regulated process during which diverse cell types originating from a 
limited and self-renewing population of hematopoietic stem cells (HSC), are stimulated to 
proliferate and differentiate to create the cellular repertoire that sustains the mammalian 
hematopoietic and immune systems (Metcalf, 2008).   
 The Fms-like tyrosine kinase receptor 3 (Flt3) is the most recent addition to the diverse family 
of hematopoietic receptors. Flt3 is activated on HSC and early myeloid and lymphoid progenitors 
by its cognate ligand (FL), to initiate downstream signaling via the PI3K/AKT and the 
RAS/RAF/MEK/ERK pathways (Stirewalt and Radich, 2003; Parcells et al., 2006). Consistent with 
the narrow expression profile of Flt3 in the bone marrow environment, signaling via the Flt3 
ligand/receptor complex primarily impacts early hematopoiesis, particularly the proliferation and 
development of HSC and B-cell progenitors ( Stirewalt and Radich, 2003; Kikushige et al., 2008). 
In recent years Flt3 and FL emerged as potent regulators of dendritic cell (DC) development and 
homeostasis (Onai et al., 2007; Waskow et al., 2008; Liu et al., 2009), and DC-mediated natural 
killer cell activation (Eidenschenk et al., 2010), thereby gaining an important role at the interface of 
innate and acquired immunity and in cancer immunotherapy (Dong et al., 2002; Wu and Liu, 2007). 
Notably, Flt3/FL-driven DC generation yields both classical- and plasmacytoid DC from bone-
marrow progenitors regardless of myeloid or lymphoid commitment, a property that is currently 
unmatched by any other receptor/cytokine system relevant for DC physiology (Liu and 
Nussenzweig, 2010; Schmid et al., 2010).  
 Flt3 is a class III receptor tyrosine kinase (RTKIII) together with the prototypic platelet-derived 
growth factor receptors (PDGFRα/β), colony-stimulating factor 1 receptor (CSF-1R), and KIT 
(Grassot et al., 2006).  Thus, Flt3 has been predicted to display a modular structure featuring an 
extracellular segment with 5 immunoglobulin (Ig)-like domains (residues 27-543), a single 
transmembrane (TM) helix (residues 544-563), a cytoplasmic juxtamembrane (JM) domain 
(residues 572-603) and a split intracellular kinase module (residues 604-958). The RTKIII family is 
closely related to the RTKV family of vascular endothelial growth factor receptors (VEGF-Rs), 
which have 7 extracellular Ig-like domains. The hallmark of RTKIII/V signaling lies in the 
activation of the extracellular receptor segments upon binding of the cognate cytokines, followed by 
intermolecular autophosphorylation and activation of the intracellular kinase domains (Lemmon and 
Schlessinger, 2010).  
 Besides the clear role of Flt3 signaling in hematopoiesis and immune system development, 
overexpression of wild type or oncogenic forms of Flt3 have been implicated in a number of 
hematopoietic malignancies (Stirewalt and Radich, 2003; Sanz et al., 2009), and inflammatory 
disorders (Dehlin et al., 2008). In particular, internal tandem duplication (ITD) in the JM-region or 
point mutations in the kinase activation loop occur in 35% of patients with acute myeloid leukemia 
(AML) resulting in constitutive activation of the receptor and uncontrolled proliferation of 




hematopoietic precursors (Kiyoi et al., 2002; Stirewalt and Radich, 2003; Parcells et al., 2006; 
Reindl et al., 2006; Fröhling et al., 2007). Such mutational fingerprints have established Flt3 as the 
predominant prognostic factor in AML cases (Eklund, 2010), and have rationalized the targeting of 
Flt3 in a clinical setting (Stirewalt and Radich, 2003; Parcells et al., 2006; Kindler et al., 2010).  
 Although the cellular and physiological role of the Flt3 ligand-receptor interaction has been 
featured prominently in the biomedical literature over the last two decades, the Flt3 signaling 
complex has remained uncharacterized at the molecular and structural level. Such insights are the 
missing link to the structural and functional diversity of RTKIII/V extracellular complexes, and 
would help provide a nearly complete picture of the entire Flt3 signaling complex given the 
available structure of the Flt3 intracellular kinase domains (Griffith et al., 2004).  A recent flurry of 
studies of RTKIII/V extracellular complexes led to a structural paradigm for RTKIII/V activation, 
whereby the receptors bind via their N-terminal Ig-like domains to the activating dimeric cytokine 
and concomitantly make homotypic contacts between their membrane-proximal domains (Liu et al., 
2007; Ruch et al., 2007; Yuzawa et al., 2007; Chen et al., 2008; Yang et al., 2008; Yang et al., 
2010; Shim et al., 2010; Leppänen et al., 2010). A universal feature of all characterized RTKIII/V 
complexes thus far is that the cytokine-binding epitope is distributed equally between extracellular 
domains 2 and 3 covering ~2000 Å2 of surface area, and that homotypic receptor-receptor 
interactions are mediated by well-conserved residues in the membrane-proximal domains (D4 in 
RTKIII and D7 in RTKV). Nonetheless, Flt3 appears to be an outlier among RTKIII/V receptors 
due to several unique features in its extracellular segment (Lyman et al., 1993; Maroc et al., 1993), 
thus raising the question whether the current structural paradigm could be extrapolated to Flt3. 
Notably, Flt3 exhibits intragenic homology relating extracellular domains 1 and 4, and domains 2 
and 5, indicative of an ancient internal duplication event during evolution (Appendix B). 
Furthermore, Flt3 contains 12 additional cysteines that are not present in any of the homologous 
receptors, and has a unique N-terminal sequence of 50 amino acids preceding Ig-like domain 1 
(Appendix A). Interestingly, a fully functional splice variant of murine Flt3 lacks extracellular 
domain 5 entirely, indicating that the domain most proximal to the cell-membrane is not critical for 
receptor activation (Lavagna et al., 1995) contrary to other RTKIII/V receptors (Broudy et al., 
2001; Yang et al., 2008; Yang et al., 2010).   
 Here, we provide the structural basis of extracellular complex formation between Flt3 and its 
cognate cytokine. Our studies establish the uniqueness of Flt3 within the RTKIII/V family and 











Protein Expression and Isolation of Flt3:FL complexes  
To support structural and biophysical studies of human Flt3 ectodomain complexes we designed 
a series of constructs for recombinant human Flt3 ectodomains (Flt3D1 (residues 27-161), Flt3D1-D2 
(residues 27-244), Flt3D1-D3 (residues 27-346), Flt3D1-D4 (residues 27-434) and Flt3D1-D5 (residues 27-
541)), based on intron/exon boundaries and sequence alignments with homologous receptors 
(Appendix A). Faced with prohibitively poor protein yields (100-200 µg per liter of medium) we 
established tetracycline-inducible cell lines in HEK293S cells deficient in N-acetylglucosaminyl- 
transferase I (HEK293S GnTI-/-) (Reeves et al., 2002) that could secrete the target ectodomain 
variants with homogeneous glycosylation (GlcNac2Man5) to mg amounts as described in Verstraete 
et al. (2011). The yields and stability of Flt3D1-D3 and Flt3D1-D2 were much lower than for all other 
constructs. Ternary Flt3:FL complexes were prepared for structural studies by mixing purified Flt3 
ectodomains with a molar excess of recombinant E. coli-derived human FL (Verstraete et al., 2009) 
followed by preparative size-exclusion chromatography on a Superdex 200 column equilibrated 
with 150 mM NaCl, 10 mM HEPES, pH 7.2. The column was calibrated using thyroglobulin (669 
kDa), ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa) and ribonuclease (13.7 kDa) as molecular weight standards.  
 
 Isothermal Titration Calorimetry 
Experiments were carried out using a VP-ITC MicroCalorimeter (MicroCal, MA) at 37° C, and 
data were analyzed using the Origin ITC analysis software package supplied by MicroCal. Purified 
recombinant Flt3 ectodomain constructs and FL were dialyzed overnight against 20 mM Hepes pH 
7.4, 150 mM NaCl at 4° C. Protein concentrations were measured spectrophotometrically at 280 nm 
using calculated theoretical extinction coefficients and all solutions were extensively degassed prior 
to use. Titrations were always preceded by an initial injection of 3 µL, and were carried out using 10 
µL injections applied 300 s apart. The sample was stirred at a speed of 400 rpm throughout. The 
thermal titration data were fit to the “one binding site model”, and apparent molar reaction enthalpy 
(ΔH°), apparent entropy (ΔS°), dissociation constant (Kd) and stoichiometry of binding (N) were 
determined. Several titrations were performed to evaluate reproducibility. 
 
Mapping of disulfide bridges and glycosylation sites by mass spectrometry 
Gel slices containing EndoH-digested recombinant Flt3D1-D5 obtained from Coomassie-stained 
polyacrylamide gels were digested with trypsin (Promega) as previously described (Vanrobaeys et 
al., 2003). After digestion overnight at 37° C, the digestion mixture were dried and redissolved in 20 
ml 0.1% formic acid. One microliter of the digestion mixture was mixed with an equal volume of 3 
mg/ml α-cyano hydroxycinnamic acid (Sigma) in 50% acetronitrile/0.1% TFA and was 




subsequently subjeted to mass spectrometric analyses on a 4800 plus TOF/TOF analyzer (Applied 
Biosystems). 
About 75 pmoles of purified recombinant Flt3D1-D5 were dissolved in 20 mM Tris-HCl, pH 8.0, 
and digested with trypsin (Promega), Glu-C and Asp-N endoproteinases (Sigma) at E/S = 1/35.  
After incubation at 37°C overnight, 1 mL of the digestion mixture were mixed with 5 ml of 3 mg/ml 
 α-cyano hydroxycinnamic acid (Sigma) in 50% acetronitrile / 0.1% TFA prior to mass 
spectrometric analyses. The remaining volume of the digestion mixture was applied on a Spheri-5 
PTC-C18 column (220 x 2.1 mm, Higgins Analytical) at a flow rate of 100 ml/min. Reversed phase 
chromatography of peptide mixture was performed on an Ettan LC (Amersham Biosciences) with 
on-line 96-well plate Frac-950 fractionator set at 20 mL/min. One microliter of the collected 
fractions was mixed with an equal volume of 3 mg/ml α-cyano hydroxycinnamic acid. 
A table with the thereotical and measured masses of analyzed peptides is provided in   
Appendix C. 
 
Crystallography of Flt3:FL complexes 
The preparation and cryoprotection of Flt3D1-D4:FL and Flt3D1-D5:FL crystals is described in 
Verstraete et al., 2011. Diffraction experiments were conducted under cryogenic conditions (100 K) 
on the X06SA (PXI) and X06DA (PXIII) beamlines at the Swiss Light Source (Paul Scherrer 
Institute, Villigen, Switzerland) and the ID23-1 beamline at the ESRF (Grenoble, France). All data 
were integrated and scaled using the XDS suite (Kabsch, 2010). 
The structure of Flt3D1-D4:FL was determined by maximum-likelihood molecular replacement 
(MR) as implemented in the program suite PHASER (McCoy et al., 2007), using the structure of 
human FL (PDB entry 1ETE, Savvides et al., 2000) and a homology model for Flt3D3 based on the 
structure of human KITD3 (PDB entry 2E9W, Yuzawa et al., 2007). This showed the presence of 
two Flt3D1-D4:FL complexes in the crystal asymmetric unit packing against each other via a broad 
interface between the two FL ligands (Appendix D). Electron density modification exploiting the 
presence of improper 4-fold non-crystallographic symmetry (NCS) and the high solvent content of 
the crystals (59%) via the program PARROT (Cowtan, 2010) revealed contiguous density for 
domains Flt3D2 and Flt3D4 (Fig. 1A), which allowed us to select the correct MR solution for a 
homology model of Flt3D4 based on KITD4, and to manually place a model for Flt3D2 based on 
KITD5. In the later stages of model building and refinement, we were able to model the core 
structure of Flt3D1 for one of two receptor complexes starting with a homology model derived from 
Flt3D4. Model (re)building was carried out manually in electron density maps after density 
modification, using the program COOT (Emsley et al., 2010). Chain tracing was facilitated by 

































FIGURE 1.  Quality of the electron density maps 
(A) Unbiased electron density for Flt3D4.  
The electron density is contoured at 1σ and was obtained after implementation of phase improvement protocols 
based on a partial model of the complex consisting of only FL and Flt3D3.The final model for domains 3 and 4 in one 
of the receptor chains in the Flt3D1-D4-FL complex structure is shown in ribbon representation.  N-linked glycans are 
shown in stick representation (magenta). This electron density map (2mFo - DFc-like) was obtained by applying 
NCS-averaging and solvent flattening protocols as implemented in PARROT, and proved to be crucial early in the 
structure determination process providing the complete electron density trace for Flt3D4, including clear electron 
density for N-linked glycans. 
(B) Quality of the electron density map to 4.3 Å resolution.   
Stereo diagram illustrating the quality of the final 2mFo-DFc electron density map to 4.3 Å resolution (contoured at 
1σ) for the Flt3D1-D4:FL complex. The figure is centered on the Flt3D2-D3 interface and junction, with the final model 
for Flt3D2 (left) and Flt3D3 (right) displayed in ribbon representation (blue). The N-linked NAG glycan residue 









Crystallographic refinement was carried out in PHENIX (Adams et al., 2010) and, at at later 
stages, in autoBUSTER 2.8.0 (Blanc et al., 2004). During refinement, tight RMSD-based NCS-
restraints (4-fold non-proper NCS) were imposed. Several loop regions that did not obey the NCS 
were pruned out from the NCS-selection. Torsion angles of FL protomers were restrained to chain A 
(residues 3 - 132) of the previously determined 2.2 Å resolution structure of human FL (pdb 1ETE, 
Savvides et al., 2000). Residues 7 – 13, which comprise the N-terminal loop that forms the major 
interaction site with Flt3D3, were excluded from the FL reference model. Hydrogens bonding 
restraints for conserved secondary structure elements in the different Ig-like domains were manually 
defined using the ResDe tool (Hintze and Johnson, 2010), and subsequently converted to Buster 
distance restraints. During refinement, a low weight on the X-ray term (w = 24 in autoBuster) and a 
single B-factor per residue were applied. TLS parameterization, in which each domain was defined 
as a single TLS group, resulted in worse refinement statistics. The sterochemistry of the final model 
was validated using MolProbity (Chen et al., 2010). A section of the final 2mFo-DFc electron 
density map is shown in Fig. 1B. 
The structure of Flt3D1-D5: FL was determined to 7.8 Å resolution by MR protocols implemented 
in PHASER (McCoy et al., 2007), using the structure of the Flt3D2-D3:FL subcomplex as determined 
in the Flt3D1-D4:FL complex. The remaining domains were placed via additional rounds of molecular 
replacement and manual placement in electron density maps after density modification. Crystals of 
the Flt3D1-D5:FL complex contained two complexes in the asymmetric unit interacting with each 
other in a fashion analogous to what we observed in the Flt3D1-D5:FL complex (Appendix D). Due to 
the low resolution of the analysis we only applied rigid-body refinement (in autoBUSTER) using the 
FL protomer (residues 3-132), Flt3D1 (residues 79 - 161), Flt3D2-D3 (residues 167-345), Flt3D4 
(residues 348-434) and Flt3D5 (residues 437-529) as rigid bodies. A single B-factor was used per 
domain. 
 
Crystallographic data deposition 
Coordinates and structure factors for the Flt3D1-D4:FL and Flt3D1-D5:FL complexes have been 
deposited in the Protein Data Bank (www.rcsb.org) and are accessible through accession numbers 
3QS7 and 3QS9, respectively. 
 
Small-angle X-ray Scattering 
Small-angle X-ray scattering data were collected at beamline X33 at DESY, Hamburg. The 
measurements were carried out at 283 K, within a momentum transfer range of 0.01 Å-1 < s < 0.45 
Å-1 where s = 4πsin(θ)/λ and 2θ is the scattering angle. All samples were measured at several solute 
concentrations ranging from 0.5 to 6 mg/ml in 50 mM NaPO4 pH 7.40, 100 mM NaCl, with 
intermittent buffer solution (50 mM NaPO4, pH 7.40, 100 mM NaCl). A standard data collection 
time of 2 min was used for all samples split into four 30-second time frames to assess and remove 




effects from radiation damage to the samples. Time frames were processed to yield radially-
averaged curves of normalized intensity versus the momentum transfer. Time frames are combined, 
excluding those that are affected by aggregation induced by radiation damage, to give the average 
scattering curve for each measurement. The data were processed using standard procedures, 
corrected for buffer contribution, and extrapolated to infinite dilution using the program PRIMUS 
(Konarev et al., 2003). The radius of gyration Rg and forward scattering I(0), the maximum particle 
dimension Dmax and the distance distribution function p(r) were evaluated using the program 
GNOM (Svergun, 1992). The molecular mass was calculated by comparison with a reference 
bovine serum albumin (BSA) sample. Constrained rigid-body refinement was carried out in 
SASREF7 (Petoukhov and Svergun, 2005) using a number of modeling scenarios. The best model 
was obtained in the case where a core structure of Flt3D2-D4:FL was fixed and Flt3D1 and Flt3D5 
allowed to move without imposing any symmetry constraints. The scattering patterns from the 
high-resolution models were calculated using the program CRYSOL (Svergun et al., 1995). 
 
Electron  microscopy 
For preparation of negatively stained Flt3D1-D5:FL complex, purified complex at ~0.05 mg/mL 
in PBS buffer was applied to the clear side of carbon on a carbon-mica interface and stained with 2 
% (w/v) uranyl acetate. Images were recorded under low-dose conditions with a JEOL 1200 EX II 
microscope at 100 kV and at nominal 40000x magnification. Selected negatives were then 
digitized on a Zeiss scanner (Photoscan TD) at a step size of 14 micrometer giving a pixel size of 
3.5 Å at the specimen level. Using the boxer routine of the EMAN image processing software 
(Ludtke et al., 1999), 25134 subframes of 96x96 pixels containing individual Flt3D1-D5:FL complex 
particles were selected interactively, CTF-corrected with CTFFIND3 (Mindell and Grigorieff, 
2003) and Bsoft (Heymann et al., 2008), and low-path-filtered at 15 Å with Imagic-5. Subsequent 
data processing was performed with Imagic-5 software package (van Heel et al., 1996). The 
translationally centered data set was subjected to multivariate statistical analysis and classification 














Isolation of recombinant Flt3 ectodomain complexes and thermodynamic 
binding profile of complex formation 
High-affinity complexes of purified glycosylated Flt3D1-D5, Flt3D1-D4, and Flt3D1-D3 with 
recombinant human FL produced in E. coli (Verstraete et al., 2009), consistent with bivalent 
binding of FL to each of the ectodomain constructs, were initially established by analytical size-
exclusion chromatography (SEC). Subsequent batches for structural studies were obtained via 
preparative SEC in the presence of excess molar amounts of purified FL (Fig. 2A-C). The elution 
profiles for all three ectodomain complexes were indicative of ligand-induced receptor dimerization. 
In constrast to Flt3D1-D5 and Flt3D1-D4, preparations of recombinant Flt3D1-D3 consistently contained a 
significant portion of receptor that was incapable of binding the ligand even in the presence of 
excess molar amounts of FL (Fig. 2A-C). Conversely, excess molar amounts of Flt3D1-D3 did result 
in a complete titration of FL towards complex formation. On the other hand, we were not able to 
observe complex formation for Flt3D1 and Flt3D1-D2 via SEC providing direct evidence that these 
ectodomain constructs do not carry a high-affinity ligand binding site. 
Characterization of Flt3 extracellular complexes by isothermal titration calorimetry (ITC) led to 
a number of consensus observations (Fig. 2D-F). Firstly, all three characterized complexes exhibit 
high-affinity binding characterized by a strongly exothermic enthalpic term coupled to an entropic 
penalty. Secondly, FL exhibits bivalent binding to both Flt3D1-D5 and Flt3D1-D4 (N=0.5, 2 molecules 
of Flt3 to 1 molecule FL). We note that the observed stoichiometry for the FL: Flt3D1-D3 interaction 
(N=0.12) is likely due to the inability of recombinant Flt3D1-D3 to engage completely in a ternary 
complex in the presence of a molar excess of FL (Fig. 2C).  Nonetheless, the ITC data clearly show 
that Flt3D1-D3 is capable of a high-affinity ternary complex just like the larger ectodomain constructs, 
and that only about 25% of recombinant Flt3D1-D3 may adopt an active conformation. Notably, the 
sequential exclusion of the membrane-proximal domains Flt3D4 and Flt3D5 leads to a modest 
decrease in affinity (Kd [Flt3D1-D5:FL] = 8.7 nM ; Kd [Flt3D1-D4:FL] = 40 nM ; Kd [Flt3D1-D3:FL] = 
74.6 nM) while the thermodynamic profiles remain similar (Fig. 2D-F). Taken together, our data 
suggest that the membrane-proximal module Flt3D4-D5 does not contribute significantly to the overall 








































FIGURE 2. FL binds bivalently to Flt3 ectodomain variants to form high-affinity complexes. 
(A-B) Isolation of Flt3D1-D5:FL and Flt3D1-D4:FL by size-exclusion chromatography (SEC). Also shown, are Coomassie-
stained SDS-PAGE strips corresponding to the peak fraction of the isolated complexes. (C) Size-exclusion 
chromatography on the Flt3D1-D3:FL mixture at the end of an ITC experiment, showing that a large amount of Flt3D1-D3 
remains in the unbound form. Identical elution profiles were obtained in standard SEC experiments as well, in the 
presence of a large molar excess of FL.  (D-F) Binding isotherms and thermodynamic parameters of FL binding to Flt3 
ectodomains obtained by ITC. All ITC experiments were carried out by titrating recombinant human Flt3 extracellular  
domains with FL. 
 




Overall structure of the Flt3 D1-D4:FL complex 
The crystal structure of the Flt3D1-D4:FL complex was determined to 4.3 Å resolution based on 


























Confronted with the recurring poor diffraction quality of Flt3D1-D4:FL crystals derivatized with 
heavy-atoms and selenomethionine-labeled Flt3D1-D4, we successfully combined molecular 
replacement strategies relying on the high resolution structure of human FL (Savvides et al., 2000) 
and a homology model for Flt3D3 (Yuzawa et al., 2007), with phase improvement protocols 
(Cowtan, 2010) exploiting the non-crystallographic symmetry and high solvent content of the 
crystals. Such approaches combined with crystallographic refinement employing information from 
high resolution structures have recently emerged as a powerful option in macromolecular structure 
determination at low resolution (Blanc et al., 2004; Huyton et al., 2007; Schroder et al., 2010). The 
TABLE I. X-ray data collection and refinement statistics. 
 
 
 Flt3D1-D4:FL  Flt3D1-D5:FL 
Data collection   
Source, Wavelength (Å) ESRF ID23-1, 0.9762 ESRF ID23-1, 1.0762 
Detector ADSC-Q315R ADSC-Q315R 
Resolution (Å) 40.00 - 4.30 (4.45 - 4.30) 35.00 - 7.80 (8.00 - 7.80) 
Space group P21 P21 










Wilson B (Å2) 135 401 
Unique reflections 20184 (1942) 5656 (382) 
Multiplicity  3.8 (3.8) 3.4 (3.2) 
Completeness (%) 98.8 (98.9) 96.6 (92.9) 
Rmeas (%)a 10.8 (75.9) 12.8 (80.7) 
Average I/σ(I) 12.04 (2.08) 9.1 (1.9) 
Refinement   
Resolution (Å) 40.00 - 4.30 (4.53 - 4.30) 35.00 - 7.80  (8.72 - 7.80) 
Reflections working set / test set 19172 / 1010 (2763 / 141) 5090 / 565 (1437 / 159) 
Rwork  /  Rfree  0.260 / 0.281 (0.268 / 0.268) 0.337 / 0.346 (0.334 / 0.313) 
R.m.s. deviations   
  Bonds (Å) 0.010 n.a. 
 Angles (°) 1.12 n.a. 
Average ADP (Å2) 169 364 
Ramachandran analysis (%)   
             Favorable 89.8 n.a. 
             Outliers 2.0 n.a. 
Protein Data Bank access code 3QS7 3QS9 
 
The values in parentheses refer to the highest resolution shell. a Rmeas = ∑h√nh/(nh-1) ∑h∑i|I(h,i)-‹I(h)›| / ∑ h∑iI(h,i), 
where nh is the multiplicity, I(h,i) is the intensity of the ith measurement of reflection h,  and ‹I(h)› is the average 
value over multiple measurements. 
 




ensuing electron density maps were exceptionally revealing and contained contiguous electron 
density for several unmodeled receptor domains, including direct crystallographic evidence for N-
linked glycans (Fig. 1A). To facilitate chain tracing we determined the atypical disulfide-bond 
network of Flt3 as well as the actual number of N-linked glycosylation sites in extracellular Flt3 by 
mass-spectrometry. We could confirm that all nine N-linked glycosylation sites are at least partially 































FIGURE 3. Crystal structure of the Flt3D1-D4:FL complex. (A) Domain organization of the Flt3 
extracellular segment. The five Ig-like domains of Flt3 (D1: residues 79-161, D2: residues 167-244, D3: residues 245-
345, D4: residues 348-434 and D5: residues 435-533) are shown as colored boxes. N-linked glycosylation sites are 
indicated with blue diamonds. Partially occupied glycosylation sites are indicated with an asterisk. Also shown is the 
disulfide bond network in Flt3D1-D4 as determined by mass-spectrometry. The putative disulfide bridges in Flt3D5 are 
shown as dashed lines, based on homology with Flt3D2 and KITD5. (B) Overall structure of the Flt3D1-D4:FL complex. The 
crystal structure of the Flt3D14:FL complex is shown in  the vertical axis of the plane. Flt3 domains follow the coloring 
scheme in panel A. Disulfide bridges are shown as yellow spheres and N-linked glycans as green sticks. The structural 
panels to the right show two alternative views of the complex with FL in ribbon representation and the receptor in surface 
representation.  
 




The structure of the Flt3D1-D4:FL complex is unlike any of the structurally characterized 
RTKIII/V complexes to date and is characterized by a number of surprising features (Fig. 3B). The 
Flt3D1-D4:FL assembly can be described as a moderately open horseshoe ring structure measuring 
100 Å x 75 Å x 110 Å, comprising FL, Flt3D2, Flt3D3 and Flt3D4. FL bivalently binds to two receptor 
molecules and is accommodated by a binding epitope at the membrane-distal tip of Flt3D3, while 
Flt3D2 leans against the concave side of Flt3D3 and is stowed underneath FL in the ring opening  
(Fig. 3B). Intriguingly, the apparent two-fold symmetry of the complex about the FL dimer 
interface only holds for the FL:Flt3D2-D3 subcomplex, as both Flt3D1 and Flt3D4 adopt asymmetric 
orientations compared to their tandem modules in the complex (Fig. 3B). Remarkably, Flt3D4 does 
not engage in any obvious homotypic interactions as seen in the KIT structure (Yuzawa et al., 
2007). The N-terminal Flt3D1 exhibits significant disorder and domain plasticity manifested by at 
least two different orientations about the D1-D2 linker region (residues 162-166), and protrudes 
perpendicularly away from the plane of the ring assembly at the level of Flt3D2 without making any 
interactions with the rest of the complex (Fig. 3B). Our electron density maps allowed us to reliably 
model only the core of the Flt3D1 structure (residues 79-161), but residual positive difference 
electron density extending away from the N-terminus of our model suggested that the atypical 50 
amino acid module preceding Flt3D1 is likely associated with the core domain structure.  
 
Flt3 employs a remarkably compact cytokine-binding epitope 
Perhaps the most unanticipated feature of the Flt3D1-D4:FL complex is that the ligand-binding 
epitope is almost exclusively contributed by Flt3D3 (Fig. 4A) for which electron density was 
exceptionally clear including information for some side-chains. This module is a member of the “I-
set” Ig domains and is structurally homologous to extracellular domain 3 of KIT (Liu et al., 2007; 
Yuzawa et al., 2007) and CSF-1R (Chen et al., 2008), featuring 8 β-strands making up the ABED 
and A’FGC β-sheets. However, the topology of Flt3D3 is unusual such that the polypeptide chain 
extending from Flt3D2 forms the N-terminal A strand in Flt3D3 (residues 246 - 249) by 
complementing strand B in a parallel fashion, while the AA’ loop of Flt3D3 (residues 250 - 258) 
adopts an extended conformation (Fig. 1B). Flt3D2, which in all other RTKIII/V complexes 
contributes roughly half of the ligand-binding epitope, packs against the hydrophobic patch 
projected by the ABED-face of Flt3D3 centered around Trp269 burying ~1000 Å2 (Fig. 4B). Flt3D2 is 
homologous to KITD5 and is a member of the C2 subset of the Ig-family (ABED/CFG topology), but 
contains an additional solvent-exposed disulfide (Cys232-Cys241) bridging strands F and G. 
Although the AB and EF loops of Flt3D2 point in the direction of the ligand they remain too far to 
engage in any interactions. The only point on Flt3D2 approaching FL within a distance that could 
mediate any form of interaction is centered on Asp180 on the AB loop of Flt3D2. However, it is not 
clear whether this interaction actually occurs because we were not able to model the side-chain of 
Asp180 (Fig. 4A).  
 























FIGURE 4. The Flt3-FL binding interface.  (A) Close-up view of the Flt3-FL binding interface. FL is 
colored in green, Flt3D3 in grey and Flt3D2 in orange. Residues that constitute the cytokine-receptor interface are shown 
as sticks protruding from spheres centered at their Cα positions. FL residues are colored in yellow and Flt3 residues 
are colored in green. (B) The unusual Flt3D2-Flt3D3 interface. Flt3D2-D4 (Cα trace in red) is shown together with FL in 
ribbon representation (green). Residues at the hydrophobic interface are shown as black sticks. Disulfide bonds in 
Flt3D2-D3 are shown as ball and sticks (yellow). (C) Structure-based alignment of diverse FL sequences revealing strict 
conservation of the PISSXF-segment (residues 10 - 15) within the N-terminal loop (coloured in red). A complete 
alignment can be found in Appendix E. (D) Structural comparison of bound versus the unbound FL.  
 
The FL binding epitope on Flt3D3 engages in extensive interactions with the N-terminal loop 
(residues 8-13) of FL leading to αA and Lys18 on αA, and is mainly contributed by the BC loop of 
Flt3D3 (residues 279-280) and strand D (residues 301-303). Additional interactions are mediated by 
the DE loop of Flt3D3 (residue 307) which contacts a small patch on the C-terminal region of helix 
αC of FL defined by residues 73 and 78. Therefore, the Flt3 ligand-receptor interaction results in a 
single contact site covering merely ~900 Å2 of buried surface area. Structure-based alignments 
using diverse FL sequences revealed a remarkably strict conservation of the PISSxF cassette as well 
as Phe81 and Leu115, which help to lock the N-terminal loop in its observed conformation (Fig. 
4C, Appendix E). 
 
 




Plasticity of FL upon binding to Flt3                               
Comparison of FL in its unbound (Savvides et al., 2000) and now in its receptor-bound form 
reveals that the cytokine ligand does not undergo any significant local structural changes at its 
receptor binding epitope (Fig. 4D). This is contrary to what has been observed in Stem Cell Factor 
(SCF) in complex with KIT, whereby the cytokine ligand undergoes a cascade of structural 
rearrangements (Liu et al., 2007; Yuzawa et al., 2007). However, the two FL subunits display a 
hinge-like rigid-body rearrangement about the dimer interface, which increases the tilt angle 
between the two protomers by 5-6° (Fig. 4D). A similar motion was previously observed in the 
SCF-KITD1-D5 complex although SCF, unlike FL, already appears to have significant variability in 
the receptor-free form as shown by the range of its intersubunit tilt angles (2° to 6°) (Yuzawa et al., 
2007). 
 
The Flt3D3-Flt3D4 domain elbow and the absence of homotypic receptor 
interactions 
A second striking feature of the Flt3D1-D4:FL complex is the absence of any obvious specific 
homotypic receptor interactions. Based on the current paradigm of RTKIII activation such 
interactions would be mediated by extracellular domain D4. While Flt3D4 does point to its tandem 
Flt3D4, in the complex, the two receptor domains stay clearly away from each other and deviate 
from the two-fold symmetry of the complex. The inability of Flt3D4 to engage in homotypic 
interactions may also explain the observed disorder for this part of the structure, as we could only 
reliably model and refine a complete Flt3D4-Flt3D4’ tandem in only one of the two complexes in the 
asymmetric unit of the crystal, whereas for the second we could only place one of the two domains.  
Closer inspection of the Flt3D4 topology and sequence reveals that Flt3D4 does not possess the 
conserved structure-sequence fingerprints seen in all other RTKIII/V homologues for this domain. 
For instance, Flt3D4 has two additional disulfide bridges, a solvent exposed cross-strand disulfide 
bridge (Cys368-Cys407) connecting strands B and E, and a second (Cys381-Cys392) connecting its 
unusual C’E loop with strand C. Most importantly, Flt3D4 displays an EF-loop that drastically 
differs both in structure and sequence from all homologues (Fig. 5A-C). The EF-loop constitutes 
the otherwise conserved ‘tyrosine corner’ motif in I-set Ig-domains (Harpaz and Chothia, 1994), 
and has been shown to mediate homotypic interactions in the case of KITD4 (Yuzawa et al., 2007) 
and VEGFRD7 (Yang et al., 2010) (Fig. 5B).  
Structural comparisons of the two independent Flt3D1-D4:FL complexes in the crystal asymmetric 
unit revealed slight orientational plasticity of Flt3D4 about the Flt3D3-Flt3D4 linker region. This 
stretch of residues and strand A of Flt3D4 are well conserved in Flt3 and KIT and other RTKIII 
suggesting a common functional role (Fig. 5D). A comparison of KIT in the cytokine-bound and -
unbound forms, showed that the KITD3-KITD4 linker region acts as a hinge to reorient KITD4 for 
homotypic interactions upon ligand binding. Despite the absence of such homotypic contacts in 




Flt3, the domain elbow defined by Flt3D3 and Flt3D4 is similar to KIT, suggesting preservation of 
this interdomain relationship in both forms of the receptor. Thus, the orientation of Flt3D4 appears to 
be restricted by a core of well-defined hydrophobic interactions mediated by Phe261 (A’ strand of 
Flt3D3), Val345 (Flt3D3-Flt3D4 linker), Phe349 (A strand of Flt3D4) and Tyr376 (BC loop of Flt3D4), 




















FIGURE 5.  The Flt3D3-Flt3D4 elbow and the absence of homotypic receptor contacts in the 
Flt3:FL complex.  
(A) The Flt3D3-Flt3D4 elbow. Flt3D3 (partially shown) and Flt3D4 are shown in ribbon representation. For clarity 
purposes only the laThe locations of the atypical disulfide bridges in Flt3D4 (Cys368-Cys407 and Cys381-Cys391) are 
indicated. Residues mediating hydrophobic interactions between Flt3D3 and Flt3D4 are shown as green sticks. Residues 
in the Flt3D3-Flt3D4 linker (346-348) are shown as yellow spheres centered at their Cα positions. The side-chains of 
residues mediating contacts between the AA’ loop of Flt3D3 and the C’E loop of Flt3D4 could not be modelled due to the 
low resolution of our analysis. The EF-loop of Flt3D4 constituting the ‘tyrosine corner’ around Y416 (green sticks) is 
shown in orange. (B) Sequence conservation of residues involved at the D3-D4 interface in KIT and Flt3 based on 
comparisons between human and murine Flt3 and KIT sequences. (C) KITD3-KITD4 orientation in the KIT:SCF 
complex.  Homotypic receptor contacts between tandem ectodomain 4 modules in the KIT-SCF complex are mediated 
by salt-bridges via residues R381 and E386 residing on the EF loops (orange) (PDB entry 2E9W). Residues at the 
hydrophobic KITD3-KITD4 interface are shown as green sticks. Residues in the KITD3-KITD4 linker region (D309-
G311) are shown as yellow spheres. (D) Flt3D4 displays an atypical EF-loop within the RTKIII/V family. The pair of 
residues mediating the homotypic contacts in KITD4 and VEGFR-2D7 is well conserved in the corresponding domains 
of all RTKIII/V members but not in Flt3D4. 
 




Architecture of the complete extracellular assembly of the Flt3 signaling 
complex 
Crystals of Flt3D1-D5:FL grew reproducibly from a number of crystallization conditions but 
proved to be of low diffraction quality despite repeated attempts to improve crystal quality by 
various methods including glycan shaving.  Nonetheless, a robust dataset to 7.8 Å resolution proved 
sufficient to elucidate the architecture of the complete extracellular Flt3 complex by molecular 
replacement based on the Flt3D2-D3: FL subcomplex as refined in the Flt3D1-D4:FL crystal structure 
(Table I). We could subsequently place into electron density and optimize by rigid-body refinement 
protocols Flt3D1 and Flt3D4, extracted from the crystal structure of the Flt3D1-D4:FL complex, as well 
as a conservative homology model of Flt3D5 derived from the structure of human KITD5 (Yuzawa et 
al., 2007). While the low resolution of the Flt3D1-D5:FL structure does not allow discussion of 
structural details, it does provide a reliable and valuable depiction of the organization features of the 












In the full-length ectodomain complex, the core structure observed in Flt3D1-D4:FL is mounted 
onto two membrane-proximal Flt3D5 facing each other to form an assembly resembling a hollow 
tennis racket (140x75x110 Å) (Fig. 6). Remarkably, the asymmetry exhibited by the tandem Flt3D4 
modules in Flt3D1-D4:FL is not present in the complete extracellular complex. Instead, the two Flt3D4 
segments face each other nearly symmetrically according to the 2-fold symmetry of the Flt3D2-D3:FL 
core structure and approach to about 20 Å from each other. While this inter-receptor separation is 
maintained at the ensuing Flt3D5 modules, the apparent two-fold symmetry breaks down. 
Furthermore, the asymmetric projection of the N-terminal Flt3D1 domains perpendicularly out of the 
plane of the racket head occurs in a manner analogous to what we observed in the Flt3D1-D4:FL 
complex. Complementary studies of the full-length ectodomain complex by negative-stain negative-
stain electron microscopy (EM), and small-angle X-ray scattering (SAXS) in solution corroborated 
the overall structural features revealed by the crystal structure (Fig. 7A,B). 
 
FIGURE 6. Assembly of the complete Flt3 ectodomain complex. Surface representations of the full-
length Flt3 ectodomain complex. The central view shows the complex with the two-fold symmetry axis of FL 
oriented vertically in the plane of the paper.  
 

















   








FIGURE 7.  Negative-stain electron microscopy and SAXS analysis of the Flt3D1-D5-FL complex.  
A. The displayed gallery of 100 class averages of the Flt3D1-D5:FL complex allows to recognize features corresponding to 
projections of the crystal structure at different orientations, notably the slightly open horseshoe ring structure with well-
defined individual extracellular domains. B. The crystal structure of the Flt3D1-5-FL complex was refined as a rigid-body 
model against the experimental scattering curve obtained by SAXS. Fitting of the theoretical scattering curve calculated 










Cytokine-mediated activation of hematopoietic cell-surface receptors is central to developing 
and sustaining hematopoiesis and the immune system. The RTKIII receptor Flt3 and its cognate 
cytokine ligand FL are arguably the most exciting new addition to the repertoire of hematopoietic 
factors, due to their activity on hematopoietic progenitors and pronounced impact on the 
development and homeostasis of antigen-presenting DC. As the importance of Flt3 signaling in 
early and late hematopoiesis continues to mount, we sought to elucidate the structural basis of the 
extracellular Flt3 receptor-ligand complex. The structural studies we report here complemented by a 
thermodynamic dissection of complex formation show that the Flt3-FL interaction is characterized 
by high-affinity bivalent binding of FL to Flt3 that does not invoke homotypic receptor interactions. 
The assembly showcases several unexpected features, which now establish Flt3 as a structural 















Figure 8.  Comparison of representative RTKIII/V extracellular complexes.  
The structures shown represent the architecture of receptor-cytokine complexes for the different members of the 
RTKIII/V family: From left to right: human Flt3:FL (this study), human KIT:SCF (pdb 2E9W), mouse CSF-1R:CSF-1 
(pdb 3EJJ), human PDGF-Rβ:PDGF-B (pdb 3MJG) and human VEGF-R2:VEGF-C (PDB 2X1X). The dimeric 
ligands are colored in magenta. Receptor ectodomains are colored as follows: D1 in pale yellow, D2 in blue, D3 in 
green, D4 in orange and D5 in grey. 
 
The Flt3:FL interaction epitope is surprisingly a fraction of typical helical cytokine-receptor 
interaction, and is dominated by contacts between a preformed N-terminal segment of FL and 
Flt3D3. Consistent with the polar receptor-cytokine interface, the thermodynamic blueprint of the 
interaction calls for an enthalpically-driven binding event. The interaction carries a concomitant 
 




significant entropic cost, which we now can rationalize in terms of the absence of a hydrophobic 
effect and the intrinsic entropy loss associated with bringing interaction partners together. 
The Flt3-FL interaction interface covers a compact ~900 Å2, which is at least 2 times less 
extensive than the buried surface area at the receptor-cytokine epitopes of all other RTKIII/V 
complexes, whereby the activating cytokine is harbored by a broad grapple defined by extracellular 
domains 2 and 3 (Liu et al., 2007; Yuzawa et al., 2007; Chen et al., 2008; Leppanen et al., 2010; 
Shim et al., 2010) (Fig. 8). Comparison with diverse helical cytokine-receptor interactions (Stroud 
and Wells, 2004; Wang et al., 2009) shows that Flt3 is the only receptor for a helical cytokine that 
uses a single interaction site to bind its cognate ligand. Heterodimeric protein-protein interactions 
bury on average ~1300 Å2 of surface area, which is strongly correlated with high-affinity binding 
(Janin et al., 2008). Flt3 and FL are clearly able to establish a tight interaction via a much more 
compact binding interface.  A plausible explanation could be drawn from the rigidity of the receptor 
epitope on FL as a preformed binding platform, reminiscent of a classical ‘lock-and-key’ binding 
mode observed in affinity-matured antibody-antigen interactions (Sundberg and Mariuzza, 2002). 
Furthermore, a series of single amino acid substitutions (H8R, S9G, P10S, S13P/F, F15L) within 
the segment contributing almost the entire receptor binding epitope on FL, abolish receptor 
activation completely (Graddis et al., 1998). This illustrates not only the possible individual 
contribution of each residue in this segment to binding but also the likely conformational stringency 
of the region. Indeed, a comparison of diverse FL sequences showed that not only the receptor-
binding epitope is exquisitely conserved but also residues that help to lock the N-terminal loop both 
in its observed receptor-bound and receptor-free forms (Fig. 4C, Appendix E). 
Comparison of the Flt3-FL interaction and representative receptor-cytokine epitopes for all 
other RTKIII/V, shows that engagement of Ig-like domain 3 (BC loop; DE loop and flanking 
residues) is the only common epitope feature of ligand binding (Fig. 8). It thus appears that binding 
of D3 of RTKIII/V to the activating cytokine satisfies a geometric requirement that allows receptor 
molecules to approach to a critical distance of ~60 Å from one another. This notion reinforces a 
fascinating aspect of RTKIII/V activation in that the cognate protein ligands are all dimeric with 
similar dimensions despite their grouping into two fundamentally different folds (4-helix bundles 
versus all-β cystine-knot scaffolds) (Savvides et al., 2000; Yuzawa et al., 2007; Chen et al., 2008; 
Leppanen et al., 2010; Shim et al., 2010). Recently, interleukin-34 (IL-34) was identified as a 
second ligand to CSF-1R (Lin et al., 2008), thus adding a perplexing dimension to RTKIII signaling 
as IL-34 bears no sequence similarity to the currently known cytokine ligands for RTKIII/V or other 
proteins. 
The uniqueness of the Flt3 extracellular complex is further highlighted by the absence of 
homotypic receptor interactions. Such interactions have recently emerged as an important aspect of 
RTKIII/V activation and are mediated by conserved structure-sequence fingerprints in the 
membrane-proximal domains (Yuzawa et al., 2007; Ruch et al., 2007; Chen et al., 2008; Yang et 
al., 2008; Yang et al., 2010). In both of our Flt3-FL complexes, the membrane-proximal modules 




remain separated by ~20 Å at the D4-D5 junction, consistent with our comparative ITC data 
showing no significant contribution by the D4-D5 module. Flt3 is the only RTKIII/V family 
member that lacks the conserved set of residues involved in homotypic interactions in the 
homologous receptors, which now offers a strong rationale for the absence of such interactions in 
the extracellular Flt3 complex. Additional support comes from the existence of a fully active murine 
Flt3 isoform that lacks Flt3D5 demonstrating the dispensability of the membrane-proximal domain 
for receptor activation (Lavagna et al., 1995), contrary to the apparent importance of KITD5 in 
signaling (Broudy et al., 2001). However, it is possible that homotypic interactions could be 
enhanced within the two-dimensional spatial confinement of the cell membrane, and as a result of 
additional interactions between TM and/or cytosolic segments of Flt3. In fact, the difference in the 
affinity for the complete ectodomain complex versus previously reported values for native Flt3 
based on cell-assays (Turner et al., 1996; Graddis et al., 1998) may reflect a combination of such 
factors. To this end, recent studies have highlighted the importance of homotypic interactions 
between TM and JM regions in RTKIII/V activation and pathology profiles (Finger et al., 2009; 
Oates et al., 2010). Interestingly, oncogenic variants of Flt3 carrying ITD in the JM segment are 
constitutively active as homodimers or as heterodimers with wild-type receptor, indicating that 
enhanced intracellular receptor interactions can drive activation (Kiyoi et al., 2002). Recently, a 
number of mutations in the extracellular segment of Flt3 were identified in AML patients                           
(Schnittger et al., 2006; Fröhling et al., 2007), which we now can map onto the Flt3 ectodomain 
(Fig. 9). However, the clinical relevance of these mutations will have to await further study.  
In the absence of structural information for unbound Flt3 we are left to wonder about any 
possible domain rearrangements in Flt3 upon FL binding. Structural studies of KIT in the bound and 
unbound forms showed that KIT undergoes a large conformational switch at the KITD3-D4 junction 
leading to homotypic receptor interactions (Yuzawa et al., 2007). However, the extensive and 
unique hydrophobic interface observed between Flt3D2 and Flt3D3 (1000 Å2), the hydrophobic 
interface between Flt3D3 and Flt3D4, and additional contacts between loops thereof, provide evidence 
that the Flt3D2-D4 ectodomain segment would be too rigid to undergo significant domain 
rearrangements. This is further supported by our structural studies of the complete extracellular 
complex, which showed that the relative orientation of Flt3D3 and Flt3D4 only differs slightly from 
that observed in the Flt3D1-D4:FL complex. Nonetheless, Flt3 does exhibit significant domain 
plasticity at the two extremities of the extracellular assembly. This is most pronounced for Flt3D1, 
which emanates from the core of the assembly without making contacts with other complex 
components. We note that the stacking of Flt3D2 against Flt3D3 provides a fixed angle for projecting 
Flt3D1 from a point approximately halfway down the height of the complex. Flt3D1 is the largest and 
most atypical domain in Flt3 and the entire RTKIII/V family, but its role in Flt3 signaling is 
currently unknown. We are thus tempted to propose that Flt3D1 could mediate intermolecular 
contacts at the cell surface and/or stabilize the unbound receptor.  
 



















FIGURE 9. Mapping of non-synonymous sequence variants identified in the Flt3 ectodomain 
of AML patients. While the majority of oncogenic alterations in the Flt3 gene are located in the JM and TKD 
regions, several mutations in the extracellular domains have recently been identified in AML patients. Expression of 
Flt3 carrying a mutation at position 451 (S451F) in BaF3 cells resulted in cytokine-independent proliferation and 
constitutive Flt3 autophosphorylation, demonstrating the oncogenic potential of this sequence variant. S451 is 
located at the solvent exposed site of strand B in the membrane proximal domain 5.  Although the D324N variant did 
not result in ligand-independent activation it is associated with a higher risk of myeloid leukemias. D324 is located in 
the EF-loop of domain 3. A possible role in leukemogenesis has not been demonstrated yet for the other sequence 
variants (T167A, V194M, Y364H). 
 
The availability of structures for the complete extracellular Flt3 receptor-ligand complex 
including a delineation of the receptor-cytokine interface, will likely have a significant impact on 
renewed efforts to antagonize Flt3 activity in a clinical setting. This is because wild type and 
mutated forms of Flt3 as well as autocrine secretion of FL have been implicated in the development 
of myeloid leukemias (Kindler et al., 2010; Sanz et al., 2009; Stirewalt and Radich, 2003; Zheng et 
al., 2004). Current strategies focus on inhibition of the intracellular kinase domains of Flt3, but are 
faced with drug specificity issues and the emergence of primary and secondary resistance to 
treatment (Kindler et al., 2010). More recently, an alternative therapeutic approach based on 
monoclonal antibodies directed against the extracellular domain of Flt3 (Piloto et al., 2006) 
indicated a possible momentum shift towards combined strategies in clinical targeting of Flt3. A 
daunting challenge in inhibiting protein-protein interactions is the extent of the interaction epitope 
which often covers >1500 Å2 and the lack of prior knowledge of functional hotspots (Wells and 
 




McClendon, 2007). In this regard, the compactness of the Flt3 ligand-receptor interface provides 
favorable perspectives for the druggability of the extracellular Flt3 binding epitope.  
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Flt3 is a type III tyrosine kinase receptor (RTKIII) expressed at the cell surface of early 
hematopoietic progenitors and, upon activation by its cognate ligand FL, initiates signaling 
pathways crucial for the development of the human hematopoietic and immune systems. Flt3 
signaling is especially important during the early stages of hematopoiesis and for the development 
of antigen-presenting dendritic cells. In this work, the first structural insights into the Flt3 ligand-
receptor interaction are presented.  
 
Recombinant production of human FL and Flt3 ectodomains and isolation 
of Flt3:FL complexes 
In the first stage of the project efficient protocols for the recombinant production of FL and Flt3 
ectodomains needed to be established. A 'soluble form' of FL could be refolded from inclusion 
bodies produced in E. coli. Optimization of the refolding protocol resulted in yields that approached 
5 mg per liter of culture. The bioactivity of our recombinant human FL was demonstrated by cell-
based phosphorylation and proliferation assays. 
 
Flt3 ectodomain variants were produced in stably transfected HEK293S GnTI-/- TetR cells. 
These cells allow for tetracycline-regulated expression and secrete proteins with limited and 
homogeneous N-linked glycosylation which can be minimized by treatment with EndoH. Contrary 
to the ectodomains of homologous receptors expressed in our laboratory, the yields for Flt3 in 
transient expression experiments were prohibitively low. The strategy to develop inducible stable 
cell lines in HEK293 GnTI-/- cells could therefore be generally applicable for structural studies 
involving eukaryotic receptor ectodomains that are difficult to express. It is further hypothesized 
that the low expression yields we observed in our transient expression experiments might explain 
why the Flt3 ligand-receptor interaction has remained so ill-characterized when compared to its 
homologues. 
 
The Flt3 ectodomain (Flt3D1-D5, residues 1 to 542) contains five immunoglobulin (Ig)-like 
domains. To delineate the ligand-binding epitope and to obtain various ligand-receptor complexes 
for structural studies by X-ray crystallography, five Flt3 ectodomain variants that were serially 
truncated at the C-terminus (Flt3D1-D5, FltD1-D4, Flt3D1-D3, Flt3D1-D2 and Flt3D1) were produced in 
stably transfected HEK293S GnTI-/- cell lines. Their ability to interact with recombinant E. coli-
derived FL was evaluated by size exclusion chromatography (SEC) and isothermal titration 
calorimetry (ITC). It was found that FL and receptor fragments Flt3D1-D5, Flt3D1-D4 and Flt3D1-D3 
form high-affinity ternary complexes in which the dimeric ligand bivalently binds two receptor 
fragments. For the Flt3D1-D2 and Flt3D1 fragments, no complex formation was observed. 
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Crystallization of Flt3:FL complexes 
Subsequently, highly pure preparations of Flt3D1-D5:FL, Flt3D1-D4:FL and Flt3D1-D3:FL ternary 
complexes, which were isolated by SEC in the presence of an excess molar amount of FL, were 
subjected to an extensive crystallization screening. No crystals were obtained for the Flt3D1-D3:FL 
complex, even when the receptor was glycan-minimized with EndoH. On the contrary, 
homogeneously glycosylated Flt3D1-D5:FL and Flt3D1-D4:FL complexes resulted in a large number of  
hits. For both complexes, crystallization conditions were characterized by the presence of 10 - 15 % 
medium molecular weight PEGs, 0.1 - 0.2 M of various salts and a pH value of 6.5 - 8.5. Crystal 
optimization and ensuing diffraction experiments showed that these crystals had an inherently low 
diffraction capacity. Flt3D1-D5:FL crystals generally diffracted only to a resolution of 10 Å, while          
Flt3D1-D4:FL diffracted to 4.5 to 5 Å. Flt3D1-D5:FL crystals that were formed with a glycan-shaved 
receptor also diffracted poorly, and for the Flt3D1-D4:FL complex, no crystals could be formed after 
the receptor had been treated with EndoH. For structural analysis of the Flt3:FL complex, we were 
therefore dependent on these weakly diffracting crystals. Screening hundreds of crystals and an 
extensive optimization of the cryoprotection protocol finally resulted in a dataset to 4.3 Å for the 
Flt3D1-D4:FL complex and a dataset to 7.8 Å for the Flt3D1-D5:FL complex.  
 
Structure solution of the Flt3D1-D4:FL complex 
 The 4.3 Å dataset for the Flt3D1-D4:FL complex could be phased by a combination of molecular 
replacement (MR) and density modification. Initially, two copies of FL, for which the high- 
resolution structure was determined previously (pdb 1ETE), were easily located. This indicated the 
presence of two Flt3D1-D4:FL complexes in the asymmetric unit. Subsequently, an MR-search with a 
structural model for Flt3D3, based on the homologous KITD3 structure (pdb 2E9W), located three 
copies for Ig-domain D3, with each copy identically packed against one FL protomer. After manual 
placement of a fourth copy of D3, the partial solution was rigid-body refined. Ensuing density 
modification protocols, employing the four-fold non-crystallographic symmetry, generated maps 
that contained well defined contiguous density for some of the missing domains of Flt3D1-4. These 
maps allowed us to select the correct MR-solution for one Flt3D4 copy, and to manually place two 
additional copies of Flt3D4 and four copies of Flt3D2. In the later stages of the structure solution 
process it was possible to locate two copies of Flt3D1. The structure was refined in autoBuster with 
tight NCS-restraints and a low weight on the X-ray term. To facilitate the chain chasing process the 
atypical disulfide bond network in the Flt3 ectodomain as well as the actual number of 
glycosylation sites were determined by mass spectrometry. Coordinates and structure factors were 







Flt3 is a structural and functional outlier in the RTKIII/V family 
The determined structure of the Flt3D1-D4:FL ternary complex showed that the Flt3:FL 
interaction is unlike any of the other structurally characterized RTKIII/V complexes to date. While 
all other RTKIII/V receptors bind their ligand in the groove presented by D2 and D3, the interaction 
of Flt3 with FL is solely mediated by Flt3D3, while Flt3D2 is tightly packed against Flt3D3 through a 
hydrophobic interface. Furthermore, the two copies of Flt3D1 that could be located emerge 
asymmetrically from the plane of the complex without making any interactions with the ligand or 
other domains of the receptor. A third remarkable feature of the Flt3D1-D4:FL complex is the absence 
of homotypic contacts between the adjacent Flt3D4 domains. According to the current paradigm of 
RTKIII activation, D4-mediated homotypic receptor-receptor contacts are formed upon ligand 
binding and are crucial to activate the intracellular tyrosine kinase domains.  
 
Flt3 ligand-receptor interface 
Similar to KITD3 and CSF-1RD3, Flt3D3 uses it BC and DE loops to accommodate the ligand. The 
receptor-binding epitope on FL is almost entirely contained in the N-terminal segment preceding the 
first α-helix. This segment was previously identified as the region most crucial for receptor binding 
by a random mutagenesis screen. Furthermore, the residues in this segment (PISSXF) and 
surrounding residues that stabilize its conformation are strictly conserved among a wide variety of 
species, suggesting that the Flt3 ligand-receptor interaction mode is conserved as well. Indeed, 
unlike the homologous KIT:SCF and CSF-1R:CSF-1 ligand-receptor pairs, Flt3 has been shown to 
have a wide species cross-reactivity. 
Although our low-resolution structural analysis does not provide information about specific 
ligand-receptor interactions, the residues present at the interface clearly indicate that FL and Flt3D3 
engage through a polar interaction. This is in agreement with our thermodynamic data that had 
shown that Flt3:FL complex formation is driven by a large exothermic enthalpy.  
 
Absence of homotypic contacts and structural analysis of the Flt3D1-D5:FL 
complex 
For the other RTKIII receptors it has been shown that D4 couples ligand-binding to receptor 
activation by mediating homotypic receptor-receptor contacts through a pair of well conserved salt 
bridges located in the EF loop of D4. Point mutations that target these salt bridges allow ligand 
binding but severely compromise signaling. It is thought that these specific contacts between 
adjacent receptors orient the intracellular tyrosine kinase domains in a signaling competent state. 
Flt3 is the only member of the RTKIII-family that lacks these salt bridges. The absence of these 
residues is in agreement with the observation that adjacent Flt3D4 do not interact. Since homotypic 
contacts are crucially important in the activation process of the other RTKIII members and, given 
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the conserved mechanism of autoinhibition of the tyrosine kinase domains, it is difficult to 
rationalize how the Flt3 receptor is activated then.  
It was hypothesized that the lack of homotypic receptor contacts in the Flt3D1-D4:FL structure 
was due to the absence of the membrane-proximal domain Flt3D5. We therefore determined the 
architecture of the complete Flt3:FL extracellular assembly by rigid-body refinement against the 
obtained 7.8 Å X-ray dataset. The resulting structure (pdb 3QS9) showed that the Flt3D1-D5:FL 
complex also adopts an open conformation, thereby demonstrating that also Flt3D5 does not mediate 
homotypic receptor-receptor interactions. In this regard, it is interesting to note that a murine Flt3 
isoform, which lacks the fifth Ig-like domain, was reported to be equally active as the full length 
receptor. 
In conclusion, our study shows that Flt3, in contrast to KIT and CSF-1R, does not form 
receptor-receptor interactions in ternary complexes formed between its ectodomain and ligand. It is 
however possible that homotypic Flt3 receptor interactions are enhanced within the two-
dimensional spatial confinement of the cell membrane, and as a result of additional interactions 
between the TM and/or cytosolic segments of Flt3. In fact, the difference in the affinity for the 
complete ectodomain complex versus previously reported values for native Flt3 based on cell-





Does receptor binding occurs in a cooperative way? 
Several lines of evidence suggest the existence of communication mechanisms between the 
receptor-binding epitopes of dimeric helical bundle cytokines. For example, in SEC experiments, 
the KITD1-D3:SCF complex does not dissociate in the presence of a high excess of ligand. This 
suggests a positively cooperative binding mode for KIT (Lemmon et al., 1997). In the determined 
structure of the murine CSF-1RD1-D3:CSF-1 complex, only one copy of CSF-1RD1-D3 was bound to 
the ligand, although the crystallization mixture contained more than a twofold molar excess of            
CSF-1RD1-D3. Here the authors suggested that the binding of one CSF-1RD1-D3 fragment lowers the 
affinity for the second (Chen et al., 2008). For all Flt3 constructs that formed a complex with the 
ligand, no dissociation in the excess of ligand was observed in SEC experiments. This suggests that 
Flt3 receptor binding is cooperative. Therefore, it would be interesting to investigate if a 
heterofunctional form of FL, in which one protomer has a mutated receptor-binding epitope, still 
displays high-affinity receptor binding. Such a ligand can be produced by co-refolding differentially 





Probing the role of the different Ig-like domains in ligand-binding and 
receptor activation by cell-based assays 
On the basis of our determined structures there is no clear function for D1. Possible roles for  
this domain include stabilizing/autoinhibiting unbound Flt3, clustering ligand-receptor complexes at 
the cell surface or mediating interactions with other players at the cell surface. Also the role of D5 
in human Flt3 remains unclear. Although there exists an active murine isoform that lacks D5, such 
an isoform has not been reported in human.  
The importance of these domains in ligand-binding and receptor activation could be investigated 
by expressing domain-deletion variants of the full length Flt3 receptor in an appropriate mammalian 
cell system. Ensuing binding assays with radiolabeled FL, and phosphorylation and proliferation 
assays could then provide valuable insights into the function of these domains. 
 
Development of small-molecule Flt3 antagonists that inhibit ligand 
binding 
It has been proposed that FL is involved in leukemogenesis by autocrine signaling loops since it 
is expressed in the majority of AML blasts. Furthermore, the dramatically increased serum levels of 
FL, following chemotherapy mitigate the inhibition and cytotoxicity of Flt3 tyrosine kinase 
inhibitors. These findings suggest a rationale for targeting FL-Flt3 interaction as a therapeutic 
strategy. The structure of the Flt3 ligand-receptor complex shows that the compact receptor-binding 
epitope of FL is almost exclusively contained in the N-terminal peptide segment preceding the first 
α-helix. Furthermore, this segment likely does not undergo conformational changes upon receptor 
binding. This finding could stimulate the development of small-molecule or peptide-based receptor 
antagonists. 
 
Obtaining a high-resolution structure of the Flt3 ligand-receptor complex 
In retrospect, the relatively weak diffraction capacity of the obtained crystals for the Flt3 ligand-
receptor complexes is likely related to the apparently inherent flexibility of the terminal Ig-domains. 
Furthermore, Flt3D1-D5 contains 9 N-linked glycosylation sites. Based upon the acquired structural 
insights, a mininal Flt3D2-D3:FL complex is an interesting target to crystallize. The compactness of 
this complex could allow the formation of crystals with higher internal order. Furthermore, Flt3D2-D3 
only contains two glycosylation sites, which could be targeted by site-directed mutagenesis. The 
expression of receptor constructs without D1 has yet to be explored. A possibly strategy also 
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Crystallization of Flt3 receptor fragments 
In the absence of structural information for unbound Flt3 we are left to wonder about any 
possible domain rearrangements in Flt3 upon FL binding. To this end, GlcNac2Man5 and EndoH-
treated Flt3D1-D5, Flt3D1-D4 and Flt3D1-D3 receptor fragments have been subjected to an extensive 
crystallization screening using an automated robotic system. However, for none of these fragments 
crystals were obtained. The crystallization of Flt3D1-D2 was not attempted because of its low 
expression yields. However, for Flt3D1 (residues 27-161) crystals could be obtained.  These crystals 
currently diffract anisotropically to a resolution of 4.7 Å. Flt3D1 contains 3 N-linked glycosylation 
sites. EndoH treated Flt3D1 failed to crystallize. Strategies to improve the crystal quality could focus 
on eliminating one or more glycosylation sites by site-directed mutagenesis, and/or on isolating 
differently glycosylated species by high-resolution ion exchange chromatography. 
It would also be interesting to see if isolated Flt3D4 or Flt3D5 domains can be crystallized. The 



























Flt3 is een type III tyrosine kinase receptor (RTKIII) die geëxpresseerd wordt aan het 
celoppervlak van primitieve hematopoietische progenitoren. Na activatie door zijn cognaat 
cytokine, Flt3 ligand (FL), initieert Flt3 signaaltransductiecascades die cruciaal zijn voor de 
ontwikkeling van het humane hematopoïetische stelsel en immuunsysteem. De door Flt3 
gemediёerde signalisatie is in het bijzonder belangrijk voor de ontwikkeling van antigen-
presenterende dendritische cellen. In dit werk werden de eerste structurele inzichten voor de Flt3 
ligand-receptor interactie bekomen. 
 
Recombinante productie van de humane FL en Flt3 ectodomeinen en 
isolatie van Flt3:FL complexen  
In het eerste stadium van het project dienden er efficiënte protocols voor de recombinante 
aanmaak van de FL en Flt3 ectodomeinen ontwikkeld te worden. Een ‘oplosbare’ vorm van FL kon 
bekomen worden door het in vitro heropvouwen van in E. coli geproduceerde inclusielichamen. 
Optimalizatie van het heropvouwingsprotocol resulteerde in een opbrengst tot 5 mg recombinant FL 
per liter E. coli cultuur. De bioactiviteit van deze vorm van humaan recombinant FL werd 
aangetoond via cel-gebaseerde fosforylatie- en proliferatie assays.  
 
Flt3 ectodomeinen varianten werden geproduceerd in stabiel getransfecteerde HEK293S GnTI-/- 
TetR cellen. Deze cellen laten tetracycline gereguleerde expressie toe en zij secreteren eiwitten met 
een beperkte N-gelinkte glycosylatie die bovendien zeer gevoelig is voor behandeling met EndoH. 
In tegenstelling tot de ectodomeinen van homologe receptoren die ook in het laboratorium 
geëxpresseerd werden, waren de opbrengsten via transiente expressie-experimenten in HEK293T 
cellen zeer laag voor Flt3. De strategie die wij gevolgd hebben om induceerbare stabiele cellijnen in 
HEK293S GnTI-/- cellen te ontwikkelen kan mogelijks algemeen toepasbaar zijn voor structurele 
studies met eukaryote ectodomeinen die moeilijk te expresseren zijn. De lage opbrengsten voor Flt3 
die wij waarnamen in transiënte expressie-experimenten verklaren mogelijks waarom de Flt3 
ligand-receptor interactie tot heden zo slecht gekarakteriseerd was. 
 
De extracellulaire regio van Flt3 (Flt3D1-D5) bevat 5 immunoglobuline (Ig) domeinen. Om de 
ligand-bindende epitoop af te lijnen, en om verscheidene ligand-receptor complexen te verkrijgen 
voor structurele studies, werden er 5 Flt3 ectodomein varianten die sequentieel getrunceerd waren 
aan de C-terminus (Flt3D1-D5, Flt3D1-D4, Flt3D1-D3, Flt3D1-D2 en Flt3D1) geproduceerd in stabiel 
getransfecteerde HEK293S GnTI-/- cellijnen. Het vermogen van deze receptorfragmenten om met 
recombinant FL te interageren werd geёvalueerd via ‘gelfiltratie-chromatografie’ en ‘isothermale 





ectodomain varianten ternaire complexen kunnen vormen met een hoge affiniteit, waarin het dimere 
ligand bivalent bindt aan twee receptoren. Voor de Flt3D1-D2 en Flt3D1 fragmenten kon geen complex 
met FL aangetoond worden. 
 
Kristallisatie van Flt3:FL complexen 
Heel sterk opgezuiverde preparaties van Flt3D1-D5:FL, Flt3D1-D4:FL en Flt3D1-D3:FL ternaire 
complexen werden onderworpen aan een extensieve kristallisatiescreening. Voor het Flt3D1-D3:FL 
complex werden geen kristallen bekomen, ook niet wanneer de receptor behandeld was met EndoH. 
Voor de homogeen geglycosyleerde Flt3D1-D5:FL en Flt3D1-D4:FL complexen echter, werden talrijke 
kristallisatiehits bekomen. Na kristaloptimalisatie werden diffractie-experimenten uitgevoerd. Deze 
toonden aan dat de kristallen een inherent lage diffractiecapaciteit hadden. Flt3D1-D5:FL kristallen 
diffracteerden slechts tot een resolutie van 10 Å, terwijl kristallen voor het Flt3D1-D4:FL complex 
diffracteerden tot 4.5 Å. Door middel van het testen van honderden kristallen, in combinatie met een 
uitvoerige optimalisatie van het cryoprotectieprotocol werden uiteindelijk een dataset tot 4.3 Å voor 
het Flt3D1-D4:FL complex en een dataset tot 7.8 Å voor het Flt3D1-D5:FL complex bekomen.   
 
Structuuroplossing van het Flt3D1-D4:FL complex 
De 4.3 Å dataset voor het Flt3D1-D4:FL complex kon gefaseerd worden via een combinatie van 
‘molecular replacement (MR)’ en ‘density modification’. Gebruikmakend van de gekende structuur 
van FL (pdb 1ETE) konden initieel twee kopijen van FL gelokaliseerd worden. Dit duidde op de 
aanwezigheid van twee Flt3D1-D4:FL complexen in de asymmetrische eenheid. Vervolgens werd een 
zoekmodel voor Flt3D3, gebaseerd op D3 van de homologe KIT receptor, ook via MR gelokaliseerd. 
Na ‘rigid-body’ verfijning van de partiёle oplossing, werden via ‘density modification’ 
protocollen elektronendensiteitsmappen bekomen die continue densiteit bevatten voor sommige van 
de niet gemodelleerde Ig-domeinen van Flt3D1-D4. Zo konden modellen voor Flt3D2 en Flt3D4 
geplaatst worden, en in latere stadia ook modellen voor Flt3D1. De structuur werd verfijnd in 
autoBuster. Ter ondersteuning van een correcte bepaling van het sequentieregister werden het 
atypische disulfidebrugnetwerk en de glycosylatieplaatsen in het Flt3 ectodomein bepaald via 
massaspectrometrie. De coördinaten en structuurfactoren van de finale structuur voor het          
Flt3D1-D4:FL complex werden gedeponeerd in de ‘Protein Data Bank’ onder de toegangscode 3QS7.   
 
De Flt3:FL interactie is een uitzondering in de RTKIII/V familie 
De bepaalde structuur voor het ternaire Flt3D1-D4:FL complex toonde aan dat de Flt3:FL 
interactie sterk afwijkt van de andere gekarakteriseerde complexen in de RTKIII/V-familie. Terwijl 
de andere receptoren van deze familie hun ligand binden in de groef gepresenteerd door Ig-
domeinen D2 en D3, interageert Flt3 met FL enkel door middel van D3. In de Flt3 receptor pakt D2 





Flt3 receptor niet interageert met het ligand of met andere domeinen van de receptor. Een derde 
merkwaardig punt in het Flt3D1-D4:FL complex is de afwezigheid van receptor-receptor interacties. 
Volgens het huidige model voor RTKIII-activatie zijn deze homotypische receptor interacties nodig 
om de intracellulaire tyrosine kinase domeinen te activeren. 
 
De Flt3 ligand-receptor interactie 
Net zoals KITD3 en CSF-1RD3, gebruik Flt3D3 zijn BC en EF loops om contact te maken met FL. 
De receptor-bindende epitoop van FL is bijna volledig gelokaliseerd in het N-terminale segment dat 
de eerste α-helix voorafgaat. Deze regio werd voorheen reeds geïdentificeerd als zeer cruciaal voor 
receptor binding via een random-mutagenese screen. Bovendien is dit segment strikt geconserveerd 
in een wijde variёteit aan soorten. 
Hoewel onze lage resolutie studie geen informatie verschaft over directe interacties, is het 
duidelijk dat FL en Flt3 elkaar binden via een polaire interactie. Dit is in overeenstemming met 
onze ITC-metingen die voorheen aangetoond hadden dat de Flt3:FL complexvorming gedreven is 
door een sterk exotherme enthalpie.  
 
De afwezigheid van homotypische contacten en de structurele analyse van 
het Flt3D1-D5:FL complex 
Voor de andere RTKIII-receptoren is het aangetoond dat D4 ligand-binding koppelt aan 
receptor-activatie door homotypische receptor-receptor interacties te mediёren. Deze contacten 
worden gevormd door een paar sterk geconserveerde zoutbruggen. Wanneer deze zoutbruggen 
gedeleteerd worden via plaatsgerichte mutagenese wordt de mogelijkheid tot signalisatie in deze 
receptoren ernstig gecompromitteerd. Men veronderstelt dat deze specifieke receptor-receptor 
interacties vereist zijn om de intracellulaire tyrosine kinase domeinen te oriënteren in een staat die 
activatie toelaat. 
Flt3 is het enige lid van de RTKIII-familie waarbij deze zoutbruggen afwezig zijn. Het 
ontbreken van deze residuen is dan ook in overeenstemming met de observatie dat er geen 
homotypische interacties gevormd worden tussen de Flt3D4 protomeren. Echter, omdat 
homotypische contacten cruciaal zijn voor de activatie van de andere RTKIII receptoren, en omdat 
het mechanisme van autoinhibitie van het tyrosine kinase domein wel geconserveerd is, is het 
moeilijk te rationalizeren hoe de Flt3 receptor geactiveerd wordt.  
Om na te gaan of homotypische interacties misschien door Flt3D5 gemediёerd worden werd de 
architectuur van het Flt3D1-D5:FL complex bepaald via ‘rigid-body’ verfijning tegen de opgemeten 
7.8 Å dataset. De resulterende structuur (pdb 3QS9) vertoonde net zoals het Flt3D1-D4:FL complex 
geen receptor-receptor interacties. Daarmee werd aangetoond dat ook Flt3D5 geen homotypische 
interacties mediёert. Hierbij is het interessant op te merken dat er in de muis een actieve isoform 





Onze studie toont dus aan dat Flt3, in tegenstelling tot zijn dichtste homologen, KIT en CSF-1R, 
geen receptor-receptor interacties vormt in ternaire complexen tussen zijn ectodomein en ligand. 
Het is echter mogelijk dat, wanneer de receptor geёxpresseerd wordt aan het celoppervlak, zwakke 
homotypische extracellulaire interacties versterkt worden door de dimensionaliteit van het 
celmembraan en als het gevolg van additionele interacties tussen de transmembranaire helices en/of 



















































































Sequence comparison of the extracellular region of Flt3, FMS (CSF-1R) and KIT. 
The NCBI-reference sequences for the human (h) and murine (m) Flt3, FMS and KIT receptors were aligned using 
ClustalW (Larkin et al., 2007). Strictly conserved residues are colored white on a black background and semi-
conserved residues are shown in black bold. The signal peptides (grey) and predicted transmembrane (TM) helices 
(blue) are highlighted. Cysteine residues in the ectodomains are colored orange. Exons borders (red) were retrieved 
from www.ensembl.org. They correspond well to the boundaries of the Ig-like domains as seen in the KITD1-D5 and 
CSF1-RD1-D3 structures (Yuzawa et al., 2007, Chen et al., 2008).  Note that Flt3 contains an extra exon preceding D1. 
Furthermore, Flt3 has a unique genomic structure in D1 and D2. Resdiues R381 and E386 of human KIT are indicated 




















Sequence comparion of Flt3D1-D2 and Flt3D4-D5  
The regions corresponding to human and murine Flt3 Ig-like domains D1 and D2 (residues 56 - 248 of hFlt3) were 
aligned with the regions corresponding to domains D4 and D5 (residues 347- 533 of hFlt3). Strictly conserved residues 
are colored white on a black background and semi-conserved residues are shown in black bold. Cysteine residues are 
colored orange. Human Flt3D1-D2 and Flt3D1-D5 share 26% sequence identity. Sequences were aligned using ClustalW 



















measured calculated   sequence   remarks 
mass  mass  positions 
 
2013.30 2013.09  248 – 265*  No glycosylation at #250 
2081.56 2081.28  96 – 118  Glycosylation at #100, disulfide bridge between #103 and #114 
3486.61 3486.78  29 – 43  Glycosylation at #43, disulfide bridge between #35 and #65 
   62 – 76*    
4156.83 4156.11  29 – 43  Glycosylation at #43, disulfide bridge between #35 and #65 
   62 – 83   
Glu-C peptides 
 
measured calculated   sequence   remarks 
mass  mass  positions 
 
1499.56 1499.61  196 – 204  Disulfide bridge between #199 and #206 
   205 – 208  
1628.60 1628.65  196 – 204  Disulfide bridge between #199 and #206 
   205 – 209* 
1573.53 1573.72  347 – 357  Glycosylation at #351 and #354 
1777.52 1777.78  347 – 360*  Glycosylation at #351 or #354 
1980.58 1980.86  347 – 360*  Glycosylation at #351 and #354 
4018.67 4018.32**  25 – 44*  Glycosylation at #43, disulfide bridge between #35 and #65 
   63 – 77*  
(4134.96) 4133.35**  25 – 44*  Glycosylation at #43, disulfide bridge between #35 and #65 
   62 – 77 
 
(4263.21) 4262.39**  24 – 44*  Glycosylation at #43, disulfide bridge between #35 and #65 
   62 – 77 
5559.91 5560.18**  25 – 58  Glycosylation at #43, disulfide bridge between #35 and #65  




measured calculated   sequence   remarks 
mass  mass  positions 
 
1735.62 1735.76  381 – 387  Disulfide bridge between #381 and #392 
   389 – 395 
1775.74 1775.71  323 – 334  Glycosylation at #323, disulfide bridge between #330 and #272 
   272 - 273 
2187,03 1983,98  491 – 508  Glycosylation at #502 
2214.78 2214.95  317 – 307  Glycosylation at #306 *** 
2485,03        2281,98  467 – 485   Glycosylation at #473  
3542.46 3542.78  133 – 161  Glycosylation at #151 
3811.30 3811.62  348 – 372  Glycosylation at #351 or #354, disulfide bridge between #368 and #407 
   406 – 410 
4014.43 4014.70  348 – 372  Glycosylation at #351 and #354, disulfide bridge between #368 and #407 
   406 – 410 
(5332.29) 5333.06**  176 – 215*  Disulfide bridges between #184 – #231 and #232 – #241 (from X-ray data) 
   231 – 234  
   240 – 243 
6614.06 6614.55**  176 – 215*  Disulfide bridges between #184 – #231 and #232 – #241 (from X-ray data) 
   220 – 234*  
   240 – 243 
8998.44 8998.13**  35 – 41  Glycosylation at 100 ***, disulfide bridges between #35 - #65  
   50 – 108       and #103 – #114 
   109 – 123  
 
* Peptide containing in-complete or on-specific cleavage  
** Averaged values 


























(A) The asymmetric unit of Flt3D1-D4:FL complex crystals. The Flt3D1-D4:FL complex crystallized in 
spacegroup P21 with two complexes in the asymmetric unit (asu). The two helical ligands in the different complexes 
(chains A-B and chains C-D) make extensive interactions in the asu. The receptor chains are labeled E, F, H and G. 
No density was visible for domains D1 of receptor chains G and H. D4 of chain G was also not modelled because of 
its weak density. (B) The asymmetric unit of Flt3D1-D5:FL complex crystals. Similar to the Flt3D1-D4:FL 
complex, the Flt3D1-D5:FL complex crystallized in spacegroup P21 with two complexes in the assymetric unit (asu). 
The contacts between the two complexes are entirely mediated by the two ligands (chains A-B and chains C-D). The 
Flt3 receptor chains are labeled E, F, H and G. The structure was refined by rigid-body refinement in autoBuster 2.8.0 



























Interspecies comparison of FL sequences. 
Sequence numbering and secondary structure assignment are according to the crystal structure of human Flt3 ligand 
(pdb 1ETE, Savvides et al., 2000). Strictly conserved residues in the included FL sequences are colored white on a 
blue background. The highly conserved N-terminal receptor-binding loop (residues 6-14) is highlighted in a red box. 
Other strictly conserved residues include the cysteines involved in disulfide bridge formation, residues Glu78 and 
Phe81, which stabilize the N-terminal loop, and residues Leu27 and Tyr30 at the dimer interface. The sequences 
were retrieved from the NCBI and Ensembl databases: Homo sapiens (NP_001450.2), Mus musculus 
(NP_038548.3), Rattus norvegicus (XP_002725623.1), Papio cynocephalus (AAO72538.1), Felis catus 
(NP_001009842.1), Ailuropoda melanoleuca (XP_002917887.1), Canis lupus familiaris (NP_001003350.1), 
Pteropus vampyrus (ENSPVAT00000010957), Ovis aries (NP_001072128.1), Bos taurus (NP_851373.1), Sus 
scrofa (ACZ63257.1), Sorex araneus   (ENSSARP00000002887), Cavia porcellus (ENSCPOP00000020385), 
Monodelphis domestica (XP_001379894), Xenopus tropicalis (XP_002938571.1). Sequences were aligned using 
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